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ABSTRACT  
INTRODUCTION:  Lupus Nephritis (LN) and Idiopathic Membranous Nephropathy (IMN) are 
immune mediated kidney diseases.  The gold standard test for diagnosis and monitoring is kidney 
biopsy.  Current treatment regimens for both diseases can be toxic with long-term effects.   
AIMS:  Assess the outcomes of less toxic steroid sparing regimens in both diseases.  To validate 
urinary biomarkers in LN.  Assess the indirect immunofluorescence test (IIFT) for identification of 
anti-PLA2R antibodies in IMN. 
METHODS:   Prospectively data was collected on 50 consecutive patients with Lupus Nephritis 
(LN) were treated with the steroid sparing RITUXILUP regimen.  Retrospectively data was 
collected on 43 patients with Idiopathic Membranous Nephropathy (IMN) who received >12 months 
of treatment with Tacrolimus Monotherapy (Tac).  Enrolment and data monitoring of the IMN 
induction trial “MTac” is described.  The urine biomarker MIF was measured in 586 urine samples 
from 59 patients; results were correlated with disease activity.  A Multiplex cytokine array identified 
Angiogenin (ANG) as a novel cytokine. ANG was measured in 342 urine samples from 34 patients 
treated with RITUXILUP regimen.  IIFT was used to identify anti-PLA2R antibodies in 59 plasma 
samples from 24 patients in the MTac trial. 
RESULTS:  RITUXILUP and Tac regimens were safe and effective with 86% response rate at 1 
year (52% CR and 34% PR) and 98% response rate respectively.  Tac can be valuable in 
relapsing or resistant disease to maintain remission.  uMIF reflected the change in disease activity,  
baseline uMIF did not predict time to CR.  ANG was identified in urine from patients with active LN.  
Levels were significantly lower when in remission.  An association between uANG and the degree 
of renal impairment but not with proteinuria was shown.  IIFT is effective and reproducible for the 
qualitative assessment of anti-PLA2R antibodies, however it is laborious and can have subjective 
variability when used in a quantitative manner.  
CONCLUSIONS:  Steroid sparing treatment may be possible in both LN and IMN; but this needs to 
be validated in RCTs.  uMIF and uANG both reflect disease activity in LN, more work is needed to 
assess if they have a unique role as a biomarker in LN or as a therapeutic target.  The clinical 
	   4	  	  
application of anti-PLA2R antibodies is being investigated widely.  The IIFT is sufficient for current 
research use, however probably not for a high throughput use. 
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CHAPTER 1:  INTRODUCTION 
 
 
The term “glomerulonephritis” is an umbrella term for diseases that are associated with 
inflammation in the glomeruli of the kidney.  The two glomerular diseases that I will be focusing on 
are Idiopathic Membranous Nephritis (IMN) and Lupus Nephritis (LN).   For both diseases I will be 
examining the current understanding of their pathogenesis; their histological classification; current 
treatment regimens available and disease-specific biomarkers.  I will then discuss the rationale 
behind the novel treatment regimens I later describe, biomarkers that are currently available and 
lastly the benefits of a “discovery approach” to identify new biomarkers.   
1.1  Systemic Lupus Erythematosus (SLE) 
In contrast to IMN, which is an organ specific disease, LN can often present as part of a 
multisystem disease, referred to as Systemic Lupus Erythematosus (SLE).  It is a chronic, 
relapsing, inflammatory, often febrile disorder, characterized by involvement of the skin, joints, 
visceral organs and serosal membranes.  Symptoms and manifestations vary widely over an 
unpredictable relapsing and remitting course.  It has an incidence of approximately 4 cases per 
100,000 people per year in the UK (Johnson, Gordon et al. (1995).   
The presentation of SLE is highly variable, ranging from mild forms to severe disease requiring 
hospitalisation.  Most commonly it manifests as a combination of constitutional symptoms with 
cutaneous, musculoskeletal, mild haematological and serological involvement (Von Feldt 1995); 
however it can be more severe, and even life threatening, when renal, haematological or CNS 
disease predominates.  There is a tendency for the disease pattern present at the time of onset to 
prevail during subsequent exacerbations (Fessler and Boumpas 1995).   
Nephritis is a serious complication of SLE affecting up to 60% of adults with SLE with an overall 
incidence of 0.4 per 100,000 population per year.  The prevalence of biopsy proven LN has been 
found to be 4.4 per 100,000 population, however this is significantly higher in women compared 
with men (7.1 and 1.4 per 100,000 population respectively) (Patel, Clarke et al. 2006).    Earlier 
	   21	  	  
treatment has a clear beneficial effect on the prognosis of lupus nephritis, and it has been shown 
that late diagnosis of lupus nephritis is correlated with a higher frequency of renal insufficiency 
(Esdaile, Joseph et al. 1994). Moreover, delayed diagnosis is associated with an increased 
incidence of ESRD, again underlining the importance of early diagnosis in this difficult to control 
disease (Faurschou, Starklint et al. 2006).   
There are both serological tests and symptom criteria that can lead to a presumptive diagnosis of 
lupus nephritis, however the “gold standard” test for LN still remains a percutaneous kidney biopsy.  
Histological analysis of kidney tissue is currently the most valuable diagnostic and prognostic tool 
in lupus patients. However, kidney biopsy can be associated with significant morbidity and, 
therefore, is often reserved for times where there is a clear deterioration in clinical features, rather 
than for monitoring of disease resolution. Furthermore, with an essentially “blind” needle biopsy 
providing a limited number of glomeruli for analysis, questions of how representative the specimen  
of kidney is are hard to ignore. A noninvasive, easily obtainable, and accurate biomarker that can 
be followed serially may therefore be of great value in monitoring lupus patients.  (Reyes-Thomas, 
Blanco et al. 2011) 
Since the 1950s when the introduction of corticosteroids (steroids) lead to the first treatment of LN, 
a balance has always been struck between disease activity and the side effects of treatment 
regimens. In the 1950s lupus changed from being a life threatening condition to being treatable 
thanks to the introduction of steroids. (Heller, Jacobson et al. 1951, Hench 1952)  Lupus nephritis 
prior to the introduction of steroids had been a death sentence with a 17% five-year survival – 
largely because at that time, the renal failure caused by the LN was untreatable as dialysis was not 
available.  Even early publications demonstrated a survival benefit of use of steroids in SLE with 
the probability of 5-year survival being 73% in patients receiving steroid treatment alone compared 
to 49% if the patient did not receive steroid treatment.  (Posnick 1963).  Unfortunately the side 
effects of high dose steroids were the compromise the patients had to accept.  
At that time there were no widely available renal replacement programs (dialysis or transplant), 
and so side effects of treatments were tolerated, as the alternative was death.  Currently dialysis 
and transplantation are widely available and both have ever-improving outcomes, therefore much 
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more consideration is needed when exposing patients to many drugs with toxic side effects.  Of 
course, it is always preferable for patients to have successful treatment of their LN and never to 
have to reach end stage renal failure (ESRF).   
After the initial improvement in outcomes with steroid treatment, came the introduction of 
cyclophosphamide in 1969.   By the 1980s it became clear that steroids in combination with an 
immunosuppressive drug (either cyclophosphamide or azathioprine) provided better outcomes 
than steroids alone and with an acceptable side effect profile.  Newer treatments introduced over 
the past 10-15 years (Mycophenolate Mofetil (MMF), Rituximab) have thus far been used either 
instead of cyclophosphamide (MMF) or as an add on treatment (Rituximab) – reviewed in more 
detail in section 1.1.3.   
However, as has been the case for over 60 years, oral steroids have remained a staple of each 
newly trialled regimen for the treatment of LN despite the growing recognition that much of the 
long-term damage accrued in patients with LN can be attributed to steroids – both the dose and 
the duration of use (Eder, Urowitz et al. 2013).   
The aim of the novel treatment regimen for LN described in this thesis was to minimise each 
patient’s exposure to oral steroids and therefore reduce these damaging effects without loss of 
efficacy. 
This project evaluated two main areas of Lupus Nephritis:  
1.  Analysis of a novel steroid sparing treatment regimen 
2.  Identification and validation of known and novel urinary biomarkers.  
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1.1.1  Pathogenesis of SLE and lupus nephritis 
 
Lupus nephritis is an immune complex glomerulonephritis (GN) that develops as a frequent 
complication of SLE. The pathogenesis of lupus nephritis involves a variety of mechanisms.   
1.1.1.1 Systemic Lupus 
Both the Innate and the adaptive immune system have many mechanisms to protect against self-
recognition and therefore protect from disease derived from our own immune system.  When there 
is compromise of these normal mechanisms autoimmune disease occurs.  Systemic Lupus 
Erythematosus is a heterogenous multisystem disease characterized by immune complex 
deposition.  Loss of B-cell tolerance leads to antibodies being produced against nuclear and 
cytoplasmic materials that contain RNA or DNA, or both.   However, these antibodies can be found 
in individuals without SLE; clinical onset of the disease is often preceded by the development of 
antibodies to multiple nuclear antigens, therefore it is thought that the recruitment of inflammatory 
cells and mediators to target organs is also required.  In genetically susceptible individuals the 
disease can be triggered by environmental factors such as microbial antigens, drugs, toxins and 
hormones.  A single cause for disease development has not yet been identified, therefore 
treatment relies on a global immunosuppressive approach, leading to significant morbidity and 
mortality from unwanted side effects.  
 
Indiscriminate recognition of endogenous nucleic acids would be incredibly detrimental, therefore 
many preventative mechanisms have evolved such as: 
1. Free self nucleic acids are rapidly cleared by extracellular and intracellular nucleases. 
2. Self nucleic acids are excluded from endolysosomes, where engagement of Toll Like 
Receptor (TLR) 3 (specific for double-stranded [ds]RNA), TLR7 or TLR8 (single-stranded 
[ss]RNA) and TLR9 (dsDNA) occurs.  
3. Mammalian nucleic acids are methylated and processed mammalian RNA is capped; 
decreasing their recognition. 
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In SLE normally a combination of these mechanisms are compromised leading to higher levels of 
chromatin in the extracellular space; nuclear antigens are then accessible to antigen-presenting 
cells leading to the immunization process (Saxena, Mahajan et al. 2011, Migliorini and Anders 
2012).   These nuclear antigens can be mistaken as viral particles that contain some protein 
component (antigen) as well as some immunostimulatory nucleic acid.  The immune system is 
primed to mount potent antiviral immunity upon the recognition of viral particles, a response that is 
initiated against the components of virus-like nuclear particles in SLE patients.   
Mechanisms of self-recognition in SLE. 
 
1.  Reduced clearance of both DNA and RNA components 
• Human SLE is characterized by the inefficient removal of apoptotic materials.  Due to 
aberrant apoptosis or decreased removal of apoptotic cells, apoptotic blebs containing 
chromatin are released.  Apoptotic materials provide both auto antigenic cargo and 
ligands that can induce pro-inflammatory cytokines. 
• Deficiency of early Classical Complement Pathway components, particularly C1q, leads 
to impaired clearance of apoptotic cells and apoptotic blebs.  C1q binding activates the 
classical complement pathway, aiding clearance by the phagocytic system.  (Nauta, 
Trouw et al. 2002) 
• Defects in the dismantling of NET (Neutrophil Extracellular Trap) is linked to SLE and 
LN (Bosch 2011, Lande, Ganguly et al. 2011).  NETosis is one of the strategies for the 
killing of microbes. Neutrophils undergoing NETosis release nucleosomes into the 
extracellular space (Villanueva, Yalavarthi et al. 2011). During this process chromatin 
structures loaded with antimicrobial peptides are externalized by activated neutrophils 
(Fuchs, Abed et al. 2007). NET contains DNA-antimicrobial peptide complexes which 
are able to activate plasmacytoid dendritic cells in a TLR9-dependent manner (Garcia-
Romo, Caielli et al. 2011) and may serve as B-cell autoantigens (Kaplan 2011).   
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• Altered degradation of apoptotic material and components of the NETs are recognized 
by autoantibodies.  IFN-a can prime neutrophils for NETosis. This enables complexes 
of autoantibodies and autoantigens to induce NETosis more efficiently, leading to an 
overall increased NET formation in patients with SLE.  Anti-RNP and other 
autoantibodies have been identified as potent inducers of NETosis (Bosch 2011, 
Kaplan 2011).   
• In a subset of patients, enhanced NETosis is accompanied by an impaired degradation 
of NETs. Nucleases are essential to disassembly of the NET, and aberrant NET 
degradation is due to (in)direct inhibition of these enzymes. Anti-NET antibodies and 
antimicrobial peptides prevent access for nucleases, but direct inhibitors of nucleases 
have also been reported (Hakkim, Furnrohr et al. 2010, Leffler, Martin et al. 2012).   
 
2.  Immune complex formation 
• Immune complexes comprising apoptotic or necrotic cell materials and SLE IgG can 
induce IFN-α following uptake by plasmacytoid DCs (pDC). (Bave, U., vallin, H., 
Alm, G. v. & Ronnblom, L).  
• The uptake of immune complexes through Fcγ-Receptors, B-Cell Receptors (BCR) 
or other accessory receptors, facilitates the trafficking of self nucleic acids to 
endolysosomal compartments, leading to Toll Like Receptor (TLR) engagement. 
• Despite the evidence that nucleic acids complexed with IgG autoantibodies promote 
systemic autoimmunity through TLR-dependent type I Interferon (IFN) production, 
apoptotic materials themselves can also induce inflammatory cytokines and 
autoimmune responses.  Dying cells taken up by conventional DCs can trigger TLR-
independent type I IFN production and adaptive immune responses.  
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3. Toll Like Receptors (TLRs).   
• pDCs have a limited life span but their persistent activation by lupus autoantigens 
via TLR7 and TLR9 enhances their survival, leading to loss of tolerance to the 
autoantigens and can render them resistant to glucocorticoid-induced death 
(Guiducci, Gong et al. 2010).   
• Defects in mechanisms of B-cell and T-cell tolerance have been identified in 
discoveries relating to the biology of Toll Like Receptors (TLRs) and have provided 
a more-comprehensive understanding of the mechanisms by which this disease is 
initiated in genetically predisposed individuals. 
4. Inflammatory Cytokine Activation 
• Immune complexes activate Tumour Necrosis Factor (TNF) in myeloid cells and 
IFNα in plasmacytoid dendritic cells (pDC).  Circulating immune complexes which 
stimulate pDCs, myeloid DCs, basophils, neutrophils and macrophages/monocytes 
results in the release of pro-inflammatory cytokines such as IL-4, IL-6, IL-1β, IL-18, 
TNF-α, type I IFN, and BAFF.    
 
5. Interferon 
• An important consequence of TLR engagement by nucleic acids is the production of 
type I IFNs (IFN-α/β), especially by pDCs.  The activated pDCs produce IFNα.   
• High levels of IFNα have been correlated to disease severity in SLE (Elkon and 
Stone 2011). IFNα is a powerful immune adjuvant that increases the capacity of 
dendritic cells to activate T-cells, enhances B-cell proliferation (Ruuth, Carlsson et 
al. 2001), suppresses regulatory T cells (TREG) (Suen, Li et al. 2009), lowers the 
activation threshold of autoreactive B-cells (Braun, Caramalho et al. 2002) and 
induces the differentiation of monocytes to myeloid dendritic cells (Blanco, Palucka 
et al. 2001).  
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• The IFN receptor–dependent secondary gene expression includes multiple antiviral 
and proliferative genes as well as the proinflammatory chemokines CXCL10 and 
CXCL5, which altogether account for the nonspecific symptoms shared by viral 
infections and SLE, such as fever, fatigue, arthralgia, and myalgia (Theofilopoulos, 
Baccala et al. 2005).   
• IFNα initiates a positive feedback loop, driving autoimmunity.   
• Although Type I IFNs are major initiators of systemic autoimmune responses, once 
a broad spectrum of cells of the innate and adaptive branches of the immune 
system are activated, additional inflammatory cytokines and chemokines are 
produced, including Type II IFN (IFN-γ), which is also a major pathogenetic effector 
in murine lupus.  
• Mutations in genes encoding intracellular enzymes involved in RNA and DNA 
handling, also lead to increased IFNα. 
 
6. B and T cell Activation 
• Innate immune system-mediated autoreactive B and T cells activation leads to the 
amplification of chronic inflammation and autoantibody production.   
• Immune complexes promote B-cell proliferation; by the combined engagement of 
BCRs with rheumatoid factor (RF) activity and (after phagocytosis and entry into 
endolysosomes) TLR9.   
• B cells capture antigen via their specific BCR so amplify antigen specific responses 
and present antigens to T cells.  (Chan, Hannum et al. 1999).   
• RNA immune complexes activate B cells to produce antinuclear antibodies (Lau, 
Broughton et al. 2005)  
• Nucleosomal DNA or DNA within immune complexes activate TLR9 on pDCs and 
drives B cell proliferation (Leadbetter, Rifkin et al. 2002).  
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• IFN-a increases the capacity of dendritic cells to activate T-cells, enhances B-cell 
proliferation (Ruuth, Carlsson et al. 2001), suppresses regulatory T cells (TREG) 
(Suen, Li et al. 2009), lowers the activation threshold of autoreactive B-cells (Braun, 
Caramalho et al. 2002) and induces the differentiation of monocytes to myeloid 
dendritic cells (Blanco, Palucka et al. 2001). 
• Lymphocyte mitogens can be induced by DNA recognition: 
o B lymphocyte stimulator (BlyS, also named B cell activating factor 
[BAFF])and A proliferation-inducing ligand (APRIL) regulate B cell 
differentiation and Ig class switching (Liu and Davidson 2011).   
o The two APRIL/BLyS receptors (transmembrane activator and CAML-
interactor (TACI) and B cell maturation protein) promote plasma cell survival, 
therefore they are currently considered as potential therapeutic targets in 
SLE (Gayed and Gordon 2010).   
 
The Two Phase Paradigm 
In 2010 Theophilopoulos et al. formulated a two-phase paradigm to explain the interconnected 
contributions of the innate and adaptive immune systems in SLE pathogenesis. (Figure 1) 
1. The first phase can be mediated by TLR-independent or TLR-dependent pathways 
triggered by endogenous or exogenous agents that result in the initial production of Type I 
IFNs, activation of DCs, and engagement of previously quiescent non-deleted or non-edited 
autoreactive T cells and B cells.  
2. Once autoantibodies are produced, the second amplification phase is initiated.  Nucleic 
acids and related subcellular particles (for example, ribonucleoproteins, nucleosomes) 
complexed with autoantibodies are taken up by conventional DCs and pDCs through FcR 
and by B cells through BCRs, leading to the engagement of nucleic-acid-sensing 
endolysosomal TLRs, enhanced immunocyte activation, inflammatory cytokine production, 
spreading of the autoimmune response and, eventually, disease. 
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Figure 1:  Initiation and amplification stages in systemic autoimmunity.  (Theofilopoulos, Gonzalez-Quintial et al. 2010) 
Abbreviations: BCR - B-cell receptor; DC - dendritic cell; FcγR - Fcγ receptor; IFN - interferon; pDC - plasmacytoid 
dendritic cell; RNP - ribonucleoprotein; TLR - Toll-like receptor.  
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Summary 
 
In summary SLE develops from a combination of genetic variants that impair mechanisms that 
normally prevent the exposure of nuclear particles to the immune system and their capacity to 
activate viral recognition nucleic acid receptors. An IFNα–dependent (pseudo) antiviral immune 
response accounts for those nonspecific SLE symptoms that are shared with viral infections. The 
auto adjuvant activity of endogenous nucleic acids promotes an adaptive immune response 
against the components of the nuclear particle, a process identical to vaccination. This leads to the 
expansion of T and B cell clones with specificities for predominantly nuclear autoantigens that 
account for the production of antinuclear antibodies, immune complex disease, and T cell–
dependent tissue damage. Hormonal and environmental stimuli can enhance these processes at 
different levels. 
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1.1.1.2  Lupus Nephritis 
Immune Complex-Mediated Renal Immunopathology 
 
The diagnostic hallmark of lupus nephritis is the “full house” pattern of immunoglobulin deposition.  
Depending on the quality of the autoantibodies, the duration, and severity of LN, immune 
complexes deposit in: 
1. Mesangium - leading to mesangial cell injury, asymptomatic proteinuria and microscopic 
haematuria. 
2. Subendothelium - leading to endothelial cell death causing chronic scarring, haematuria and 
proteinuria.  
3. Subepithelium - damaging the podocytes leading to secondary membranous GN and 
nephrotic syndrome.  
4. Peritubular capillaries.  
The traditional concept that circulating immune complexes in lupus passively deposit in the kidney 
has been challenged by novel data (Nowling and Gilkeson 2011, Yung and Chan 2012).  
Glomerular immune complexes can form in situ by secondary binding to nucleosomes from renal 
cells (Mortensen and Rekvig 2009).  Another potential intra-renal source of nucleosomes are 
neutrophils undergoing NETosis, due to the release of neutrophil extracellular traps (NETs) (Bosch 
2011). NETS are found in the glomeruli in LN (Hakkim, Furnrohr et al. 2010). 
The immune complexes activate glomerular cells by Fc receptor (FcR) ligation (Niederer, 
Clatworthy et al. 2010).  The nucleic acid component of immune complexes activates intra-renal 
inflammation by TLRs in intra-renal macrophages and dendritic cells (Allam, Lichtnekert et al. 
2009).  Immuno-stimulatory nucleic acids activate glomerular endothelium, mesangial cells, and 
macrophages to produce large amounts of pro-inflammatory cytokines and IFN-α and IFN-β 
(Anders, Lichtnekert et al. 2010).  The functional significance of this intra-glomerular IFN signaling 
is poorly understood but seems to contribute to renal damage in LN and could trigger the formation 
of tubule-reticular structures, or inclusions, that represent an ultra-structural characteristic of IFN 
signaling (Rich 1981).  Together, the ligation of TLRs, complement receptors, and FcRs activate 
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renal cells to release pro-inflammatory cytokines and chemokines, and induce the luminal 
expression of selectins and adhesion molecules inside the microvasculature (Allam and Anders 
2008, Wang, Ito et al. 2010).  
Intrarenal immune complex deposits activate complement (Tojo and Friou 1968), which 
demonstrates the dual role of complement factors in LN (Sekine, Ruiz et al. 2011).  Complement 
deficiency impairs opsonisation and removal of lupus autoantigens from the extracellular space, 
whereas complement factors also directly cause immune complex–related renal inflammation and 
immunopathology (Bao, Haas et al. 2011, Sekine, Kinser et al. 2011).   
Antibody-deficient mice still develop LN; therefore, B cells have pathogenic effects beyond 
antibody production (Jacob and Stohl 2010), including auto-antigen presentation to autoreactive T 
cells and local pro-inflammatory effects (Chan, Hannum et al. 1999).  
 
Recruitment of Leucocyte Subsets 
 
Cytotoxic T cells, Th17 T cells, as well as B cells infiltrate the kidney in LN (Teichmann, Ols et al. 
2010). The members of the chemokine family specifically direct different leucocyte subsets by 
distinct chemokine receptors into different renal compartments.  Leucocyte recruitment is tightly 
regulated. (Kulkarni and Anders 2008) 
Infiltrating leucocytes can form de novo perivascular tertiary lymphoid organs inside the kidney, 
which involve the clonal expansion and ongoing somatic hypermutation of B cells in proximity to T 
cell aggregates (Chang, Henderson et al. 2011).  Tertiary lymphoid organs have only been 
described in less than 15% of biopsies in patients with newly diagnosed LN (Steinmetz, Velden et 
al. 2008).   Such B cells undergo intra-renal proliferation and activation, which contributes to local 
inflammation and tissue pathology in addition to their role for systemic and intra-renal autoantibody 
production (Chan, Hannum et al. 1999, Espeli, Bokers et al. 2011).  This data provides a rationale 
for B cell–targeted therapies in LN (Bekar, Owen et al. 2010, Ramanujam, Bethunaickan et al. 
2010).  T cell and macrophage infiltrates also contribute to immunopathology in LN (Katsiari, 
Liossis et al. 2010, Apostolidis, Crispin et al. 2011). 
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Maladaptive Tissue Repair Contributes to CKD Progression 
 
Damage to renal parenchymal cells triggers healing responses that contribute to renal pathology.  
Focal tuft necrosis is followed by a migration of parietal epithelial cells in the glomerular tuft where 
they produce extracellular matrix contributing to Focal Segmental Glomerular Sclerosis (FSGS) 
progressing to global or segmental glomerulosclerosis.  During this process, the parietal cells 
maintain their polarized epithelial phenotype and lay down extracellular matrix on top of the 
podocytes. (Smeets, Kuppe et al. 2011) 
In addition, cellular glomerular crescent formation results from activation of parietal epithelial cells 
that fill the urinary space by uncoordinated proliferation (Smeets, Uhlig et al. 2009).  This process 
can be triggered by glomerular basement membrane breaks that allow plasma leakage into 
Bowman’s space, where mitogenic plasma components such as fibrinogen trigger hyper-
proliferation of the parietal epithelial cells (Ryu, Migliorini et al. 2012).  At later stages, the parietal 
epithelial cells lose their polarity and produce matrix all around themselves, which creates 
honeycomb matrix deposits in Bowman’s space that turn cellular crescents into fibrocellular 
crescents with glomerulosclerosis.  When the majority of glomeruli are affected by 
glomerulosclerosis this is refererred to as class VI LN (see section 1.1.2). 
Summary 
Lupus nephritis is characterized by glomerular immune complex deposition.  There is evidence for 
both circulatory and intra-renal origins of these immune complexes; however with the identification 
of intra-renal NETosis and the subsequent nucleosome exposure there is a current leaning 
towards a greater role of the intra-renal formation of immune complexes. 
Immune complexes lead to complement activation, Fc receptor ligation and activation of intra-renal 
inflammation via TLR ligation on intra-renal macrophages and dendritic cells.  Together this leads 
to release of pro inflammatory cytokines and chemokines (including interferon) leading to the 
infiltration and proliferation of lymphocytes and macrophages. 
Once the damage has been done, unless interrupted, there is a maladaptive tissue repair process 
contributing to the progression of Chronic Kidney Disease (CKD) in patients with lupus nephritis. 
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1.1.2  Classification of LN 
 
The first publication attempting to classify LN was in 1964 by Pollak et al. titled: “The natural 
history of the renal manifestations of Systemic Lupus Erythematosus”.   Using a classification 
based solely on light microscopy, the authors subdivided LN into normal; lupus glomerulitis; active 
lupus glomerulonephritis and membranous lupus glomerulonephritis and they also scored active 
and inactive lesions.  They followed 87 patients from 7 months to 8 years. They demonstrated a 
good prognostic value with deaths from renal failure in only 2/40 patients with normal biopsies, 
glomerulitis or membranous dying of renal failure, compared with 26/47 in those with active lupus 
glomerulonephritis (Pollak, Pirani et al. 1964).  
In 1974, the World Health Organisation (WHO) first divided LN into five different histological 
patterns.  This was modified in 1982 to include subdivisions relating to activity and chronicity of 
lesions at which time classification of class VI lesions was also introduced.  Further modification in 
1995 placed emphasis upon the significance of segmental necrosis, reflecting an increasing 
understanding of the pathogenesis of lupus nephritis.   
The WHO classification was revised in 2004 under sponsorship of the International society of 
Nephrology (ISN) and the Renal Pathology Society (RPS) in order to accommodate the 
developments in clinico-pathologic and pathogenetic insights that had accumulated since the 1995 
modification to the WHO classification (Weening, D'Agati et al. 2004).  The ISN/RPS classification 
preserves the simplicity of the original classification system and is based exclusively upon 
glomerular pathology, adding qualitative and quantitative differences between class III and IV 
lesions, emphasising the importance of standardised definitions for clinically relevant lesions as 
well as uniformity in reporting between centres (Seshan and Jennette 2009).  An alternative “flow 
chart approach” to the ISN/RPS classification was published in 2006, demonstrating the clarity and 
simplicity of the classification (Elliot, Cairns et al. 2006). – See Figure 2.  
The concept of active and chronic renal lesions was first introduced by Pirani, Pollak, and 
Schwartz (Pirani, Pollak et al. 1964). Austin et al (Austin, Muenz et al. 1984) devised a system of 
applying semi-quantitative scores for activity and chronicity by grading and adding the individual 
morphologic components in a given biopsy as a guide to treatment and prognosis. Activity and 
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chronicity scores are used as an adjunct to the WHO classification of lupus nephritis by many 
(Weening, D'Agati et al. 2004).  In 2011 Marcus Clark et al also clearly demonstrated that the 
degree of tubulo-interstitial inflammation and scarring can predict outcomes in lupus nephritis and 
that the immunological mechanisms underlying the tubulo-interstitial inflammation may provide 
novel targets for therapeutic intervention (Hsieh, Chang et al. 2011). 
 
 
 
Figure 2:  Flow chart approach to the ISN/RPS Classification of Lupus Nephritis.  (Elliot, Cairns et al. 2006)  
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1.1.3  Treatment 
 
As previously described, prior to the introduction of corticosteroids in the 1950’s Lupus Nephritis 
had a terrible prognosis with only 17% five year survival.  With steroids five year survival improved 
up to 55%.  (Heller, Jacobson et al. 1951, Hench 1952, Costenbader, Desai et al. 2011)  
With the introduction of cyclophosphamide in 1969 there were the first small case series and trials 
published, showing that the treatment of LN with steroids with another agent (either 
cyclophosphamide or azathioprine), greatly improved outcomes and prevented progression to end 
stage renal failure (ESRF) with 5 year survival rates improving to 80% (early studies reviewed in 
(Ginzler, Bollet et al. 1980)).   The focus then switched from overall survival to the prevention of 
renal failure.   
In 2004 Contreras et al published the first trial with an approach shift to induction and maintenance 
treatment, or as they put it “sequential therapies”.  (Contreras, Pardo et al. 2004) This approach 
recognized that preserving renal function from outset and preventing flares much improved 
outcomes over many years.  This has subsequently been acknowledged in several long-term 
studies clearly demonstrating that the absence of an early response to immunosuppressive 
therapy (persistent proteinuria and failure to normalise renal function at 6 months) is the most 
important long-term poor prognostic factor in LN (Houssiau, Vasconcelos et al. 2004, Korbet, 
Lewis et al. 2013). Conversely, the positive predictive value for a good long-term renal outcome is 
as high as 90% in patients who experience a reduction in proteinuria of at least 50% by 6 months.  
Therefore it is very important for SLE patients to receive an early diagnosis of renal involvement, 
prompt therapy and very close follow-up during the first months.  It has been proposed by EULAR 
that a change in treatment is warranted in non-responding patients after 6–12 months of treatment, 
but this is based on anecdotal clinical practice rather than trial data. (Bertsias, Tektonidou et al. 
2012, Houssiau and Lauwerys 2013) 
In the last few years, there have been a significant number of large randomised controlled trials 
formulated on the induction of remission model that have focused either on evaluating less toxic 
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regimens with the main goals of minimising or avoiding cyclophosphamide and/or trying to define 
the role of targeted therapies in particular B cell depletion.   
The key current treatments for LN will be reviewed: glucocorticoids, cyclophosphamide, MMF and 
Rituximab.  I will then discuss the reasoning behind the novel steroid sparing regimen that is 
proposed in this thesis. 
1.1.3.1 Glucocorticoids (GCs) 
GCs have a wide spread anti-inflammatory and immunosuppressive actions, as they act upon 
nearly all immune active cells, and influence cytokines, chemokines and adhesion molecules, thus 
altering leucocyte migration, impairing vasodilatation and decreasing vascular permeability.  They 
can also alter cellular differentiation programs and therefore shape the subsequent response. 
(Coutinho and Chapman 2011) 
Oral GCs are a standard component of all treatment regimens in lupus nephritis. They are 
associated with serious side effects and are loathed by patients for their image altering affects.  
These alone are a key reason for poor patient adherence with medication in this difficult chronic, 
relapsing disease.  However, in the late 1940s it was the discovery of the very potent anti-
inflammatory and immunosuppressive properties of GCs (Hench, Kendall et al. 1949) that 
dramatically improved the prognosis of severe systemic lupus erythematosus (SLE), with survival 
rates increasing markedly from 50% at 3 years in 1953 (Jessar, Lamont-Havers et al. 1953) to 92% 
at 10 years in recent series of patients treated with steroids in combination with other treatments 
(Cervera, Khamashta et al. 2003).  
In particular, intravenous pulse methylprednisolone (MP) therapy, introduced as treatment for 
severe lupus manifestations in the 1970s (Cathcart, Idelson et al. 1976), displays remarkable and 
prompt beneficial effects in acutely ill SLE patients suffering from renal impairment, central nervous 
system disease, arthritis, pleuro-pericarditis, fever or severe thrombocytopenia (Isenberg, Morrow 
et al. 1982, Chatham and Kimberly 2001).  Unfortunately, many patients, especially those taking 
>7.5 mg per day for long periods, experience the serious consequences of GC therapy, including 
increased risk of infection, avascular osteonecrosis, osteoporosis, myopathy, diabetes mellitus or 
	   38	  	  
Cushingoid features, as well as skin bruising and cataracts, as described in the work by Gladman 
et al below. 
Most of these side effects impact upon a patient's body image, being a huge source of emotional 
distress in young (sometimes teenage) female patients, who are the principle victims of SLE. 
Several longitudinal studies performed in SLE patients have revealed that GCs are the main cause 
of damage, as determined by the Systemic Lupus International Collaborating Clinics 
(SLICC)/American College of Rheumatology (ACR) damage index (DI). (Gladman, Ginzler et al. 
1996) Thus, the mean DI rose from 0.33 at baseline to 1.9 after 15 years of follow-up in an 
inception cohort, and damage was considered as definitely GC-related in 16% and 49% of the 
cases at baseline and last follow-up, respectively.  (Gladman, Urowitz et al. 2003).   
In another series of incident cases, the accrual of organ damage was found to correlate with the 
mean daily prednisolone dose, with the risk increasing for doses higher than 6 mg per day 
(Thamer, Hernan et al. 2009).  
Finally, damage accrual was found to be associated with higher risk of mortality, every 1-point 
increase in DI being associated with a 1.32 times more risk to die during follow-up (Chambers, 
Allen et al. 2009). These data reinforce the concerns of both physicians and patients about the use 
of GCs. (Lightstone 2013) 
1.1.3.2  Cyclophosphamide (CYP)  
Cyclophosphamide is an alkylating agent.  These compounds crosslink DNA by adding an alkyl 
group (CnH2n+1) to the guanine base of DNA, at the number seven nitrogen atom of the imidazole 
ring. This induces inhibition of DNA replication, leading to cell death. CYP exerts its cytotoxic effect 
on both resting and dividing lymphocytes. It has been shown to suppress T-helper cell functions 
with prolonged reduction of B cells due to the slower rate of recovery of B lymphocytes from an 
alkylating agent. 
CYP has been the mainstay for treatment of lupus nephritis for more than 30 years.  The 
pioneering studies by investigators at the National Institute of Health (NIH) demonstrated the 
importance of IV CYP in the management of lupus nephritis.  The EUROLUPUS trial from 2002 
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demonstrated that low dose cyclophosphamide was as effective in the achievement of remission 
and in relapse rate as a high dose IV cyclophosphamide regimen. Both regimens were given in 
conjunction with IV methyl prednisolone and oral steroids and then followed by maintenance with 
oral steroids and azathioprine.  However, the low dose cyclophosphamide group experienced 
significantly fewer severe infections over the 5 years following treatment (Houssiau, Vasconcelos 
et al. 2002, Houssiau, Vasconcelos et al. 2010). 
The problem with CYP is that despite clear efficacy in treating LN, it has a high rate of toxicity, 
even in lower doses.  Many patients experience severe infections, approximately half of all women 
of child bearing age will experience ovarian failure, other side effects include alopecia, herpes 
zoster, and haemorrhagic cystitis.  Additionally, cyclophosphamide has the potential of 
predisposing patients to malignancies in the long term (Houssiau, Vasconcelos et al. 2004, Zhu, 
Chen et al. 2007). 
With CYP many of the severe side effects are dose related cumulative toxicity and are also age 
related.  Ovarian failure has been found to be both dose and age related: the higher the cumulative 
dose and the older the female patient the more likely she will suffer ovarian failure (greater than 
10g cumulative dose in females aged over 30 years) (Alarfaj and Khalil 2014).  Dose related 
cumulative toxicity is also associated with malignancies, such as bladder cancer: Knight et al 
demonstrated that patients who developed bladder cancer had a much higher average cumulative 
dose compared with those who did not (113g versus 25g); they also showed that for every 10g 
increment in cyclophosphamide dose the risk of developing bladder cancer doubled (Knight, 
Askling et al. 2004).  This cumulative dose effect is particularly relevant to patients with lupus 
nephritis due to the relapsing nature of the disease, leading to repeated courses and therefore 
accumulation of toxicity even if using low doses. 
1.1.3.3  Mycophenolate Mofetil (MMF) 
MMF is a relatively well-tolerated immunosuppressive agent used after kidney, liver and heart 
transplants. Mycophenolic acid, the active metabolite of MMF, selectively and noncompetitively 
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inhibits inosine monophosphate dehydrogenase in the de novo purine synthesis pathway; the only 
pathway used by lymphocytes, selectively targeting the lymphocytes.   
This enzyme facilitates the conversion of inosine monophosphate to xanthine monophosphate, an 
intermediate metabolite in the production of guanosine triphosphate.  As MMF results in the 
depletion of guanosine nucleotides, it impairs RNA, DNA and protein synthesis, therefore 
selectively suppressing the proliferation of T and B lymphocytes, the formation of antibodies and 
the glycosylation of adhesion molecules.  Pharmacokinetics and metabolism of MMF suffer no 
major perturbations in renal impairment (Chan, Li et al. 2000).  
MMF has been shown to be a safe and effective treatment for the induction and maintenance of 
remission in LN.  In 2005 it was shown to be more effective at inducing remission with a more 
favourable safety profile when compared with IV cyclophosphamide (at 0.5-1g per squared metre 
of body surface area) (Ginzler, Dooley et al. 2005), however this was not replicated in the larger 
multi centre ALMS trial where they failed to show that MMF was superior to IV CYP as an induction 
treatment for lupus nephritis. The results of the latter trial have led to the conclusion that MMF is 
equally effective as IV CYP (Appel, Contreras et al. 2009). In a patient population of young women 
of child bearing age, it produced almost no cases of amenorrhoea and no cases of hair loss.  
Evidence from renal transplantation is that MMF may also reduce cardiovascular risk relative to 
other immunosuppressants (Chan, Li et al. 2000, Moore and Derry 2006). 
One of the major drawbacks of MMF for the lupus population is that it has been shown to be 
associated with congenital malformations.  The American Food and Drug Administration (FDA) has 
notified healthcare providers that use of MMF is associated with increased risk of first trimester 
pregnancy loss and increases the risk of congenital malformations, especially external ear and 
facial abnormalities, including cleft lip and palate, anomalies of the distal limbs, heart, oesophagus 
and kidney (Ostensen, Lockshin et al. 2008).  
Patients therefore have a difficult choice: they must not get pregnant whilst taking CYP as it is 
teratogenic and it can cause ovarian failure; MMF doesn’t cause ovarian failure, but is teratogenic 
– so patients must still be cautioned against pregnancy whilst taking MMF.  This is also 
problematic in long term maintenance; the largest study to date has demonstrated the superiority 
	   41	  	  
of MMF over azathioprine in preventing relapses in responders (Sinclair, Appel et al. 2007)(ALMS 
maintenance study). The smaller MAINTAIN study also demonstrated fewer relapses in patients 
receiving MMF compared with azathioprine, but the difference failed to reach statistical 
significance (Houssiau, D'Cruz et al. 2010).   Since getting pregnant with active lupus nephritis 
carries a poor prognosis, it can be reasonable to treat with MMF, and wait for at least 6 months 
post remission to switch to azathioprine and therefore allow safe conception. 
1.1.3.4  Rituximab 
Rituximab is a human chimeric anti-CD20 monoclonal antibody.  Rituximab specifically binds to the 
B-cell-specific antigen CD20, a cell surface protein believed to function in B cell cycle initiation and 
differentiation.  CD20 protein is expressed on immature and mature B lymphocytes, but not in early 
B cell precursors or plasma cells.  Rituximab is a very effective B cell depleting agent in vivo, 
inducing the lysis of these cells mediated by complement and by Fc receptor-bearing cytotoxic 
cells as well as by inducing their programmed cell death.  It has been hypothesised that the main 
action whereby Rituximab reduces disease activity in SLE, is via the depletion of B cells that were 
acting as an antigen-presenting cell to T cells (Vigna-Perez, Hernandez-Castro et al. 2006).  
Rituximab was an attractive agent to try in SLE, not just because it targets B cells, key cells in the 
pathogenesis, but also because there was extensive clinical experience in the use of rituximab for 
the treatment of B cell lymphoma, even in repeat doses.  The long term safety profile of Rituximab 
has generally been good, though there are some reports now of symptomatic persistent secondary 
hypogammaglobulinaemia after repeat dosing.  Greater caution has been advised for repeat 
dosing in patients with persistently low IgG levels.  (Casulo, Maragulia et al. 2013) 
Rituximab was introduced to the treatment of LN more as an “add on” treatment in those with 
refractory disease and it has shown to have some benefit. (Fra, Avanzi et al. 2003, van 
Vollenhoven, Gunnarsson et al. 2004, Edelbauer, Jungraithmayr et al. 2005, Leandro, Cambridge 
et al. 2005, Sfikakis, Boletis et al. 2005, Van den Bergh, Selleslag et al. 2005, Jacobson, van 
Vollenhoven et al. 2006).  However the only randomised controlled trial of rituximab in lupus 
nephritis, the Lupus Nephritis Assessment with Rituximab (LUNAR) trial, comparing MMF + 
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steroids + placebo with MMF + steroids + rituximab in 144 patients with class III or class IV lupus 
nephritis, failed to achieve the primary end point of superiority in the proportion of patients in 
Complete Remission (CR) or Partial Remission (PR) at 52 weeks in the rituximab treated arm: CR 
defined as normal serum creat (if it was abnormal at baseline) or a serum creat <115% (if it was 
normal at baseline), an inactive urinary sediment and uPCR <50; PR defined as serum creat 
<115% of baseline, no red blood cell casts and at least a 50% decrease in uPCR to <100 (if 
baseline was <300) or to <300 (if baseline was >300) (Rovin, Furie et al. 2012).  At one year there 
was no difference in the proportion achieving CR but a 15% increase in those achieving a PR in 
the Rituximab group. LUNAR was underpowered to detect the significance of the increase in PR 
rates seen (reviewed in (Lightstone 2012)).  Another problem with LUNAR, and the many 
observational studies, is the continued reliance on long-term oral steroids.  In the LUNAR study the 
data suggests that patients were failing to have their steroids cut according to planned taper, 
highlighting how difficult it is to wean steroids once started.  This may reflect treatment for extra-
renal manifestations but it is likely that clinicians were reluctant to cut steroids in the face of on-
going proteinuria, and presumed disease activity in the absence of repeat biopsies.   
1.1.3.5  Steroid Sparing Regimen  
As already discussed, whilst trials have suggested MMF may be equivalent to pulsed IV CYP in 
inducing remission of LN, only prednisolone, aspirin and hydroxychloroquine are licensed for the 
treatment of LN in the UK.  Steroids are common to all standard protocols. The relapsing remitting 
course of LN means that patients routinely require long-term treatment (Houssiau, Vasconcelos et 
al. 2010, Dooley, Jayne et al. 2011). In general, decisions on dose and duration of steroid 
treatment tend to be influenced by individual physician preference rather than clinical parameters 
(Walsh, Jayne et al. 2010).   In renal transplantation the use of induction regimens with depleting 
antibodies has allowed the safe introduction of steroid free maintenance regimens (Borrows, 
Loucaidou et al. 2005), this was driven by the short and long term effects reported in the transplant 
population due to high dose and extended steroid exposure. In systemic vasculitis, use of 
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rituximab, has allowed reduction of concomitant immunosuppression (Mansfield, Hamour et al. 
2011).  
In LN, as with transplantation, the long term damage from extended exposure to steroids has now 
been widely reported, therefore evidence of the efficacy of “steroid sparing” regimens is now 
required.  It has previously reported that rituximab can be an effective treatment for LN in patients 
already on oral steroids and allowed for a steroid dose reduction (Pepper, Griffith et al. 2009). 
Following on from this we wanted to do a pilot cohort using rituximab to replace maintenance oral 
GCs. There is little argument that MMF plus steroids or IV cyclophosphamide plus steroids are 
effective combinations in the treatment of lupus nephritis.  
However, we proposed that a combination of rituximab, low dose IV methyl prednisolone and MMF 
without oral steroids can also be an effective regimen. The avoidance of steroids has huge 
potential benefits in this group of patients, particularly as they often require immunosuppression for 
many years. They may avoid not only the unpleasant cosmetic effects of steroids (with the 
associated psychological damage), but also the long-term damage attributable to steroids.  
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1.2 Idiopathic Membranous Nephropathy  
 
Idiopathic Membranous Nephropathy (IMN) is an autoimmune condition, which exclusively targets 
the kidney.  As with LN current treatment regimens are often highly toxic with poor efficacy.  In this 
section, the development and analysis of a novel and perhaps less toxic treatment regimen is 
described. I will also discuss details of a RCT, currently still recruiting, that aims to improve efficacy 
and minimize treatment toxicity, a well as work done to detect anti-PLA2R antibodies in the trial 
patients. 
 
1.2.1  Epidemiology of Membranous Nephropathy 
 
Membranous nephropathy (MN) is the commonest cause of nephrotic syndrome (NS) in 
Caucasian adults but a rare cause of NS in those under the age of 15 years.  This was 
demonstrated in the published Spanish data on the clinic-pathological correlations of >9000 
consecutive renal biopsies, where MN was the attributable cause in a quarter of all adults with NS 
who were biopsied.  (Rivera, Lopez-Gomez et al. 2004) 
In contrast, in patients of African descent, the commonest cause of NS is not MN but Focal 
Segmental Glomerular Sclerosis (FSGS) (Haas, Meehan et al. 1997).  The higher prevalence of 
FSGS in the black population has been linked to the Trypanolytic variants of the APOL1 gene.  
(Kopp, Nelson et al. 2011) Therefore the ethnicity of the patient population will determine the 
relative incidence of MN.   
In the Netherlands MN has an incidence of 10 per million population per year (Hofstra and Wetzels 
2008).  It is most commonly diagnosed in the 5th and 6th decades of life and is uncommon in 
children (Cattran 2001).  Up to one-third of patients will have an underlying systemic disease such 
as malignancy or infection thought to be driving the disease, and will therefore be deemed to have 
“secondary membranous glomerulonephritis (Glassock 1992), the rest have primary or “idiopathic” 
Membranous Nephropathy (IMN).  Around 10-20% of patients with lupus nephritis may show MN 
at renal biopsy (Ponticelli C 2005).  SLE may present with nephritis as the sole disease 
manifestation, pre-dating other clinical features and immunological markers of the disease by 
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years.  These patients show an apparent IMN at presentation with the clinical or serological 
features of SLE absent.  On renal biopsy there are no signs suggesting the secondary nature of 
the MN, apart from possibly a mild mesangial proliferation.  They may then over a period of 1-14 
years patients develop extra renal features suggestive of SLE and increased serum levels of ds-
DNA antibodies (Adu, Williams et al. 1983).   
In patients with MN, between 60-70% present with nephrotic syndrome. The remaining 30% or so 
will have nephrotic range proteinuria (>3.5g/24 hrs).  60% of those with sub-nephrotic range 
proteinuria will progress to nephrotic syndrome within 1-2 years (Hladunewich, Troyanov et al. 
2009). 
1.2.1.1 Natural History of MN 
MN is a chronic disease that can have spontaneous remission and relapses.  One-third exhibit 
spontaneous remission which usually occurs within the first 2 years after presentation; A second 
third of patients exhibit chronic persistent proteinuria with preservation of renal function and the 
final third slowly progress to ESRF (Zucchelli, Ponticelli et al. 1987, Donadio, Torres et al. 1988).  
The percentage of patients entering into spontaneous remission is much lower when patients are 
selected with higher levels of proteinuria at presentation (i.e. >8g/24 hours) (Donadio, Torres et al. 
1988).   
In the white population with NS a 10-year renal survival of >70% has been reported. However, 
some studies that have reported on renal survival have included non-nephrotic patients. Schieppati 
et al. reported on outcomes in a population where 37% of their population were non-nephrotic and 
56% of them had <5g/24 hours of proteinuria, and despite this 25% of this population had reached 
ESRF by the end of 8 years (Schieppati, Mosconi et al. 1993).  MN remains the 2nd or 3rd leading 
cause of ESRF among the primary glomerulonephritis types across Europe and the US 
(Maisonneuve, Agodoa et al. 2000).  Nephrotic patients, particularly those with MN are also at an 
increased risk of infection, life-threatening thromboembolic disease and cardiovascular events 
(Kerlin, Ayoob et al. 2012).   
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1.2.1.2 Prognostic Factors 
Due to the variation in outcomes within the same disease one of the challenges has been 
identifying who to treat and when, particularly as standard treatment regimens have significant 
toxicity.  Evaluating prognosis is critical in making these decisions.  An accurate prognostic marker 
would allow targeting of immunosuppressive treatments to patients at high risk for renal disease 
progression.  (Glassock 2004, Cattran 2005) 
The current evidence does not support the notion that histology plays much of a role other than 
diagnosis; it does not predict prognosis or response to immunosuppression treatment.  (Troyanov, 
Roasio et al. 2006)   
From data derived from The Toronto Glomerulonephritis Registry a model for the identification of 
patients at risk of developing ESRF was developed. (Pei, Cattran et al. 1992) This model takes into 
consideration the initial Creatinine Clearance, the slope of the Creatinine Clearance and the lowest 
level of proteinuria during an initial 6 month observation period.  This model has good performance 
characteristics and has been validated in both Italy and Finland. (Cattran, Pei et al. 1997)  
Based on this model: 
1. A patient with normal Creatinine Clearance (CrCl), proteinuria <4g/24hrs and stable renal 
function over a 6 month observation period would have excellent long term prognosis and 
low risk for progression. 
2.   A patient with normal renal function and whose CrCl remains unchanged in a 6 month 
observation period but has >4g but <8g/24hrs proteinuria would have a 55% probability of 
developing CKD and are medium risk for progression. 
3. A patient with persistent proteinuria >8g/24hrs, independent of degree of renal dysfunction 
has 66-80% probability of progression to ESRF within 10 years and is at high risk of 
progression.   
4. Patients who have never been nephrotic or who have achieved a complete remission (CR) 
of proteinuria have an excellent long-term survival.   
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Achieving a partial remission (PR) has also been recognized as a predictor of long-term positive 
outcomes.  When looking at patients with MN and NS, the 10 year survival was 100% in CR group 
and 90% in the PR group, compared with 45% in the no remission group.  The rate of decline in 
renal function for PR and CR was also similar at -2mls/min/year and -1.5mls/min/year respectively, 
compared with -10mls/min/year in the no remission group.  (Troyanov, Wall et al. 2004) 
Urinary excretion ratios of various urinary proteins (α1-microglobulin, β2-microglobulin, IgM and 
IgG) have been found to be helpful when assessing the severity of the renal injury and have been 
shown to predict outcome.  (Bazzi, Petrini et al. 2001, Bakoush, Torffvit et al. 2003, Branten, du 
Buf-Vereijken et al. 2005) However their quantification is not widely available and therefore they 
have not been adopted into routine clinical practice and have not been widely validated. 
There have also been dramatic steps forward in the last 5 years in understanding the pathogenesis 
of IMN with the identification by Beck et al. in 2009 of the anti-phospholipase A2 receptor (PLA2R) 
antibody occurring in association with the disease (Beck, Bonegio et al. 2009).  It is likely that 
increased understanding of the association of this antibody with IMN and the ability to quantify the 
antibody, will also enhance the prospects of identifying the patients in whom the disease is benign 
and those who will progress to ESRF, and may also lead to the design of more targeted 
immunotherapy for the disease. 
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1.2.2  Histological Classification of MN 
When a patient first presents with signs and symptoms suspicious of MN (or any 
glomerulonephritis) the gold standard test is a kidney biopsy.  From this much information can be 
gathered regarding the activity and extent of the disease and the degree the kidney has already 
become scarred.  Therapy is typically determined by what has been found in the biopsy.  However 
monitoring the progress of the therapy and resolution of disease can be quite difficult, without the 
use of repeated renal biopsies, which can pose a significant risk of harm to the patient.   
1.2.2.1 Light microscopy: 
Although standard light microscopy can show a normal kidney in very early disease, later changes 
are characterized by glomerular capillary wall thickening, glomerular basement membrane (GBM) 
projections evident on the silver-methanamine staining (silver spikes) and absence of glomerular 
hypertrophy. Mesangial hypercellularity may indicate underlying SLE.  Renal function is best 
predicted by the magnitude of interstitial (diffuse mononuclear cells; tubular atrophy; and interstitial 
fibrosis) rather than glomerular changes.  
1.2.2.2  Immunohistochemistry: 
Immune deposits consist of IgG (predominantly IgG4) and complement components (C3 and C5b-
9 “membrane attack complex”), in a fine granular, diffuse pattern, detectable in all capillary loops.  
Positive staining for IgA or IgM, or staining in mesangial areas, is highly suggestive of underlying 
SLE.   
1.2.2.3  Electron Microscopy: 
Electron dense deposits (EDD) (responsible for IgG-positive staining) are observed in the sub-
epithelial space with foot process effacement overlying the deposits.  The GBM projects between 
the EDDs (responsible for silver spikes) and becomes thickened whilst engulfing the EDDs.   
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Staging: 
Electron microscopy findings are used to categorise MN into four stages: 
Stage 1:  Subepithelial deposits with podocyte foot process effacement and normal GBM 
thickness; 
Stage 2:  GBM projection between deposits; 
Stage 3: new GBM surrounds deposits; 
Stage 4: highly thickened GBM, with loss of clear “spike” pattern of GBM projections and 
with increasing deposit lucency. 
These biopsy stages do not correlate with clinical disease severity, treatment response, or 
outcome. (Troyanov, Roasio et al. 2006)  
Histological variants: 
 Focal sclerosis:  Predicts rapid progression to ESRF.  
Glomerular crescents:  Rarely can be associated with anti-GBM antibodies on a 
background of MN. 
Atypical deposits:  IgA or C1q positive immunofluorescence, mesangial cell proliferation 
and mesangial or sub-endothelial deposits indicate an increased likelihood of underlying 
malignancy. 
Pan-immuno-reactivity: Positive IgM and/or IgA, alongside IgG, particularly in mesangial 
areas and sub-endothelial areas, is indicative of underlying SLE. 
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1.2.3 Possible pathogenic mechanisms leading to histological appearance 
 
 “Membranous Glomerulonephritis” is a pathological term.  It was first described in 1946 as a 
category of glomerular disease within the spectrum of Ellis Type 2 glomerulonephritis, clinically 
described as having a more gradual onset, marked proteinuria and oedema.(Glassock 2010)  
However, it wasn’t until 1957 that David Jones separated membranous glomerulopathy as a 
distinct entity from other causes of nephrotic syndrome (i.e. minimal change disease, FSGS and 
membrano-proliferative glomerulonephritis) by applying the special stain periodic acid-silver 
methenamine to human renal biopsy specimens.  (Jones 1957).  The pathological structure that 
was identified as membranous glomerulopathy was described as the thickening of the capillary 
wall and alteration in basement membrane structure.  Subsequently in 1959, the electron-dense 
deposits occupying the spaces between the altered GBM were identified using electron 
microscopic methods applied to renal biopsy specimens (Movat and Mc 1959). In 1957, using 
immunofluorescence, Mellors et al. identified the presence of immunoglobulins in the deposits  
(Mellors, Ortega et al. 1957).  
Therefore the diagnostic features of IMN were clearly described:  
1. Alteration in basement membrane structure;  
2. Subepithelial electron dense deposits;  
3. IgG deposition within the EDD.   
These are still the fundamental features used today to identify membranous glomerulonephritis. 
(Glassock 2010)  
1.2.1.1  Heymann Nephritis 
To further investigate the pathogenesis of MN, Heymann et al. in 1959 first described a 
reproducible and useful experimental animal model of MN that involved injecting rats with an 
antigenic preparation of kidney extracts.  This model became known as “Heymann Nephritis” (HN).  
It was originally thought that HN was an autoimmune disease and work on this model over several 
decades, has shed light on the immune events and molecular basis for the podocyte injury in the 
membranous lesions, generating numerous hypotheses regarding their relevance in human 
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disease (Kerjaschki and Farquhar 1982, Kerjaschki, Miettinen et al. 1987).  However, despite 
conscientious efforts to search for the HN antibody (anti-megalin – like antibodies) in patients with 
IMN and attempts to identify the HN antigen (megalin - a unique constitutive antigen expressed on 
the podocyte of rats (Saito, Pietromonaco et al. 1994)) as a component of the normal human 
podocyte cell membrane, no pathogenic connection was found. (Whitworth, Leibowitz et al. 1976)  
1.2.1.2  Human Podocyte Antigens 
Neutral Endopeptidase 
In 2002 Debiec et al. published work into the development of neonatal MN in infants born to 
mothers genetically lacking neutral endopeptidase (NEP).  This is a membrane-associtated 
podocyte antigen that digests peptides.  As the foetus did not lack NEP, foeto-maternal allo-
immunization occurred and anti-NEP antibodies developed in the mothers.  These antibodies 
crossed the placental barrier and interacted with the foetal podocyte NEP.  The baby developed 
immune complexes (containing both IgG1 and IgG4) leading to the clinical development of 
membranous nephropathy with proteinuria and nephrotic syndrome (Debiec, Guigonis et al. 2002). 
This work provided proof that human IMN could result from an antibody response to a podocyte 
related antigen, rather than due to circulating immune complex deposition. 
 
M-type Phospholipase A2 Receptor 
The search for the human IMN antigen continued.  The problem was approached by several 
laboratories using serum from individuals with MN to screen human glomerular proteins by 
immunoblot analysis.  It was recognized that a number of these sera contained antibodies that 
specifically recognized a high molecular weight glycoprotein in normal human glomeruli.   
In 2009 Beck et al. published extensive experimental work detailing how they identified the M-type 
phospholipase a2 receptor (PLA2R) on podocytes as an antigen in idiopathic membranous 
nephropathy.  The key to their technique was that they recognized that this high molecular weight 
glycoprotein (which they identified as PLA2R) was detected only using Western Blot under non-
reducing conditions.  This suggested the presence of one or more epitopes in the molecule whose 
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conformation was dependent on disulphide bonds.  This is a potential explanation as to why some 
laboratories had not been able to identify this protein using similar techniques. (Beck and Salant 
2010).  
What Beck and colleagues did was to perform Western Blot analyses on extracts of normal human 
glomeruli from donor kidneys with serum from patients with idiopathic membranous nephropathy.  
They then found that antibodies against PLA2R identified a glomerular protein band of the same 
size as that recognized by the serum from a patient with membranous nephropathy.  PLA2R itself 
was not detectable in either the serum of patients with IMN or in control serum.  PLA2R-IgG 
complexes were also not found in serum samples from either group.  However PLA2R was 
detected in human glomeruli and more specifically in podocytes. Mesangial cells, however, did not 
stain for PLA2R.  They demonstrated the way in which PLA2R co-localises with IgG on kidney 
biopsy samples from patients with IMN, but that this co-localisation did not occur in patients with 
Class V lupus nephritis.  To further illustrate that the IgG demonstrated on the IMN biopsies 
reacted with PLA2R they extracted the IgG from IMN biopsies and using Western Blotting showed 
that the IgG detected native and recombinant PLA2R, which was not found with the IgG extracted 
from biopsies with other glomerular diseases.  (Beck, Bonegio et al. 2009) 
In Debiec’s work in patients with anti-NEP, the histological staining of IgG1 (in combination with 
IgG4) corresponded with the development of proteinuria, but not IgG4 alone.  In 2009 Beck et al 
were unable to correlate the presence or absence of anti-PLA2R IgG antibodies on histological 
staining with the severity or duration of disease.   
The exact physiological role of PLA2R remains unclear (Rouault, Le Calvez et al. 2007) as does its 
role in the pathogenesis of IMN.  Beck et al. hypothesized that it may be a target for antibody 
binding leading to a complement-mediated podocyte injury as in experimental models of MN 
(Nangaku, Shankland et al. 2005) or that the antibodies may act as receptor agonists or 
antagonists, altering podocyte architecture and barrier function.  (Beck, Bonegio et al. 2009)   
 
The role of PLA2R antibodies in clinical practice is discussed further in section 1.3.2.1.   
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There is the remaining question of why patients develop antibodies to PLA2R?  Salant 
hypothesized that the development of IMN may be the result of three conditions (Salant 2013): 
1. The presence of HLA-DQA1 alleles that confer susceptibility to autoimmunity.  
Saeed et al recently published a large case-control association study of 1512 
patients with both anti-PLA2R antibody positive and anti-PLA2R antibody negative 
MN.  They found a strong epistasis between an HLA-DQA1 SNP variant and a 
PLA2R1 SNP variant (which had been shown to be strongly associated with 
PLA2R-positive MN).    
2. Polymorphism of PLA2R1 that creates a unique conformation that can represent a 
target for autoantibodies, and  
3. Production of hypogalactosylated IgG4 anti-PLA2R1 that activates the alternative  
complement pathway.  
Much more work needs to be done to investigate (a) who develops anti-PLA2R antibodies,; (b) 
what their role is in the pathogenesis of proteinuria; (c) what happens to them during treatment 
(and does this differ with different treatments); and (d) the role of anti-PLA2R antibodies in 
predicting relapse of the disease.  Could the presence/absence/level of anti-PLA2R antibodies 
potentially act as a reliable biomarker of disease activity in IMN?  
1.2.1.3  Pathogenesis of Proteinuria 
The movement of plasma proteins larger than 70kD across the glomerular basement membrane 
(GBM) is thought to be restricted by both a charge selective and a size selective barrier (Goode, 
Shires et al. 1996). The charge selective barrier is thought to be mainly the result of poly-anionic 
glycosaminoglycans in the GBM, which restrict the passage of small poly-anionic plasma proteins 
(70 to 150 kD in size) – the main one of which is albumin. (Orth and Ritz 1998) The size selective 
barrier, which is thought to consist of pores in the GBM meshwork, restricts the passage of larger 
plasma proteins (>150kD).  The defect in MN results mainly from a loss of size selectivity 
(Shemesh, Ross et al. 1986), however the exact pathogenesis of the proteinuria associated with 
disease severity in IMN remains unclear.  Is it related to immunoglobulin deposition leading to 
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complement activation or is it another non-complement dependent mechanism involving T-cells 
leading to damage to the selective permeability properties of the capillary wall, as has been 
suggested in some of the experimental models?  It has also been shown that even in clinical 
complete remission from proteinuria, some sub-epithelial deposits persist on electron microscopy 
(over time they do acquire a more electron-lucent character) indicating that the presence of 
immunoglobulin deposits per se does not lead to proteinuria.   Treatment with rituximab has led to 
decreases in IgG4, but not total IgG, deposition in glomeruli (Ruggenenti, Cravedi et al. 2008). It 
has been shown in the work done with anti-NEP that the C5b-C9 membrane attack complex is in 
the electron dense deposits (EDDs), suggesting that this spontaneous allo-immune disease might 
be complement dependent in a manner analogous to Heymann nephritis (Debiec, Guigonis et al. 
2002, Ronco and Debiec 2007).  It has also been hypothesized that proteinuria may be as a result 
of T-cell infiltration of the glomeruli.  Small numbers of activated T cells transiently trapped in 
glomerular structures could elaborate soluble diffusible substances that alter the integrity of the 
podocyte-dependent permselectivity barrier in glomeruli (Penny, Boyd et al. 1998). 
 
Proteinuria and the Podocyte Cytoskeleton  
The dynamic regulation of the podocyte cytosekeleton is essential to normal kidney filter function.  
Mutations affecting several podocyte proteins lead to the rearrangement of the actin cytoskeleton 
and this leads to proteinuria.  Proteins regulating podocyte actin dynamics are therefore crucial for 
sustained glomerular filter function.  In MN the podocytes overlying the areas of GBM with active 
disease (i.e with sub-epithelial deposits) are effaced and therefore proteinuria results.  This 
demonstrates the interaction between immunoglobulin deposition and impairment of podocyte 
function in MN (Faul, Asanuma et al. 2007). 
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1.2.4  Clinical presentation, Outcomes and Treatment 
1.2.4.1  Who to treat? 
There is now a consensus view that all patients with Nephrotic Syndrome (NS) for a period of >six 
months or with the presence of severe, disabling or life threatening symptoms related to the NS 
secondary to Idiopathic Membranous Nephropathy (IMN) should be treated with an 
immunosuppressive regimen (KDIGO 2012).  As previously described NS in itself has its own 
morbidity with higher incidences of infection, thromboembolic disease and cardiovascular disease. 
Recent published data indicates that in NS due to IMN, maintenance of remission is the factor 
most strongly associated with reduced risk of renal replacement therapy (RRT) or death 
(McQuarrie, Stirling et al. 2012).   
1.2.4.2  Steroid and Cytotoxic Regimens 
In 1984 Ponticelli et al. published the first Randomised Controlled Trial (RCT) for the treatment of 
IMN.  They compared symptomatic treatment with a six-month course of alternating monthly 
methylprednisolone and chlorambucil.  They showed significantly (p=0.001) higher rates of 
complete and partial remissions in the treated group compared with the controls (Ponticelli, 
Zucchelli et al. 1984). At 5 and 10-year follow-up, low relapse rates with this regimen were 
observed thus demonstrating that this “six-month (regimen) increased the probability of remission 
of proteinuria and protected from renal function deterioration even in the long-term. It may have 
also avoided dialysis or death within 10 years to about one third of nephrotic patients with 
membranous nephropathy” (Ponticelli, Zucchelli et al. 1989, Ponticelli, Zucchelli et al. 1995). In 
1992, the same group published another RCT comparing the methylprednisolone/chlorambucil 
regimen with a six-month regimen of methylprednisolone alone.  They found that time to remission 
was shorter in the combination therapy group compared with the single therapy group, however 
the significance of this difference had diminished by 4 years (Ponticelli, Zucchelli et al. 1992). 
However as these trials enrolled patients with normal renal function it is difficult to interpret the 
results as to the efficacy of this regimen in all patients with IMN.  In a recent review article the 
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benefits of alkylating agents were summarized as giving a 5-year renal survival of 86%–92%, 
producing remission rates ranging from 64% to 85%, and a relapse rate of 25% at 5 years (Hofstra 
and Wetzels 2010). 
However effective the methylprednisolone/alkylating agent combination has proven to be it must 
be remembered that it is a toxic regimen with short term side effects including: anaemia, 
leucopaenia, thrombocytopaenia, anorexia, nausea, liver test abnormalities, interstitial 
pneumonitis, macroscopic haematuria and haemorrhagic cystitis. Given the older age of the 
majority of IMN patients, the damage these drugs can do must be taken into account.  The longer-
term side effects are infertility and malignancy. The increased risk of malignancy was recently 
highlighted by van den Brand et al. who reported patients with IMN treated with a 
cyclophosphamide based regimen had a 3-fold increase in the incidence of malignancy (all cause) 
compared with the IMN patients not exposed to cyclophosphamide.  For a 55-year old patient this 
translated into an increase in annual cancer risk from approximately 0.3% to 1%. (van den Brand, 
van Dijk et al. 2014).  It is worth noting that with the Ponticelli regimen only a third of patients 
presenting with nephrotic syndrome secondary to IMN but normal renal function managed to avoid 
dialysis or death. Although an improvement on what came before, it was still some way short of a 
truly safe and effective treatment regimen.   
1.2.4.3  Mycophenolate Mofetil 
As previously described, MMF is a relatively well-tolerated immunosuppressive agent in LN. For 
IMN it has not been found to be beneficial when used as a single agent in a trial versus 
symptomatic therapy.  When used at a dose of 2g/day for a period of 12 months, there was no 
significant difference in degree of proteinuria or rate of remission at 1 year (Dussol, Morange et al. 
2008). When combined with steroids there is both retrospective and RCT data to suggest that it is 
clinically effective and even equivalent to a steroid and a cytotoxic drug regimen (Branten, du Buf-
Vereijken et al. 2007, Chan, Lin et al. 2007). However, when discussed in a recent review article it 
was still felt that the data available regarding the use of MMF in IMN are “insufficient to draw any 
firm conclusions about the use of MMF for induction of remission” (Ponticelli and Glassock 2014). 
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1.2.4.4  Calcineurin Inhibitors (CNIs)  
CNIs bind with high affinity to a family of cytoplasmic proteins present in most cells: cyclophilins for 
cyclosporine (CyA) and FK binding proteins for tacrolimus (Tac). The drug-receptor complex 
specifically and competitively binds to and inhibits calcineurin, a calcium and calmodulin-
dependent phosphatase.  This process leads to a reduction in production of cytokines and 
ultimately the proliferation of lymphocytes is reduced, specifically by the inhibition of nuclear factor 
of activated T cells (NFAT) signaling in T cells (Wiederrecht, Lam et al. 1993).  CNIs have also 
been shown to have a direct effect on the podocyte, blocking the calcineurin-mediated 
dephosphorylation of the actin organizing protein synaptopodin, stabilizing its actin cytoskeleton 
(Faul, Donnelly et al. 2008).  It is currently unclear whether it is the effect on the immune system or 
the direct effect on the podocyte, which gives CNIs their efficacy in the treatment of IMN. 
CNIs were first introduced as an immunosuppressive agent in transplantation in the 1970s (CyA 
and then Tac in the 1990s) and have been shown to be relatively safe agents for use in the 
medium and long term, with few side effects. Most often in combination with steroids, Tac has 
been shown to be diabetogenic, however this has also been noted without steroids, but to a lesser 
extent (Tan, Kaczorowski et al. 2006).  This is because Calcineurin is critical to β-cell growth and 
function. CNIs contribute to New Onset Diabetes After Transplantation (NODAT) through a dose 
related and partially reversible islet cell toxicity with impairment of insulin gene expression and 
secretion (Heit 2007). Acute nephrotoxicity (within 3 months of commencement) is observed with 
the use of CNIs and has been shown to be due to arteriolar vasoconstriction leading to glomerular 
ischemia; however it is reversible on cessation of the CNI (English, Evan et al. 1987). Chronic 
nephrotoxicity, very well described in native kidneys of non renal transplant recipients, is 
demonstrated histologically by striped interstitial fibrosis, tubular atrophy, medial arteriolar 
hyalinosis and tubular micro-calcification (Myers, Ross et al. 1984).  There is a dose-dependent 
reduction in GFR and renal plasma flow with CNIs, due to decreased vasodilators, increased 
vasoconstrictors, direct toxicity to the tubular epithelium and impairment of protein synthesis in the 
endoplasmic reticulum (Naesens, Kuypers et al. 2009). Chronic nephrotoxicity does not have the 
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same reversibility as acute nephrotoxicity and a balance has to be struck between adequate 
immunosuppression and this chronic process.  Tac has a less nephrotoxic effect than CyA and, as 
it also has an improved lipid profile in comparison with CyA, and is now generally accepted as the 
CNI agent of choice (Chapman 2011).  Genetic polymorphisms of the cytochrome p450 system 
influence the metabolism of Tac (Thervet, Anglicheau et al. 2003).  In order to minimize the risks of 
nephrotoxicity the measurement of trough levels is recommended. 
CyA and Tac have been shown to be effective agents for remission induction in NS secondary to 
IMN in the context of randomized controlled trials (Cattran, Appel et al. 2001, Praga, Barrio et al. 
2007).  High relapse rates were reported in both trials on cessation of therapy.  Cattran et al. 
compared CyA and prednisolone with placebo and prednisolone. All patients were treated for 26 
weeks and then the treatment was withdrawn. They reported a 75% remission rate by 26 weeks in 
the treatment group, however of those who reached remission, 43% had relapsed by 52 weeks, 
but it should be noted that all those who relapsed achieved a PR rather than CR.  Influenced by 
Cattran et al’s. high relapse rate, Praga et al. compared tacrolimus monotherapy with optimal 
medical treatment for a longer period of 12 months followed by a 6 months taper. They reported a 
94% remission rate at 18 months (40% CR and 54% PR) in the treatment group, however 47% 
relapsed after withdrawal of treatment. It is not clear what proportion of relapses were from CR or 
PR.  Neither trial took into consideration the time to achieve remission when considering duration 
of therapy. 
In 2013 Howman et al. reported on the large multi-centre UK based RCT (n=108) examining 
whether CNI treatment preserves renal function in patients with IMN who already have declining 
renal function.  CyA monotherapy was compared with supportive treatment alone and with 6 
months of alternating prednisolone and chlorambucil. The primary outcome was to avoid a further 
20% decline in renal function. The prednisolone and chlorambucil group fared better (i.e. were less 
likely to have deteriorating renal function) whereas the CyA and supportive groups fared more 
poorly, but were comparable to each other.  There were, however, significantly more adverse 
events in the prednisolone and chlorambucil group (Howman, Chapman et al. 2013). Due to the 
haemodynamic effects of CyA on glomerular blood flow, a small decline in renal function is often 
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expected and those patients with already declining renal function are likely to be more sensitive to 
this. Therefore the primary outcome of a further 20% decline in function may not have been the 
right marker to judge the success of the CyA treatment.  Also the initial dose of CyA of 5mg/kg 
used by Howman et al. was higher than the dose used by Cattran et al. in 2001. This was a 
particular discussion point of the paper as it was a likely confounding factor in the trial outcome.   
Since 2002 the Renal Dept. at St. Mary’s Hospital and subsequently at the West London Renal 
and Transplant Centre (from 2005) have been using Tac monotherapy as the first line treatment 
regimen for patients with Nephrotic Syndrome secondary to IMN who do not show any reduction in 
proteinuria after 12 weeks of treatment with Angiotensin Converting Enzyme Inhibitors (ACEI) and 
Angiotensin Receptor Blockers (ARB), and/or who are severely nephrotic at presentation (albumin 
<20g/L with uPCR >300mg/L).  What is unique about this regimen is that it advocates the use of 
Tac monotherapy to maintain remission in patients who have had previous relapses or who, due to 
frailty or comorbid disease, would be at high risk of complication from further nephrotic relapses 
and/or further induction immunosuppression.  The outcomes of this novel treatment are described 
in patients who have received Tac monotherapy for more than 12 months, looking at baseline 
characteristics, time to remission from nephrotic syndrome, renal function, relapses, treatment 
failures, adverse events (including new onset diabetes and malignancies), progression to ESRF 
and patient mortality. The histology on those re-biopsied during the follow up period has also been 
collated and is described. 
1.2.4.5  MTac Trial (Tacrolimus monotherapy vs Tacrolimus and Mycophenolate Mofetil for the 
treatment of IMN). 
As described above one of the main reported concerns with the use of CNIs in IMN is the relapse 
of the disease on withdrawal of treatment.  Limited data suggests MMF may be effective in 
induction of remission in IMN when used in combination with steroids.  With this in mind in 2009 a 
single centre RCT was commenced comparing Tac monotherapy with Tac and MMF.  The 
hypothesis of the trial was that with the addition of MMF to Tac for the treatment of nephrotic 
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syndrome secondary to IMN would reduce the relapse rate following cessation of treatment. Giving 
this increased immunosuppression up front may also reduce the time taken to remission.  
All patients with biopsy proven IMN are initially treated with maximum tolerated doses of ACEI’s 
and/or ARB’s for at least 3 months.  Patients who remain significantly proteinuric (PCR>100 
mg/mmol with hypoalbuminaemia or PCR >300 mg/mmol with normal or low serum albumin) are 
consulted for consideration of enrolment in the trial. Patients are randomised to receive tacrolimus 
monotherapy or tacrolimus in combination with MMF therapy at a 1:1 ratio.  Treatment is initially for 
1 year.  
Remission of proteinuria is defined as complete if urinary PCR <30 mg/mmol, and partial if urine 
PCR decreases by >50% but is still above 30 mg/mmol. Patients not obtaining complete or partial 
remission after 1 year are withdrawn from the trial and alternative therapies considered.  When 
patients have been in remission for 12 months on treatment the tacrolimus is withdrawn over 6 
months. Those on MMF and tacrolimus will then have their MMF stopped prior to tacrolimus 
withdrawal over 6 months. Patients are offered a renal biopsy prior to withdrawal of therapy. This 
may help predict relapse and show any evidence of tacrolimus toxicity, which may help guide 
subsequent therapy in the case of relapse. Patients are being followed for at least 3 years. The 
primary endpoint is the efficacy of MMF in preventing relapse of nephrotic syndrome on withdrawal 
of tacrolimus therapy. This is being measured initially at 6 months post withdrawal of tacrolimus 
therapy.  The secondary end points are:  (i) the time to remission from proteinuria; (ii) the degree of 
remission of proteinuria (i.e. complete or partial) and (iii) the rate of decline of renal function 
measured by the MDRD equation for the glomerular filtration rate. 
Within this thesis the recruitment and monitoring of these patients will be described, however as 
the trial is not yet fully recruited outcome data are not yet available.   
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1.3  Biomarkers in Glomerulonephritis 
 
In both LN and IMN the “gold standard” marker of disease activity is the histological examination of 
renal tissue.  Undertaking a kidney biopsy has its own morbidity associated with it, due to the risk 
of a significant blood loss.  This risk can often be higher in this population as many patients would 
have had some degree of anticoagulation if they have nephrotic syndrome and also the bleeding 
risk is higher if there is impaired renal function.  Therefore, identifying a less invasive reliable 
marker of disease activity would allow physicians to monitor their patients’ disease without having 
to expose them to the risks of repeated kidney biopsies. 
Biomarkers can be defined as “cellular, biochemical, molecular, or genetic alterations by which a 
normal or abnormal biologic process can be recognized and/or monitored and that may have 
diagnostic or prognostic utility” (Illei, Tackey et al. 2004).   
Reliable biomarkers may assist in precise evaluation of disease activity, identify patients at risk for 
organ damage or recurrent flares, and facilitate early and accurate evaluation of responses to 
treatment (Liu, Manzi et al. 2005).   
Required criteria for a given measured parameter to serve as a biomarker have been proposed 
and include the following:  
(1) It is biologically plausible and relevant to disease pathogenesis,  
(2) It should accurately reflect changes in disease activity, and  
(3) It is simple to measure for routine use (Liu, Manzi et al. 2005).  
 
However, despite great progress in our understanding of The pathogenesis of SLE and LN, intense 
interest, and a need for the development of such biomarkers, none has been proven to date to 
truly reflect disease activity, predict the risk of future organ involvement, response to treatment, or 
prognosis (Illei, Tackey et al. 2004, Illei, Tackey et al. 2004, Liu, Manzi et al. 2005).   
There are traditional serum biomarkers of SLE, however they have not proved to be a good 
representation of the activity of lupus nephritis. the following auto-antibodies are those that have 
shown some specificity for LN in patients with SLE.  
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• Anti-double stranded DNA (dsDNA) antibodies are highly specific for a diagnosis of SLE.  
High titres of IgG anti-dsDNA antibodies have been associated with active 
glomerulonephritis both in serum and in the form of glomerular deposits.  
• Anti-C1q antibodies have fair sensitivity and specificity for the diagnosis of LN, suggesting 
that the presence of anti-C1q antibodies may be a valuable adjunct for predicting LN and 
assessing renal activity (Yin, Wu et al. 2012); however, currently they are not generally in 
clinical use. 
These auto-antibodies, in combination with complement levels, can be helpful clinically, but the 
correlation between these and lupus renal disease is imperfect. Sensitivity and specificity for active 
lupus nephritis among all SLE patients diverge according to different studies and tests used 
(enzyme immunoassay vs. immunofluorescence) and are depicted in Table 1. 
 
Test Sensitivity Specificity 
Anti-dsDNA 53-100% 50-69% 
C3 56-79% 51-64% 
C4 53-74% 64-65% 
Anti-C1q 53-81% 64-71% 
 
Table 1 – Performance of historical biomarkers in active Lupus. (Esdaile, Joseph et al. 1996, Oelzner, Deliyska et al. 
2003, Moroni, Radice et al. 2009) 
 
It is also interesting to note that these sensitivities and specificities also varied according to the 
gold standard used. Esdaile et al. evaluated these markers as predictors 3, 6, and 9 months prior 
to a renal flare as determined by the renal components of the Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) (Esdaile, Joseph et al. 1996), while Moroni et al. looked more 
specifically at sensitivity and specificity of detecting nephritic and proteinuric flares of patients who 
already carried the diagnosis of lupus nephritis (Moroni, Radice et al. 2009).  In this prospective 
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longitudinal study by Moroni et al., anti-dsDNA, anti-C1q, C3, and C4 all had poor positive 
predictive values (ranging from 28% to 38%). Although the best multivariate analysis model for 
renal flare prediction was obtained by combining anti-C1q with C3 and C4, the data clearly showed 
that anti-C1q antibodies were less reliable in predicting flares in non-proliferative nephritis and 
flares in the presence of anti-phospholipid antibodies. (Reyes-Thomas, Blanco et al. 2011) 
None of these traditional markers has been shown to possess the ability to predict histology. The 
lack of specificity of our current markers for lupus nephritis and inability to predict histology 
highlight the need for a true biomarker for lupus nephritis. 
With respect to lupus nephritis, urinary biomarkers may be more specific for kidney damage than 
serum biomarkers, particularly in SLE patients with active systemic disease. Also, obtaining urine 
for laboratory testing is much easier and less invasive, making urine a more ideal biological sample 
for a disease that requires repetitive screening.  The most well known and used urine marker of 
disease activity is of course protein, with 24 hour total protein, grams/Litre of protein or a spot urine 
protein:creatine ratio (PCR) being used in all definitions of remission from lupus nephritis.  
However, proteinuria provides a crude measurement of disease activity and does not differentiate 
between active lupus, scarred glomeruli with podocyte damage and other glomerular diseases.  
For the past 20 years different markers in urine have evaluated to see if in isolation or in 
combination they could add information that would guide management of the disease.    
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1.3.1  Urinary biomarkers in LN 
Several potential urinary biomarkers for lupus nephritis have already been identified.  These are 
cytokines, chemokines and adhesion molecules such as: Monocyte Chemotactic Protein-1 (MCP-
1/CCL2), Macrophage Migration Inhibitory Factor (MIF), interleukin (IL)-6, vascular cell adhesion 
molecule (VCAM)-1, CXCL16, IP-10 and a novel tumor necrosis factor (TNF) superfamily member, 
TNF-like weak inducer of apoptosis (TWEAK).  Since MCP-1 was one of the first identified as a 
potential biomarker in renal disease, much work has been carried out to see if it has a role in 
clinical practice.  This is described in detail below and is a good illustration of how it can be very 
difficult to transfer a clear biological role into a relevant clinical role.  With regards to MIF there is a 
significant amount of published data with regards to its complex biological activity, however there 
are only preliminary reports with regards to its role as a potential urinary biomarker in lupus 
nephritis in relatively small cohorts of patients.   
1.3.1.1 Monocyte Chemotactic Protein-1 (MCP-1/CCL2) 
MCP1 is a key chemokine (chemotactic cytokine), whose urinary levels have been associated with 
disease activity in lupus nephritis.  It is a small heparin binding protein and was the first discovered 
human chemokine from the CC subfamily of chemokines  (Rollins 1997). Located on chromosome 
17 (chr.17, q11.2), human MCP-1 is a 13kD protein composed of 76 amino acids (Van Coillie, Van 
Damme et al. 1999). Monocyte/macrophages are the major source of MCP-1 (Yoshimura, 
Robinson et al. 1989) althoughMCP-1 is produced by many other cell types, including endothelial, 
fibroblasts, epithelial, smooth muscle, mesangial, astrocytic, monocytic, and microglial cells 
(Deshmane, Kremlev et al. 2009). These cells are important for antiviral immune responses in the 
peripheral circulation and in tissues.  
MCP-1 acts by binding to G-protein-coupled 7-transmembrane domain receptors on the surface of 
cells targeted for activation and migration. MCP-1 binding to CC chemokine receptor 2 (CCR2) 
leads to intracellular calcium release and activation of protein kinase C (PKC). PKC activates NF-
κB, which up-regulates several genes that produce proteins that influence directional cell motion. 
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MCP-1–CCR2 binding also activates Rho family proteins, which influence cell motility through 
regulation of actin-dependent processes. Other intracellular kinases, such as ERK1, ERK2, JAK2, 
JNK1 and p38 are also known to be involved in MCP-1 signal transduction (Melgarejo, Medina et 
al. 2009, Yadav, Saini et al. 2010).  
MCP-1 is a potent chemo-attractant for monocytes, but it is also important for memory T 
lymphocytes, natural killer cells and basophils.  It induces migration but it also has other effects on 
these target cells, such as release of enzymes, expression of adhesion molecules and histamine-
release. It triggers the firm adhesion of monocytes to vascular endothelium under flow conditions, 
followed by monocyte extravasations through vascular endothelium (Van Coillie, Van Damme et al. 
1999, Melgarejo, Medina et al. 2009).  
MCP-1 has been shown to have a role in the pathogenesis of kidney diseases in experimental 
animal models, including experimental crescentic glomerulonephritis (nephrotoxic nephritis) (Tam, 
Karkar et al. 1996, Lloyd, Minto et al. 1997), lupus nephritis (Rovin and Phan 1998, Kelley and 
Rovin 2003) and diabetic nephropathy (Chow, Nikolic-Paterson et al. 2006).   
MCP-1 has also been detected in human tissue and urine samples in various renal diseases 
including crescentic glomerulonephritis (Tam, Sanders et al. 2004), lupus nephritis (Noris, 
Bernasconi et al. 1995, Wada, Yokoyama et al. 1996), diabetic nephropathy (Tam, Riser et al. 
2009), renal allograft rejection (Grandaliano, Gesualdo et al. 1997) and Adult Polycystic Kidney 
Disease (APKD) (Zheng, Wolfe et al. 2003).  It has also been shown to be a potential intervention 
point for the treatment of various diseases (Hayashida, Nanki et al. 2001, Sorensen, Ransohoff et 
al. 2004).  Selective targeting of MCP-1 has proved to be an effective treatment in suppressing 
kidney diseases in experimental animal models (Wada, Yokoyama et al. 1996).  Blockade of MCP-
1 would have a great therapeutic potential in a wide range of renal diseases. Such therapies now 
need to be validated in clinical studies. (Kim and Tam 2011) 
Revisiting the criteria for a good biomarker:  MCP-1 is biologically plausible and relevant to disease 
pathogenesis in LN and it is also relatively simple to measure in routine use. Somewhat 
problematically however, it currently does not accurately reflect changes in disease activity that is 
solely attributable to active LN. As such it has yet to find a role in routine clinical practice.  This is 
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partly because the available data are mostly from relatively small studies, but also there is an 
uneasy feeling amongst clinicians that measuring urinary MCP-1 is an expensive version of 
measuring proteinuria.  More investigation needs to be done to validate the advantage of 
measuring urinary MCP-1 over conventional markers, such as serum creatinine or proteinuria, in a 
bigger cohort of patients with different renal diseases.  
1.3.1.2  Macrophage Migration Inhibitory Factor (MIF) 
The biological activity of MIF was first described back in 1966 when the 12.5 kD protein was said 
to be “highly conserved and structurally unique” (David 1966). In 1989 it was cloned and since then 
studies using recombinant human MIF neutralizing antibodies and MIF-deficient mice have helped 
define the role of MIF in both the innate and adaptive immune responses (Calandra, Bernhagen et 
al. 1994, Bacher, Metz et al. 1996). MIF exists preformed in macrophages, T cells and the 
corticotrophic cells of the anterior pituitary gland and can act as a physiological counter-regulator 
of glucocorticoid action within the immune system.  
A pathogenic role for MIF has been established in experimental models of arthritis and uveo-
retinitis (Mikulowska, Metz et al. 1997, Leech, Metz et al. 1998, Kitaichi, Matsuda et al. 2000).  It 
has been shown that it is expressed by many cell and tissue types (skin, pituitary gland, testes, 
pancreas, eosinophils, macrophages) (Nishino, Bernhagen et al. 1995, Meinhardt, Bacher et al. 
1996, Waeber, Calandra et al. 1997, Rossi, Haslett et al. 1998, Steinhoff, Meinhardt et al. 1999).  It 
has a pathogenic role in experimental kidney disease.  MIF mRNA and protein is constitutively 
expressed in many cells in the normal kidney, including glomerular and tubular epithelial cells, 
endothelial cells, fibroblasts and vascular smooth muscle cells (Lan, Mu et al. 1996, Lan, Yang et 
al. 2000). Up-regulation of MIF is found in both human and experimental kidney disease including 
renal allograft rejection (Lan, Mu et al. 1996, Lan, Yang et al. 1998, Lan, Yang et al. 2000). It 
contributes significantly to macrophage and T-cell accumulation and progressive renal injury.  MIF 
has many mechanisms of action; it is a stress factor, a pro-inflammatory cytokine, a growth factor 
and a hormone.  It mediates renal injury through the innate and adaptive immune systems, the 
induction of cytokines, chemokines and adhesion molecules as well as interactions with 
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glucocorticoids and the hypothalamic-pituitary-adrenal axis (Lan 2008). Its functional importance in 
experimental kidney disease has been demonstrated with the use of anti-MIF antibody preventing 
and reversing renal injury in crescentic anti-GBM glomerulonephritis (Lan, Bacher et al. 1997). 
Mice null for MIF are protected against immune mediated lupus nephritis (Hoi, Hickey et al. 2006). 
MIF exerts its biological activities via signalling through its CD74 (MHC Class II) / CD44 receptor 
complex to activate downstream ERK 1/2 MAP Kinase. This also requires Src Tyrosine Kinase 
(Shi, Leng et al. 2006). Upregulation of MHC class II and CD44 is found in diseased kidney 
glomerular cells and tubulo-interstitial cells as well as in infiltrating macrophages and T-cells and 
correlates with renal scarring (Kirimca, Sarioglu et al. 2001). 
MIF is a pro-inflammatory cytokine, but what makes it unique compared with other inflammatory 
cytokines (eg. IL-1,TNF-α), is that it exists preformed and stored in the cytoplasm of macrophages 
and the other intrinsic cells of the kidney.  MIF is released after stimulation by cellular stress, 
endotoxin, exotoxin, infection, inflammation and immune responses.  Once released, MIF induces 
expression of other inflammatory cytokines/mediators (IL-1,2,6,8, TNF-α, INF-γ), with these further 
inducing inflammatory and immune responses.  This illustrates the role MIF has as a critical 
mediator sitting upstream from the inflammatory cascade.  It has been shown that when anti-MIF is 
administrated in experimental anti-GBM glomerulonephritis it prevents and reverses disease in 
association with a marked reduction of pro-inflammatory cytokines including IL-1 and TNF-α (Lan, 
Bacher et al. 1997, Yang, Nikolic-Paterson et al. 1998). 
Unlike the other pro-inflammatory cytokines that are inhibited by glucocorticoids, MIF is induced by 
glucocorticoids and acts as an antagonist of glucocorticoid action within the immune system (figure 
3). 
  
	   68	  	  
 
Figure 3:  Role of MIF in the inflammatory cascade.  MIF is rapidly released from intracellular reservoirs in response to 
renal injury and steroids.  Once released it induces IL-1 and TNF-α which then stimulate further MIF production.  It also 
blocks the effects of glucocorticoids to further promote inflammation (Lan 2008). 
 
The process of glucocorticoid induced MIF secretion is tightly regulated and follows a bell-shaped 
dose-response curve, indicating that MIF release is inhibited at high anti-inflammatory 
concentrations of glucocorticoids (Calandra, Bernhagen et al. 1995). It has been hypothesized that 
MIF induced renal injury may be associated with an antagonistic action upon the anti-inflammatory 
and immunosuppressive effects of glucocorticoids (Lan 2008). The mechanisms by which MIF may 
antagonize glucocorticoids has been summarized by Flaster et al. in 2007:   
1. MIF upregulates cytoplasmic phospholipase A2 (an important target for the anti-
inflammatory actions of glucocorticoids). 
2. MIF may antagonize the anti-inflammatory inhibition of NF-κB. 
3. MIF antagonizes glucocorticoid induction of MAP kinase phosphatase therefore up 
regulating the MAP-kinase associated inflammatory response (Flaster, Bernhagen et al. 
2007). 
Brown et al. in 2002 published their results looking at whether urinary MIF could be measured in a 
reliable manner using Enzyme Linked Immunosorbent Assay (ELISA). They looked at the 
correlation between urinary MIF / serum MIF / MIF expression in histological samples and 
glomerular disease activity and found a significant correlation between the urine MIF concentration 
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and renal MIF expression, but not with serum MIF, indicating a renal origin for the excreted urine 
MIF.  The urine MIF concentration also correlated with the degree of renal dysfunction, histologic 
damage, and leucocytic infiltration, but not with the amount of proteinuria.  They concluded that 
urine MIF concentration is significantly increased in proliferative forms of GN and correlates with 
the degree of renal injury. Urine MIF levels reflect MIF expression within the kidney and may be a 
useful non-invasive tool for monitoring patients, particularly those with crescentic GN and 
particularly in disease exacerbation (Brown, Nikolic-Paterson et al. 2002). 
In summary MIF is biologically and clinically relevant to disease pathogenesis although not all the 
details are completely clear as yet. Using ELISA, it has been shown to be simple to measure in a 
robust and reproducible manner and in preliminary studies done so far on small cohorts of patients 
it has been shown to accurately reflect changes in disease activity.  In contrast with MCP-1 urinary 
MIF did not correlate with proteinuria.  Therefore with a large cohort of well-defined patients it may 
be possible to validate MIF as a urinary biomarker of lupus nephritis activity.  Also, given its unique 
relationship with glucocorticoids, evaluating its usefulness in a group of patients treated with a 
steroid-sparing regimen may provide a clearer indication of the role of MIF in the pathogenesis of 
LN without the influence of exogenous glucocorticoids. 
1.3.1.3 Other potential urinary biomarkers in LN. 
Interleukin (IL)-6, vascular cell adhesion molecule (VCAM)-1, CXCL16, IP-10 and a novel tumor 
necrosis factor (TNF) superfamily member, TNF-like weak inducer of apoptosis (TWEAK) have all 
been put forward as potential urinary biomarkers in LN.  When assessed against the biomarker 
criteria: they are all biologically plausible, they mostly accurately reflect changes in disease activity 
and they vary in how simple they are to measure (Reyes-Thomas, Blanco et al. 2011).  As urinary 
biomarkers they currently are not making their way into clinical practice, however some (such as 
TWEAK) are being targeted by novel treatments currently being used in early clinical trials.  In the 
process of assessing their suitability as biomarkers new insights into pathophysiology can be 
gained.  
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1.3.2  Disease Biomarkers in IMN 
1.3.2.1  Anti-M-type Phospholipase A2 Receptor  
Role in Diagnosis 
Since the publication of the seminal paper by Beck et al. in 2009 first describing anti-PLA2R 
antibodies much more work has been done to find clinical correlations with the concentration of 
circulating anti-PLA2R antibodies. Anti-PLA2R antibodies are consistently identified in 
approximately 70% of patients with what has clinically and histologically been labeled as IMN 
(Beck, Bonegio et al. 2009, Hofstra, Beck et al. 2011, Bech, Hofstra et al. 2014). A not insignificant 
rate of positivity has also been found in patients with cancer associated secondary MN; Qin et al. 
found a 30% positivity rate in this population (Qin, Beck et al. 2011). It therefore remains important 
to exclude secondary causes in all patients regardless of whether they have detectable anti-
PLA2R antibodies. 
Role in Monitoring Disease Activity and Response to Treatment 
From the 2011 Hofstra publication, a correlation between anti-PLA2R antibody levels, clinical 
status and proteinuria was also found, however there were only 54 samples from 18 patients.  
Beck et al. then went on to publish a correlation of anti-PLA2R antibody depletion with remission in 
patients treated with Rituximab and showed a 59% and 88% PR at 12 and 18 months respectively 
in those who had a decline or depletion of anti-PLA2R antibodies within 12 months of treatment 
with Rituximab compared with 0 and 33% in those with persistent anti-PLA2R antibodies (Beck, 
Fervenza et al. 2011).  More recently Bech et al. published data on the relationship between anti-
PLA2R antibody positivity and response to treatment.  They used historic serum samples from 48 
patients who had previously been identified as IMN and had been treated with CYP or MMF in 
combination with corticosteroids.  At baseline 71% (34 patients) of their population had detectable 
antibodies and treatment resulted in a rapid decrease in antibody titre.  They did not find a 
correlation between antibody level at baseline and treatment response, however they did find that 
antibody status at the end of treatment predicted long term outcome.  Of the 34 patients who were 
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antibody positive, 24 were antibody negative at the end of treatment and at 5 years 58% of those 
24 patients remained in a persistent remission whereas all of those who had persistent antibodies 
had relapsed by 2 years (Bech, Hofstra et al. 2014). 
Immunohistochemical staining for PLA2R  
In 2012, immunohistochemical analysis for PLA2R on renal biopsies with membranous 
nephropathy correlated with circulating anti-PLA2R antibodies and therefore indicated that it may 
be an effective tool for identifying patients with IMN.  Biopsies from 88 patients with a diagnosis of 
MN were examined.  61 patients stained strongly positive for PLA2R; 60 of those patients had 
detectable circulating anti-PLA2R antibodies.  Interestingly they also stained kidneys from normal 
individuals and from those with other glomerular injuries and both groups were found to have only 
a faint positivity (Hoxha, Kneissler et al. 2012). 
Anti-PLA2R Antibodies post-Transplantation 
In 2012 Debiec et al. described the identification of circulating IgG3 anti-PLA2R antibodies in a 
case of recurrent membranous nephropathy post-transplantation. The patient previously known to 
have IMN was biopsied on day 13 post-transplantation and histology demonstrated granular 
staining for C3, C5b-9, C1q and IgG3, with electron microscopy confirming subepithelial deposits.  
They were then able to demonstrate that the glomerular deposits contained PLA2R and then 
confirmed the patient had circulating IgG3 anti-PLA2R antibodies.  After treatment with Rituximab 
the patient’s proteinuria and creatinine both stabilized and the circulating PLA2R antibodies 
became undetectable (Debiec, Hanoy et al. 2012). In 2013 Larsen et al. described how staining for 
anti-PLA2R was useful in determining recurrent MN from de novo MN in transplant recipients.  
They identified 22 patients with a histological diagnosis of MN in their transplanted kidney. 12 of 
the 22 had IMN as their native disease and the remainder had an alternate native disease. 83% of 
patients with IMN as their native disease stained strongly for PLA2R on their transplant biopsy 
compared with only 8% of those with de novo MN (Larsen and Walker 2013). 
Summary 
With the information currently available, assessing for anti-PLA2R antibodies is certainly 
biologically plausible and moreover relevant to disease pathogenesis as it has been shown to 
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accurately reflect changes in disease activity. However the methodology is not a simple one for 
routine clinical use. 
This thesis discusses the ease of use of the first commercially available kit for the detection of anti-
PLA2R antibodies and the preliminary results in the MTac trial patient population.  
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1.3.3  Discovery of new biomarkers 
Part of the role of looking for relevant biomarkers is the journey to reach an understanding of their 
biological role and to look at them as a potential target for therapy.  There is an abundance of 
cytokines that could potentially have a role in the pathogenesis of LN and therefore be potential 
clinical biomarkers.  To go from the cytokine to the disease can often take much longer and be 
much less fruitful if in the end the cytokine chosen is found not to be clinically relevant.  The other 
method is to do a reverse approach from the disease back to the cytokine, which may well be more 
fruitful and may lead back to novel biological pathways.  There are now commercially available 
multiple cytokine arrays, where well chosen “cases” and “controls” can be examined to see if there 
are any cytokines that are clearly more active in some disease processes than others.  If a distinct 
pattern is discovered in this way, further work can subsequently be done to confirm and strengthen 
the findings.   
By identifying a cohort of patients at diagnosis where the intention is to treat with a predefined 
protocol, it minimises the variables when attempting to analyse the biomarker once treatment is 
initiated.  In this way the use of a multi-cytokine array to identify novel cytokines from the urine of 
patients with active LN, treated with the novel steroid sparing regimen, is described, along with the 
validation work done on the novel cytokine identified. 
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SUMMARY, AIMS AND HYPOTHESES 
 
 
In summary, both Idiopathic Membranous Nephritis and Lupus Nephritis are complex relapsing 
autoimmune conditions.  Despite the advances in treatment and diagnosis over the past 50 years; 
the gold standard diagnostic test, renal biopsy, has an associated morbidity in itself. The current 
biomarkers available are crude and nonspecific and the current treatment regimens have long-term 
side effects that are undesirable.  In short we should be doing better. 
 
Aims of this Thesis 
 
1. To explore the outcomes of new steroid sparing treatment regimens in both LN (Rituxilup 
regimen) and IMN (Tacrolimus Monotherapy), and to discuss their relevance to new and 
ongoing trials. 
2. To describe the rationale, enrolment and monitoring of a single centre RCT in IMN (MTac 
trial). 
3. To assess the validity of a previously described urinary biomarker (MIF) in LN using clinical 
data from a well described cohort. 
4. Demonstrate the use of a discovery method to identify and validate a new urinary 
biomarker (Angiogenin) in LN. 
5. Assess a new commercially available kit for ease of use in the clinical setting for 
identification of serum anti-PLA2R antibodies in patients enrolled in the MTac trial with 
biopsy proven IMN. 
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Hypotheses 
 
1. Lupus Nephritis can be treated effectively with a steroid-sparing regimen. 
2. Tacrolimus Monotherapy can be an effective long-term treatment for Idiopathic 
Membranous Nephropathy. 
3. Urinary MIF is a valid biomarker of Lupus Nephritis Activity. 
4. Through a discovery method it will be possible to identify and then validate a novel urine 
biomarker.  
5. Serum anti-PLA2R antibodies levels act as a biomarker for Idiopathic Membranous 
Nephropathy that can be used in routine clinical practice. 
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CHAPTER 2:  MATERIALS AND METHODS 
The methods and materials involved in all aspects of the thesis will be discussed in this chapter.  
Firstly, the data collection for the analysis of the novel treatment regimens will be described.  The 
steroid-sparing regimen in LN (Rituxilup) was done in a prospective manner with outcomes defined 
at inception.  The analysis of long-term tacrolimus monotherapy in IMN was done in a retrospective 
manner with outcomes according to the results that were found.  Then the RCT in IMN – the MTac 
trial – is discussed along with the rigorous prospective data collection and safety monitoring 
associated with an RCT.   
Secondly, the methods and analysis of the disease biomarkers will be described.  This includes the 
correlation of the urinary cytokines with clinical outcomes. The description of the discovery 
cytokine array and the anti-PLA2R antibody Indirect Immunofluorescence test is discussed and the 
samples from the patients in the MTac trial described. 
 
2.1  Novel Treatment Regimens in Glomerulonephritis 
This is divided into three sections.  Firstly, the prospective data collection and analysis for cohort of 
patients treated with the steroid sparing Rituxilup regimen.  Secondly, the retrospective review of 
the use of long-term tacrolimus monotherapy for the maintenance of remission in patients with 
IMN.  Lastly, the Mtac trial will be described and discussed, including the trial protocol, enrolment, 
data collection and monitoring. 
2.1.1 Steroid Sparing Regimen for the Treatment of Lupus Nephritis 
The Renal Department at Imperial College Healthcare and NHS Trust (ICHNT) opened in 2005 as 
a result of the merger of Charing Cross, Hammersmith and St. Mary’s renal units.  It is the largest 
renal centre in the UK with >3000 RRT patients and a catchment population approaching 2.5 
million.  It has a cross disciplinary Lupus Centre treating multi system disease relating to SLE.   
As a result of the published success that had already been shown with steroid sparing regimens in 
transplantation and with increasing evidence of the effectiveness of rituximab in LN a new 
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treatment protocol was devised.  It was designed and agreed by the Glomerulonephritis Clinical 
Research Group at ICHNT. All the elements of the protocol had been used previously for the 
treatment of lupus nephritis, but not in this specific combination. It was adopted at the outset of the 
cohort as the standard treatment protocol for all patients with lupus nephritis who were not 
currently taking oral steroids and who did not have cerebral or other life-threatening forms of lupus.  
2.1.1.1 Patient Population 
Inclusion Criteria 
From 1st January 2006 until 1st November 2010, all patients at the WLRTC with biopsy proven 
active ISN/RPS class III, IV, or class V lupus nephritis, not taking long-term oral steroids, were 
treated with the new “Rituxilup” protocol.  All patients had at least 12 months follow-up. 
Exclusion Criteria 
Patients were excluded if they had previously received rituximab; had life threatening 
complications (e.g.: cerebritis); had a rapidly progressive glomerulonephritis or required renal 
replacement therapy.  
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2.1.1.2 RITUXILUP Protocol 
Treatment Regimen 
Days 1 and 15:   
Rituximab 1g and IV Methyl Prednisolone 0·5g. 
From Day 1:  
MMF, initially 500mg BD, titrated (to a maximum dose of 1·5g BD) to 12 hour trough 
mycophenolic acid (MPA) levels of 1·2 – 2·4 mg/L, providing leucocyte count and 
gastrointestinal symptoms (i.e. no side effects) allowed.  
Maintenance: 
Mycophenolate Mofetil 500mg BD initially, dose increased to 1g BD in stages, and 
then reduced if 12 hour trough mycophenolic acid levels >2.4mg/l 
Hydroxychloroquine 200mg BD (start at 200mg OD and increase after 1 week) 
Prednisolone may be required in patients with extra-renal disease or in patients 
already on maintenance prednisolone. Prednisolone was intended to be withdrawn 
over two months where possible. 
Adjuvant therapy: 
  Angiotensin receptor blocker (ARB) +/- Angiotensin converting enzyme inhibitor  
  (ACEI)  
Statin to maintain cholesterol < 4mmol/L 
  Clexane 20mg OD if Albumin < 20g/L 
Aspirin 75mg OD if Albumin > 20g/L 
Proton pump inhibitor if on aspirin 
Penicillin V 250mg BD – if patient is persistently hypocomplementaemic 
South Asian:  Isoniazid 150mg OD and Pyridoxine 50mg weekly 
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If patients were non-responsive to maintenance therapy or were rapidly deteriorating or develop 
cerebral involvement, a clinical decision would be taken as to whether an alternative treatment 
regimen would be more appropriate.   
Investigations: 
At baseline:   
  Full Blood Count (FBC), Urea and Electrolytes (U&Es), Liver Function Tests (LFTs)  
Serum Immunology:  double stranded DeoxyriboNucleic Acid (dsDNA); Anti Nuclear 
Anitbodies (ANAs); Extractable Nuclear Anitbodies (ENAs); Complements (C3 and 
C4); Immunoglobulins (Igs); Lymphocyte Subsets (including CD20 positive B-cells).   
Viral screen: Hepatitis B & C, Cytomegalovirus (CMV), Epstein Barr Virus (EBV), 
Varicella Zoster Virus (VZV).    
Human Immunodeficiency Virus (HIV) (with consent) 
Complete urinalysis and microscopy and PCR. Ideally this was completed on day of 
biopsy and first day of therapy.  
Week 2 and 3: 
FBC, U&Es and lymphocyte subsets 
Urinalysis and microscopy and PCR 
Week 4 
Repeat immunology: ds DNA. C3, C4, Immunoglobulins, lymphocyte subsets.  
FBC, U&Es and B cell count 
Urinalysis and microscopy and PCR 
 
Immunology was repeated monthly, thereafter. 
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Follow up 
The interval at which patients were seen in the follow up clinic was determined by their clinical 
response.  Once patients were in a stable complete remission their appointments were extended to 
a maximum of eight-weekly intervals. 
2.1.1.3  Definition of Remission and Relapse 
Complete biochemical remission (CR) was defined by the combination of a urine protein:creatinine 
ratio (PCR) of less than 50mg protein/mmol creatinine and serum creatinine no greater than 15% 
above baseline.  
 
Partial remission (PR) was defined by a urine PCR <300 mg/mmol, i.e. non nephrotic, with a >50% 
reduction from baseline and serum creatinine no greater than 15% above baseline. 
 
At 12 months, patients with urine PCR > 50mg/mmol and proteinuria that was not displaying an on-
going decline on consecutive measurements underwent a further renal biopsy. Those with inactive 
disease on biopsy (evidenced by the absence of active class III or IV lesions on light microscopy 
and the absence of new sub-epithelial deposits on EM) were defined as being in histological 
remission (HR) and were not offered augmentation of their immunosuppression.   
 
Relapse was defined as a persistent increase of >30% in serum creatinine or proteinuria.  
B-cell counts were measured by CD20 flow cytometry with B-cell depletion defined as CD20+ <5 
cells/mL. 
2.1.1.4  Data Collection 
All data was collected in an anonymous prospective manner.  Data to be collected was decided at 
the point of initiation of this treatment regimen.  The outcome data was presented at national and 
international conferences.  All the data was stored in an anonymous fashion in a password-
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protected spreadsheet on a NHS trust computer.  Some retrospective data did require gathering to 
clarify changes in treatment regimens and adverse events. 
2.1.1.5 Statistical analysis 
Continuous variables are expressed as median (Range or Inter Quartile Range (IQR) where 
stated). Differences between groups and across first year time-points were analysed using one-
way Analysis of Variance (ANOVA) with Bonferroni Corrected Post Hoc tests, using log 
transformation and geometric mean for skewed variables. Time to remission or relapse was 
estimated by the Kaplan-Meier method, with differences between groups assessed with the log 
rank test. Results with p-values less than 0·05 were considered significant. Statistical analyses 
were performed using SPSS version 16·0 (SPSS Inc., Chicago, IL). 
2.1.1.6  Ethical Considerations 
This novel protocol was designed and agreed by the Glomerulonephritis Clinical Research Group 
at Imperial College Healthcare NHS Trust. As mentioned previously, all individual elements of the 
protocol had been used previously for the treatment of lupus nephritis, but this trial marked the first 
use of this particular combination of drugs. This was adopted at the outset of the cohort as our 
standard treatment protocol for all patients with lupus nephritis who were not currently taking oral 
steroids and who did not have cerebral or other life-threatening forms of lupus. It was not an 
experimental protocol, but was our standard clinical protocol and in discussion with the Chair of the 
local Research Ethics Committee it was agreed that therefore Ethics approval was not required. 
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2.1.2  Tacrolimus Monotherapy for the Treatment of Idiopathic Membranous 
Nephropathy 
A single-centre retrospective review of all patients who had received greater than 12 months 
treatment was undertaken.  It is already understood that tacrolimus monotherapy is a good agent 
for inducing remission in patients with IMN, however what was unknown was which patients 
benefitted from being maintained on longer term tacrolimus for maintenance of remission, the 
effect that this would have on renal function and whether there were any associated adverse 
events arising as a consequence of treatment. 
2.1.2.1  Patient Population 
This was a retrospective review of all patients between 2002 and 31st December 2012 with 
nephrotic syndrome and biopsy proven idiopathic membranous nephropathy treated with 
tacrolimus monotherapy for a period of > 12 months.  NS was defined as urinary Protein Creatinine 
Ratio (uPCR) >300mg/L (or >3g/L protein on urine dipstick or >3g/24hr urinary protein if uPCR not 
available) and serum albumin <33g/L.  If only Albumin Creatinine Ratio (ACR) available, this was 
converted to PCR as per Lamb et al. (Lamb, MacKenzie et al. 2009).  All patients were screened 
for secondary causes with lupus serology, hepatitis serology, CT chest/abdomen/pelvis and 
intraluminal investigations if indicated. 
Patients were identified in 3 different ways and then cross-referenced.  Initially, a historic list of 
patients from St. Mary’s Hospital who had previously been identified as having IMN and who had 
been treated with Tac were reviewed.  Next, a list of all patients with biopsy proven IMN was 
obtained from the histopathology database, where all biopsy diagnoses are coded.  Thirdly, a list of 
all patients having Tacrolimus levels measured was obtained from the Leslie Brent Laboratory, 
where all renal patients have their drug levels checked.  From this a provisional list of patients with 
MN who had been treated with Tacrolimus since 2002 was obtained.  To then ascertain that no 
secondary cause of the MN was found and to confirm the duration of their treatment, clinic 
correspondences, drug level monitoring and notes review were undertaken.  On notes review each 
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patient had a data collection proforma completed, to gather information regarding serial serum and 
urine biochemistry, trough Tacrolimus levels, histology, changes to treatment and adverse events. 
2.1.2.2  Treatment 
All patients received BD tacrolimus monotherapy titrated to target trough tacrolimus levels of 6-
8ng/ml.  The targeted BP for each patient was 125/75mmHg; this was achieved initially using ACEI 
and/or ARB as tolerated, additional antihypertensive agents were used if required.  Patients with 
an albumin of <20g/L received thromboprophylaxis with subcutaneous daily low molecular weight 
heparin unless otherwise formally anticoagulated. 
2.1.2.3  Outcomes 
Remission from nephrotic syndrome was subdivided into partial and complete.  A partial remission 
was defined as uPCR <300 mg/mmol (or dipstick <3g/L if uPCR not available) with a greater than 
50% decline in uPCR from baseline and an improving serum albumin.  A complete remission (CR) 
was defined as uPCR <50 mg/mmol (or dipstick <0.3g/L if uPCR not available) with a normal 
serum albumin.  A relapse was recognized if the uPCR was greater than 300 mg/mmol with a 
falling serum albumin on 2 consecutive measurements.  To be classified as a PR or CR, the uPCR 
and serum albumin targets had to be reached on at least two consecutive occasions. Renal 
function was assessed by regular measurements of serum creatinine. Time to death or starting 
renal replacement therapy for chronic renal failure was also analysed.  Adverse events that were 
recorded were new malignancies, new diagnosis of diabetes and deaths.    
2.1.2.4  Follow-Up 
Patients were followed up in nephrology clinic at intervals appropriate to their clinical condition.  
BP, urine analysis and weight were documented at each visit.  Serum biochemistry and full blood 
count were sent at the time of the appointment or during the previous week.  It was routine practice 
to measure a 12-hour trough tacrolimus level at each clinic visit and the tacrolimus dose altered 
appropriately. 
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2.1.2.5  Tacrolimus levels 
Twelve hour trough tacrolimus levels were measured at each clinic visit.  Tacrolimus dose was 
titrated according to the level to achieve a trough level of 6-8ng/L.  If a patient did not show a 
response with trough levels in this range, with preserved renal function, they would have their 
levels titrated to 8-12ng/L. 
2.1.2.6  Rebiopsies 
All re-biopsies were reviewed and reported.  Indications for rebiopsy were classified as: a) non-
response; b) nephrotic relapse; c) rising creatinine and d) pre-withdrawal of tacrolimus.  The 
results of the biopsies were also analysed based upon the biochemical markers at the time the 
biopsy was taken. 
2.1.2.7  Ethical Considerations 
This was a retrospective review of clinical practice.  Data was collected and stored in an 
anonymous fashion.  No formal ethical approval was required. 
2.1.2.7  Statistical Analysis 
Continuous variables are expressed as median (IQR or Range where stated). Results with p-
values less than 0·05 were considered significant. Time to remission was estimated by the Kaplan-
Meier method.  Statistical analyses were performed using GraphPad Prism version 6.00 for Mac 
(GraphPad Software, San Diego California USA, www.graphpad.com). 
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2.1.3  Randomised Controlled Trial in IMN – MTac Trial 
This was a single centre RCT designed to investigate if combining mycophenolate mofetil (MMF) 
with tacrolimus has a beneficial effect over tacrolimus therapy alone in the treatment of IMN. 
Tacrolimus monotherapy has been shown to be effective in producing remission from heavy 
proteinuria but patients often relapse when the tacrolimus is withdrawn. This trial was designed to 
investigate whether the addition of MMF allows the subsequent withdrawal of tacrolimus without 
precipitating relapse. A secondary outcome measure will be whether the addition of MMF to 
standard therapy with tacrolimus will be more effective in obtaining remission of proteinuria and 
preserving renal function. 
2.1.3.1 Trial Investigators 
The trial was designed by Dr. Megan Griffith in consultation with the Glomerulonephritis research 
group at the ICHNT.  The principle investigators were Dr. Megan Griffith (Principal Investigator or 
PI), Dr. Tom Cairns and Dr. Neill Duncan.  In 2009 ethical approval was given and the enrolment 
commenced.  As a clinical research fellow I contributed to the data collection, patient education, 
consenting patients and it was my responsibility to present the monthly safety reports to the 
glomerulonephritis research group in its role as the safety monitoring committee.  I also designed 
the Case Report Form (used to collect all data prospectively after each clinic visit) in accordance 
with data required for trial outcomes (See Figure 4). 
To contribute to the trial in this way I obtained my Good Clinical Practice (GCP) qualification.  The 
data that I collated monthly was collected via the Case Report Forms (Figure 4).  I collected and 
presented all data in an anonymous fashion, reporting all adverse events, serious adverse events 
(SAE) and patient recruitment.  I also assisted the PI when she was reporting Serious Adverse 
Events (SAE) and Suspected Unexpected Serious Adverse Reactions (SUSAR) to the trial 
sponsor in the prerequisite 24 hours. 
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Figure 4: Case Report Form MTac Trial.  First two pages filled at enrolment.  Third page filled at each clinic 
visit. 
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2.1.3.2  MTac Trial Protocol 
Trial Design 
This is a randomized controlled trial in a single centre of tacrolimus alone vs tacrolimus and MMF 
therapy in 32 patients with heavy proteinuria secondary to idiopathic membranous 
glomerulonephritis diagnosed by renal biopsy. Initially recruitment was aimed at 32 patients (16 to 
each arm of the trial), however due to the loss of a number of patient to follow up and the need to 
switch some patients to alternative regimens for clinical reasons, an amendment was submitted 
and approved in 2013 to extend this to 40 patients (20 to each arm of the trial).  Recruitment 
commenced March 2009 and final data collection date for primary outcome measure has been set 
as February 2016. 
Inclusion criteria (requires all) 
1 .Idiopathic membranous glomeulonephritis on renal biopsy 
2.Proteinura – protein/creatinine ratio (PCR) >100 mg/mmol with hypoalbuminaemia or PCR >300 
mg/mmol with normal serum albumin despite 3 months treatment with maximum tolerated doses of 
ACEIs and ARBs (or shorter if life-threatening complications of nephrotic syndrome require 
institution of immediate immunosuppression.) 
3. Male or female patients aged 18 to 80 years. 
Exclusion Criteria 
1 Hepatits B hepatitis C or HIV positive 
2 Malignancy (all patients must have had a CT chest, abdomen and pelvis and other investigations 
if clinically indicated). 
3. Untreated infection 
4. Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically 
acceptable form of contraception. 
5. Any condition judged by the investigator that would cause the study to be detrimental to the 
patient. 
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Trial Protocol 
The research is being conducted via the glomerulonephritis clinic at Hammersmith Hospital. All 
patients with significant proteinuria secondary to membranous glomerulonephritis on renal biopsy 
are being considered for the trial. Patients are normally screened for hepatitis B, C and HIV, and 
undergo CT chest, abdomen and pelvis to exclude viral and malignant causes for their 
membranous nephropathy (these are the current standard investigations in all patients with 
membranous nephropathy.) All patients are initially treated with maximum tolerated doses of 
ACEIs and ARBs for at least 3 months as is standard current treatment. Patients who remain 
significantly proteinuric (PCR>100 mg/mmol with hypoalbuminaemia or PCR >300 mg/mmol with 
normal serum albumin) despite treatment with maximum tolerated doses of ACEIs and ARBs have 
a consultation discussing the trial and once consent is obtained are randomised to receive 
tacrolimus monotherapy or tacrolimus in combination with MMF therapy. The initial dose of 
tacrolimus is 2mg twice a day and this is titrated to achieve levels of 5-12 ng/ml. The initial dose of 
MMF is 500mg twice a day, and this is titrated to achieve mycophenolic acid levels of 1.5-3.0 mg/L. 
Patients with a previous history of tuberculosis, or deemed at high risk due to Asian origin will 
receive isoniazid 150mg once a day and pyridoxine 50mg once a week. 
Treatment is initially for 1 year. Remission of proteinuria will be defined as complete if urinary PCR 
<30 mg/mmol, and partial if urine PCR decreases by >50% but is still above 30 mg/mmol. Patients 
not obtaining complete or partial remission after 1 year will be withdrawn from the trial and 
alternative therapies considered.  When patients have been in remission for 12 months on 
treatment the tacrolimus is withdrawn over 6 months. Those on MMF and tacrolimus will then have 
their MMF stopped prior to tacrolimus withdrawal over 6 months. Patients will be offered a renal 
biopsy prior to withdrawal of therapy. This will help predict relapse and show any evidence of 
tacrolimus toxicity, which may help guide subsequent therapy in the case of relapse. Continuation 
in the trial is not dependent on undergoing renal biopsy. Patients will be followed for at least 3 
years. Patients may withdraw from the trial at any point without any compromise to their clinical 
care.  Trial protocol summarized in figure 5. 
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Evaluations 
The patients will initially be seen weekly until stable and then monthly until remission is achieved. 
They will then be reviewed 2-3 monthly for the rest of the trial depending on clinical need. At each 
clinic visit blood samples are sent for full blood count, U&Es and drug level monitoring.  Urine 
samples are sent for PCR.  
 
Withdrawal and treatment failure 
Patients can be withdrawn at patient or physician request. The reason for withdrawal will be 
recorded in the patient’s records. 
Patients not achieving remission at 1 year will be withdrawn from the trial and alternative 
treatments considered. They will remain under follow up in the clinic as is current standard 
practice. 
 
Primary Endpoint 
Efficacy of MMF in preventing relapse of nephrotic syndrome on withdrawal of tacrolimus therapy. 
This will be initially measured at 6 months post withdrawal of tacrolimus therapy. 
Secondary end points  
The time to obtaining remission from proteinuria 
The degree of remission of proteinuria obtained (complete or partial) 
The rate of decline of renal function measured by the MDRD equation for glomerular filtration rate 
 
Statistical Analysis  
As declared in initial Trial Protocol:  This will be carried out under the direction of Mr Bernard North 
-Statistics department Imperial College London. The sample size was based on the main outcome 
measure, time to relapse, and compared using a 1-sided log rank test assuming a 1% drop-out 
rate and a 50% survival rate in the tacrolimus group and a 95% survival rate in the tacrolimus and 
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MMF group with an alpha level of 0.05 and 80% power. The NCSS PASS package was used. 
Hintze J (2004) Number Crunching Statistical Systems (PASS). The statistical analysis will be 
done by using a 1 sided log rank test. 
 
Duration 
This was initially calculated as 5 years, with 24 months recruitment and 36 months follow up, 
however this has been extended to 7 years as recruitment has been extended from 32 patients to 
40 patients.  Primary end points will be analysed when patients obtaining remission for 1 year have 
stopped tacrolimus therapy for 6 months. Secondary end point analysis of response to treatment 
will occur when patients have been on treatment for 12 months. 
 
Adverse Events and Data Monitoring 
It is anticipated that the treatment will be well tolerated as this regimen has been extensively used 
in renal transplant recipients. All adverse events are actively sought and recorded in the patients’ 
notes and on the case report forms. The data and progress of the trial is reported to and monitored 
by the West London Renal and Transplant Glomerulonephritis Research Group at Hammersmith 
Hospital on a monthly basis. 
All Serious Adverse Events (SAE) and Suspected Unexpected Serious Adverse Reactions 
(SUSAR) are reported within 24 hours to the committee chairman Prof Liz Lightstone and to the 
sponsor, Dr Robina Coker, i.e all events irrespective of their relation to study medications, that are 
either life threatening, result in hospitalization, result in death, result in persistent or significant 
disability or incapacity. The sponsor then reports any such SAE or SUSAR to the regulatory 
authority in accordance with the European Directive 2001/20/EC. 
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Entry (eligibility criteria) 
↓ 
Randomisation 
(20 patients per limb) 
↓      ↓ 
Tacrolimus 2mg BD     MMF 500mg BD 
adjusted to obtain levels of 5-11 adjusted to obtain levels of 1.5-3.0 and 
Tacrolimus 2mg BD adjusted to obtain levels of 5-11 
 
(treatment for minimum 12months maximum 24 months) 
↓ 
Patients in remission for 12 months 
↓       ↓ 
Stop MMF 
Withdrawal of tacrolimus over 6 months       Withdrawal of tacrolimus over 6 months 
 
↓ 
Monitor patients for relapse of nephrotic syndrome 
 
Figure 5:  MTAC Trial Overview 
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2.2 Disease Biomarkers in Glomerulonephritis 
Disease biomarkers were examined in both LN and IMN.  Three different biomarkers were 
examined two previously described and one novel: urinary MIF in LN (previously described); 
urinary Angiogenin in LN (novel) identified using a discovery method and serum anti-PLA2R 
antibodies in IMN (previously described).  Urinary MIF and urinary Angiogenin had been measured 
using ELISA methodology in a blind fashion in >1100 urine samples from patients with LN; the 
results from patients where clinical and biochemical outcomes were available were correlated with 
histology, clinical response and treatment regimen.  Anti-PLA2R antibodies are thought to be the 
pathogenic antibody in IMN; the seminal publication used Western Blot technique to identify the 
antibodies, which for a clinical biomarker is a very labour intensive technique. A new indirect 
immunofluorescence technique that is now commercially available for use in the clinical setting 
was tested and assessed.  This was done on the serum of patients with biopsy proven IMN 
enrolled in the centre based MTac trial.  
 
2.2.1 Urinary Biomarkers in Lupus Nephritis 
2.2.1.1 Collection and Storage of Urine Samples  
Collection of urine samples commenced at the beginning of 2005 and continued to the end of 
2009.  When possible the samples were collected at the time of biopsy, at all clinic appointments 
and prior to treatment.  The fresh urine was stored at 4°Centigrade (C) for a maximum of 24 hours 
before processing.  A 1ml aliquot was analysed for urine creatinine.  The urine was centrifuged at 
3000 Revolutions Per Minute (RPM) for 10mins to separate debris.  The urine was formed into 
aliquots and stored at -80°C.  It was also intended that for each urine sample processed a urine 
protein creatinine ratio was measured from the same urine sample.   
2.2.1.2 Data from the measurement of Urinary MIF by Enzyme-Linked Immunosorbent Assay  
In total uMIF was measured by ELISA (R&D Systems cat. DY289 see Appendix 1 for detailed 
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methods) in 1140 urine samples with LN.  From those 1140, 587 were identified as being from 59 
patients with documented biopsy proven ISN/RPS class III/IV/V LN.  33/60 had been treated with 
the previously described steroid sparing Rituxilup regimen; 17/60 had been treated with Rituximab 
+ MMF + weaning dose of oral steroids (Rituxirescue regimen) and 9/60 received MMF +/or 
cyclophosphamide + steroids (Other).  uMIF levels had been normalised for urinary creatinine. 
We investigated:   
1.  The relationship between uMIF/creat +/- 5 wks of biopsy and uMIF/creat in samples collected at 
26-52 wks post biopsy.  The samples collected at 26-52 wks post biopsy were subdivided into:  
complete remission (CR=uPCR<50mg/mmol with a <15% rise in serum creat); partial remission 
(PR=uPCR 50-300mg/mmol) and no remission (NR=uPCR>300mg/mmol). (See figure 6). 
2.  The difference in uMIF/creat (at presentation and during follow up) between patients on 
maintenance steroids and those who had been treated with a steroid sparing regimen. 
 
 
 
Figure 6:  Flow diagram of uMIF analysis.  RL= Rituxilup regimen; RR=Rituxirescue regimen; 
Other=Cyclophosphomide+/-MMF+oral steroids. 
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2.2.1.3  Statistical Methods 
Continuous variables are expressed as median (IQR or Range where stated).  Correlation was 
calculated using Spearman Rank. Differences between levels according to disease activity were 
analysed using Kruskal-Wallis non-parametric ANOVA and significance calculated by Dunn’s 
Multiple Comparison test.  Results with p value less than 0·05 were considered significant. 
Statistical analyses were performed using SPSS version 16·0 (SPSS Inc., Chicago, IL) and 
GraphPad Prism version 6.00 for Mac (GraphPad Software, San Diego California USA, 
www.graphpad.com). 
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2.2.2 Discovery Approach to Novel Urine Cytokine Detection 
The discovery method used was a Human Cytokine Array (RayBiotech Human Cytokine Array 
C2000(RayBiotech, Inc. Norcross GA 30092. USA)).  This was chosen as we could screen for as a 
diverse selection of cytokines/related proteins (174 in total) in a single sample (The full list 
available in table 2).  Included in the array were cytokines with previous published correlation with 
Lupus Nephritis such as MCP-1.  
 Urine samples from individual patients were individually screened for the presence of novel 
cytokines with this technique. Arrays membranes were incubated with 1.2mls of undiluted spot 
urine samples, according to the manufacturer’s protocol. Membranes were then exposed to Kodak 
x-omat film at room temperature. Each cytokine was assayed in dot represents a cytokine in 
duplicates with the same array (Figure 7). 
 
Figure 7:  The principles of the methods of the cytokine array. 
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Table 2: Detail of Discovery Cytokine Array: Human Cytokine Antibody Array Series 2000 that includes MCP-1 
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Urine from 8 patients was individually screened for the presence of novel cytokines with this 
technique. 
• 2 patients with active Class IV LN prior to any treatment being given 
• 2 patients with active Class V LN prior to any treatment being given 
• 2 patients with Class IV LN in complete remission 
• 2 patients with proteinuria due to primary Focal Segmental Glomerular Sclerosis (FSGS) 
 
Array membranes were incubated with 1.2mls of undiluted spot urine samples, according to the 
manufacturer’s protocol. Membranes were then exposed to Kodak x-omat film at room 
temperature. Each cytokine was assayed in dot represents a cytokine in duplicates with the same 
array. High concentration of angiogenin was detected in the urine samples of patients with active 
lupus nephritis. 
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2.2.3 Validation of Discovery Array  
Specific ELISA had been performed to validate and quantify a novel cytokine discovered by the 
antibody array. Urine Ang (uAng) had been measured in 342 urine samples from 34 patients 
collected over a 4 year period, during which all patients had at least 1 episode of biopsy proven 
ISN/RPS Class III/IV/V LN treated with the same treatment protocol: the steroid sparing Rituxilup 
regimen.  For each urine sample there was a corresponding serum biochemistry, proteinuria 
quantification and frequently immunology profile.   
The exact methodology of the angiogenin ELISA is available in Appendix 2.  uAng levels were 
normalised for urinary creatinine (creat) level. 
2.2.3.1  Analysis of urinary Angiogenin concentration data 
Analysis was performed to assess the urine cytokines’ performance in relation to disease activity.   
33 samples were within +/- 5 weeks of diagnostic biopsy; 28 samples were within +/- 5 weeks of 
partial remission (PR=uPCR <300mg/mmol with a >50% reduction from baseline with <15% rise in 
serum creat) and 30 samples were within +/- 5 weeks of complete remission 
(CR=uPCR<50mg/mmol with <15% rise in serum creatinine). 
For this novel cytokine the following were investigated: 
a) The relationship between uAng/creatinine ratios and serum creatinine and urine 
protein/creatinine ratio (uPCR) in the samples taken within +/- 5 weeks of biopsy 
b) Relationship between disease activity and uAng/creatinine ratios.  
2.2.3.2  Satistical Methods 
Continuous variables are expressed as median (IQR or Range where stated).  Correlation was 
calculated using Spearman Rank. Differences between levels according to disease activity were 
analysed using Kruskal-Wallis non-parametric ANOVA and significance calculated by Dunn’s 
Multiple Comparison test.  Results with p values less than 0·05 were considered significant. 
Statistical analyses were performed using SPSS version 16·0 (SPSS Inc., Chicago, IL) and 
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GraphPad Prism version 6.00 for Mac (GraphPad Software, San Diego California USA, 
www.graphpad.com). 
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2.2.4 Phospholipase A2 Receptor Antibody Measurement 
In 2009 the seminal paper on the description of anti-PLA2R antibodies in IMN was published.  
They described how circulating IgG reactive to PLA2R was identified in the serum of patients with 
IMN using Western Blot technique. This technique can be time consuming, labourious and difficult 
to replicate, therefore unsuitable as a commercial kit.  Here the Indirect ImmunoFluorescence Test 
is described when used to test for anti-PLA2R antibodies in the plasma samples from patients 
enrolled in the MTac trial. 
2.2.4.1  Plasma Samples from patients enrolled in MTac trial 
The MTac trial had been enrolling since 2009 and this test was not available until 2012.  Pre 
treatment samples were available in some of these patients. The stored plasma samples were 
stored at -25 degrees centigrade within the storage facilities of the Leslie Brent Laboratory.  
Plasma was stored for testing at relevant clinical points, such as achievement of a CR or when it 
was thought the patient could be relapsing. 
2.2.4.2  Anti- Phospholipase A2 Receptor Indirect Immunofluorescence Test 
In 2011 an Indirect Immunofluorescence Test (IIFT) for anti-PLA2R antibodies became 
commercially available (Euroimmun©); this test had already obtained a CE mark from the 
European Economic Area (EEA), indicating the manufacturer’s assurance of validity for the test.  It 
was designed to qualitatively or semi-quantitatively determine human anti-PLA2R antibodies in 
serum or plasma.  The Anti-PLA2R IIFT kit makes use of cells transfected with human PLA2R 
contained in BIOCHIP slides.  These BIOCHIP slides are incubated with patients’ plasma (in our 
case) where antibodies (IgA, IgG and/or IgM) against PLA2R bind to the transfected cells if 
present. Through the binding of a fluorescein-labeled secondary antibody (Anti-Human IgG [Goat] 
~ FITC), which binds to the bound anti-PLA2R antibodies, a positive reaction is indicated by 
cytoplasmic fluorescence, with some fluorescence of the cell membrane made visible with a 
fluorescence microscope (Figure 9). 
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Kit Contents 
1. 10 Slides, each containing 5 x 2 BIOCHIPS coated with PLA2R-transfected and control-
transfected cells (figure 8). 
 
 
 
HEK 293 PLA2R-transfected   HEK 293 Control plasmid transfected     
Figure 8:  Detailed view of Euroimmun IIFT BIOCHIP 
     
2. Fluorescein labeled anti-human IgG (goat), ready for use. 
3. Positive control: anti-PLA2R antibodies ready for use. 
4. Negative control: autoantibody negative, ready for use. 
5. Salt for PBS pH 7.2 
6. Tween 20 
7. Embedding medium, ready for use. 
8. Cover glasses (62mm x 23mm). 
Detailed Methods – Modified from manufacturer’s instructions 
1. Prepare: The reagent tray was checked.   The individual packets containing the BIOCHIP 
Slides were opened once they had reached room temperature. The BIOCHIP Slides were 
not touched. 
2. Dilute: Samples were diluted for a qualitative evaluation rather than a quantitative 
evaluation.  Plasma samples were diluted 1:10 with PBS-Tween. (11.1µl of sample in 100µl 
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of PBS-Tween and mixed thoroughly by vortex mixing for 4 seconds).    Positive and 
negative controls were included with every test.  Control sera were mixed thoroughly before 
use. 
3. Pipette: 25µl of diluted plasma was added to each reaction field of the BIOCHIP avoiding 
air bubbles.  
4. Incubate: The reactions were started by fitting the BIOCHIP Slides into the corresponding 
recesses of a reagent tray.  It was ensured that each sample made contact with its 
BIOCHIP and that the individual samples did not come into contact with each other. The 
BIOCHIP Slides were incubated for 30 min at room temperature. 
5. Wash: The BIOCHIP Slides were rinsed with a flush of PBS-Tween and immersed 
immediately afterwards in a cuvette containing PBS-Tween for at least 5 min, shaking 
occasionally. 
6. Pipette: 20µl of fluorescein-labelled secondary antibody (Anti-Human IgG [Goat] ~ FITC) 
was applied onto each reaction field of a clean reagent tray.  All drops were added before 
continuing incubation. A stepper pipette was used for this. The labeled anti-human serum 
was mixed with a pipette before use. To save time, conjugate was pipetted onto separate 
reagent trays during incubation with the diluted serum. 
7. Incubate: One BIOCHIP Slide at a time was removed from the PBS-Tween and within five 
seconds the back and the long edges were blotted with a paper towel and immediately put 
the BIOCHIP Slide into the recesses of the reagent tray. The areas between the reaction 
fields were not dried.  A check was done for correct contact between the BIOCHIPs and 
liquids.  From that point onwards the slides were protected from direct sunlight. They were 
incubated for 30 min at room temperature. 
8. Wash: The BIOCHIP Slides were rinsed with a flush of PBS-Tween using a beaker and 
then put into a cuvette containing PBS-Tween for at least 5 min. 10 drops of Evans Blue 
(150 µl) for each 150 ml phosphate buffer was added for counterstaining. 
9. Embed: Glycerol/PBS (embedding medium) was placed onto a cover glass – drops of 10 µl 
per reaction field; A polystyrene embedding template was used. One BIOCHIP Slide was 
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removed from the PBS-Tween and the back and all four edges were dried as well as the 
surface around, but not between, the reaction fields with a paper towel. The BIOCHIP Slide 
was put with the BIOCHIPs facing downwards, onto the prepared cover glass checking 
immediately that the cover glass was properly fitted into the recesses of the slide. This was 
then done in the same way with the next BIOCHIP Slide. 
10. Evaluate: The slides were then read using the fluorescence under the microscope.  If the 
reaction was positive the antibodies against PLA2R react with the transfected cells of the 
substrate.  They caused a fluorescence of the cytoplasm, partly including the cell 
membrane.  The cell nuclei are only weakly stained.  If the cell nuclei or the cytoplasm of 
ALL the cells was stained then anti-nuclear antibodies or antibodies against mitochondria 
and other cell antigens may have been present.  If the positive control showed no 
fluorescence pattern or the negative control showed a clear specific fluorescence pattern 
the results were not used.  Only a qualitative evaluation was done on these samples (i.e. 
no reaction at 1:10 was a negative test and positive reaction at 1:10 was a positive reaction 
indicative of IMN (figure 9)).   
  
Figure 9: Courtesy of Euroimmun.  Transfected cells: antibodies against PLA2R as they would be seen under a 
fluorescence microscope with control HEK 293 cells on the right. 
 
2.2.4.3 Samples Analysed  
Fifty-nine samples were tested in total on 24 patients.  21/55 samples were either pre treatment of 
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within 4 weeks of commencing treatment (1 sample taken at 4 weeks not included in this count as 
patient in CR at 4 weeks).    11/59 samples were within 52 weeks after the patient had reached CR 
(range 0-46 weeks).  Of the remaining 27 samples 9 were in patients >52 weeks after reaching 
CR, when the patient would have been withdrawing from immunotherapy and the remaining 18 
were >4 weeks after commencing immunotherapy and before reaching CR (range of 18-161 weeks 
after initial enrolment).    
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CHAPTER 3:  NOVEL TREATMENT REGIMENS 
In this chapter the results of the Rituxilup prospective cohort in LN and the retrospective analysis of 
Tacrolimus monotherapy in IMN will be reported and discussed.  An update on recruitment and 
data monitoring from the MTac trial will be presented, however as this trial is not yet fully recruited 
outcomes cannot be presented.  The results lead into the discussion regarding future treatments 
on the horizon for both conditions and an update on clinical trials that are currently recruiting. 
3.1 Hypothesis 1:  Lupus Nephritis can be treated effectively 
with a steroid sparing regimen (Rituxilup regimen). 
The Rituxilup regimen was introduced by the Imperial College Healthcare NHS Trust (ICHNT) in 
2006 as their standard of care for treating LN without life threatening complications or rapid 
progression/dialysis requiring cyclophosphamide.  Here the outcomes of the first 50 consecutively 
treated patients are reported, including: demographics, remission rates; relapses; non-renal flares 
and adverse events.  These results incorporate and expand upon published results from 2013 
(Condon, Ashby et al. 2013). Rebiopsy in patients with persistent proteinuria is discussed with 
results from both this cohort and patients previously treated with oral steroids who subsequently 
received Rituximab and MMF, and then had their oral steroids weaned (the “Rituxirescue” 
regimen). 
 
3.1.1  Results 
3.1.1.1 Demographics and Baseline Parameters 
I analysed the outcomes of the first 50 consecutive patients that were treated with the Rituxilup 
protocol.  Follow up data was available on 49/50 with a median follow up of 163 weeks (52-237). 1 
patient was lost to follow up after moving abroad.  
Of the 50, 39 (78%) were female, 40% were Caucasian, 30% were Asian (denotes individuals who 
originate from the Indian sub-continent); 64% dsDNA antibody positive and/or low serum C3/C4; 
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diffuse proliferative nephritis (IV or IV+V) was present in 40% of the patients and 44% had pure 
class V lesions; a significant proportion (40%) had systemic features at presentation.  Detailed 
demographics are reported in Table 3. 
3.1.1.2 Baseline biochemistry 
Severity varied according to renal histology with higher mean serum creatinine, lower mean serum 
albumin and higher mean urine PCR seen in patients with Class IV LN compared with those with 
Class III or V (Figure 10). The cohort had severe LN at baseline with median (IQR) values for 
serum albumin of 24g/L (18-31g/L), serum creatinine 92 µmol/L (78-130 µmol/L), and urine PCR 
422 mg/mmol (175-894mg/mmol).  
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Patient No. Sex Age  Class LN Ethinicity Anti-dsDNA abs Low C3+/or C4  Non-Renal Symptoms 
Previous 
Treatment 
1 M 54 V Caucasian - - - Tac 
2 M 31 V Asian* - - - - 
3 F 29 IV Caucasian + + G,MC,MS,N CS,MMF,CyP,HCQ 
4 F 25 V African-Carib + - MC, H - 
5 F 46 IV Asian* + + G,H - 
6 F 26 IV+V Asian* + + MC,MS HCQ 
7 M 54 V Oriental - - H HCQ 
8 M 52 IV Caucasian + - H HCQ, MTX 
9 F 67 IV Caucasian - + - - 
10 F 74 V Caucasian - + H - 
11 F 47 V Caucasian - - - CS,Aza,Tac 
12 F 28 IV Oriental - - MC, H - 
13 F 60 IV Caucasian + + H - 
14 F 43 III Asian* + - MC - 
15 F 30 V African-Carib + - H CS,HCQ 
16 M 46 V Caucasian - - - - 
17 M 69 V African-Carib - - - - 
18 F 66 V Caucasian - + - CS,Aza 
19 F 39 IV Caucasian + + G,MC,MS,H,N HCQ 
20 M 20 IV Caucasian + + H CS,Aza 
21 M 61 V Asian* - - - - 
22 M 19 V Caucasian - - - CS 
23 F 46 IV+V African-Carib + + H - 
24 F 73 V Caucasian - - - - 
25 F 50 IV+V Asian* + + G,MC,MS,H CS,HCQ 
26 F 42 V African-Carib - - H - 
27 F 59 V Mixed + - - CS 
28 F 33 III Mixed + + - CS,HCQ 
29 M 69 V Asian* - - - - 
30 F 55 V Asian* + + MC,H CS,MMF,Aza 
31 F 34 IV Oriental + + H - 
32 F 46 IV Caucasian - + H - 
33 F 36 III Caucasian + + MC,MS CS,HCQ 
34 F 75 V Asian* - - - - 
35 F 53 V Caucasian - - - - 
36 F 29 III+V Caucasian + + MC,MS,H CS,MMF,HCQ,Aza 
37 F 31 III+V Asian* - + H HCQ 
38 F 26 IV+V Oriental + + H - 
39 F 24 III Caucasian - - - CS,MMF 
40 F 30 III Asian* + + MS,H,CR HCQ 
41 F 38 V Asian* - - - - 
42 F 48 V Mixed + + H CS,Aza 
43 F 30 IV Asian* + + G, H CS 
44 F 25 IV Asian* + + G,MC,MS,H,CR - 
45 F 25 IV Oriental + + - - 
46 F 67 IV Caucasian - - - - 
47 M 19 IV African-Carib + + G,MS,H - 
48 F 19 IV Mixed - - - - 
49 F 68 III+V Asian* + + G, MC CS,CyP,HCQ 
50 F 70 V Caucasian - - - - 
 
dsDNA Ab Quantitative Assay - negative < 30u/ml: Low C3 <0.7g/L; Low C4 <0.16g/L.    Non Renal Symptoms (As described in the BILAG 
Index(Hay, Bacon et al. 1993)): G=General; MC=Mucocutaneous; MS=Musculoskeletal; N=Neurological; H=Haematological; CR=Cardio-
Respiratory; V=Vascular.  Previous Therapies: CS=Corticosteroids; MMF=Mycophemolate Mofetil; CyP=Cyclophosphamide; Aza=Azathioprine; 
HCQ=Hydroxychloroquine; Tac=Tacrolimus; MTx=Methotrexate. *Asian denotes individuals from Indian sub-continent.   
Table 3.  Baseline demographics of the Rituxilup cohort.    
	   110	  	  
 
 
Figure 10. Baseline biochemistry by histological class. 
Distributions of baseline urine protein:creatinine ratio (PCR), serum albumin and creatinine according to histological class with mean / 
geometric mean parameter values.  P values for the existence of a class effect on each parameter are given at the top, with the only 
significant post hoc difference given within the chart. 
 
  
3.1.1.3 Remission induction 
By the data cut off point of 1st November 2010, 45/50 (90%) of patients achieved CR or PR at 
median time of 37 weeks (IQR 4-200 weeks) (Figure 11a). Overall, CR was achieved in 36 patients 
(72%) at median time of 36 weeks (IQR 11-58 weeks) (Figure 11a), with their latest median 
creatinine being 70 µmol/L (IQR 63-106 µmol/L). Persistent partial remission (PR) was achieved in 
nine patients (18%) at median time of 32 weeks (IQR 19-58 weeks). Their median creatinine by 
latest follow up was 76 µmol/L (IQR 64-200 µmol/L) and median PCR 174mg/mmol (IQR 68-408 
mg/mmol). By 26 weeks 16/50 (32%) had achieved a CR and 15/50 (30%) had achieved a PR. By 
one year this had increased to 26/50 (52%) in CR and 17/50 (34%) in PR (Figure 11a). The time to 
CR or PR was not influenced by class of LN at baseline (Figure 11b). 
There were 24 patients who had not achieved a PCR <50mg/mmol by 52 weeks.  Of these, 4/24 
had a falling PCR (2/4 subsequently reached CR by data cut off point) and 5/24 had or were in the 
process of being switched to alternative treatment regimens (2/5 had relapsed from PR and 3/5 
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had failed to respond (2/3 before 12 months and 1/3 at 16 months)).  There were therefore 15 
patients eligible for re-biopsy under the regimen protocol.  2/15 failed to attend.  Of the 13 who 
were re-biopsied, 8 had achieved histological remission (6/8 subsequently progressing to CR by 
census date), 4 had active disease (3/4 were redosed with rituximab (1/3 now in CR) and 1/4 had 
her MMF dose optimised (achieved CR before later relapse)). The final repeat biopsy show 
histological remission with respect to lupus nephritis but showed diabetic nephropathy from her 
pre-existing diabetes.  
Overall, there was no significant change in mean serum creatinine (Figure 12). For those with 
baseline serum creatinine <110 µmol/L, the median (IQR) creatinine at baseline was 80µmol/L 
(range 73-87µmol/L) falling to 73 µmol/L (range 66-87 µmol/L) at 1 year and 68 µmol/L (range 63-
73 µmol/L) by 3 years. Of the 20 patients with baseline serum creatinine >110 µmol/L, 18 (90%) 
showed improvement over time falling from a baseline median of 146 µmol/L (126-191) to 125 
µmol/L (range 76-164 µmol/L) at 1 year and 133 µmol/L (range 105-171 µmol/L) at 3 years. Only 6 
patients overall had a rise of >15% above baseline at latest follow up; 3 of whom initially achieved 
PR and then relapsed. 
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Figure 11a.  Time to remission and relapse.  Kaplan-Meier curves showing the proportion of patients under observation 
achievingcomplete and partial remission by time since treatment, and the proportion (of all patients) that relapsed. The vertical dashed 
line marks the 1-year time point. 
 
 
Figure 11b.  Time to complete remission by histological class. 
Kaplan-Meier curves showing similar time to achieve complete biochemical remission regardless of baseline histological class (p = 
0.96). 
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Figure 12. Change in renal function during the first year. 
Box whisker distribution of renal function parameters during the first year after treatment, with p-values for the existence of a time point 
effect. Mean urine PCR and serum albumin are significantly different from baseline at every follow up time point (p<0.001 for all 
comparisons with Bonferroni correction). 
 
3.1.1.4 Histological Remission 
Eight of nineteen patients who had achieved a stable PR ((based on persistent proteinuria with a 
PCR >50mg/mmol) had repeat biopsies demonstrating histological remission (HR) on the basis of 
absence of active lesions and no new sub-epithelial deposits on Electron Microscopy (EM) 
(figure13).  Six of the eight went on to achieve CR at a median time of 26 weeks after their repeat 
biopsy without a change in treatment.  
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Figure 13:  Electron Microscopy from patient rebiopsied for persistant proteinuria.  At baseline (figure 11a) the 
patient had a Class IV-S (A/C) + V  LN.   At that time Creat was 57 and PCR 917; At rebiopsy, (figure 11b) 1 year into 
treatment, creatinine was 50 µmol/L and PCR 167mg/mmol. Patient went on to biochemical remission 6 weeks after the 
second biopsy was taken, without any change in treatment. 
 
 
 
Figure 13a EM pre treatment. Glomerular capillary loop showing gross capillary wall thickening by numerous and large 
subepithelial and subendothelial electron dense deposits (EDD). There are also abundant mesangial EDD. 
 
 
 
 
 
 
Figure 13b EM after 1 year.   Glomerular capillary loop showing reduction of capillary wall thickening vs to pre-
treatment, with subendothelial areas of rarefaction, corresponding to resolving sub-endothelial deposits. Also fewer 
subepithelial and mesangial EDDs.  
  
	   115	  	  
3.1.1.5  Non Responders 
 
There were 4 patients who were non responders.  
 
Patient 1:  37 year old Caucasian female initially referred from Rheumatology.  She had 
pancytopenia and headache as systemic features of SLE.  Her serology was strongly positive with 
high titre dsDNA >1000lU/ml; low C3 and C4; ANA, Anti RNP/SM/SSA/SSB all positive.  Baseline 
creatinine was 91µmol/L with an eGFR of >60 ml/min/1.73m2; however she was extremely 
nephrotic with a PCR of 1525mg/mmol and a serum albumin of 22g/L.  The rheumatologists had 
commenced her on 40mg prednisolone orally prior to referral.  Her renal biopsy demonstrated 
Class III LN and she was commenced on the Rituxilup protocol.  At the time of her first dose of 
methyl prednisolone her oral steroids were stopped.  Due to her pancytopenia her dosing with 
MMF was intermittent and her MPA levels were often sub-therapeutic.  10 months after 
commencing treatment she had a further biopsy which showed active Class III + V LN.  She was 
re-dosed with Rituximab and commenced on IV Cyclophosphamide and her MMF was stopped.  At 
5 years after initiation of treatment she had a serum creatinine of 86umol/L. 
 
Patient 2:  42 year old Black African female.  No systemic features and serology was negative.  
Creatinine at time of biopsy was elevated at 125µmol/L and PCR was 175mg/mmol.  On biopsy 
she was found to have a Class V LN, reportedly with 70% background scarring.  She had an initial 
response with a fall in proteinuria 55mg/mmol, however at that time her creatinine rose to 
155µmol/L and subsequently she became more proteinuric up to 149mg/mmol.  She maintained 
therapeutic MPA levels during her follow up, with a mean MPA level of 2.36.  With a rising 
creatinine and increasing proteinuria she had a repeat biopsy, which demonstrated again an active 
Class V LN and she was switched to a Eurolupus regimen.  Her creatinine at 5 years after initiation 
of treatment was 169umol/L.  
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Patient 3:  19 year old Caucasian male who presented with nephrotic syndrome, no systemic 
features, no detectable dsDNA antibodies and C3 and C4 within normal range.  Serum creatinine 
71µmol/L, and severely nephrotic with serum albumin 8g/L and PCR 592mg/mmol.  Prior to biopsy 
this man had been commenced on 60mg prednisolone on the assumption that this was likely 
minimal change disease.  His biopsy demonstrated a class V LN.  His oral steroids were stopped 
when he received the Rituxilup regimen.  He had a gradual improvement in his serum albumin up 
to >33g/L by 18 months.  However his proteinuria never fell below nephrotic range.  He was invited 
for re-biopsy but failed to attend.  His renal function remained reasonably stable through out.  He 
was an infrequent attender, with assumed poor adherence to his medications.  Consistent with 
this, of the few MPA levels available, his mean level was sub therapeutic at 0.93. By August 2013 
(6 years post initial presentation) his creatinine had risen to 133µmol/L.  He then defaulted until 
April 2014 when he presented with accelerated phase hypertension and end stage renal failure.  It 
was clear he’d not taken any medications for his lupus or BP for some time.   
 
Patient 4:  46 year old Caucasian female who presented with leucopenia, nephrotic syndrome, and 
hypocomplementaemia but with a negative dsDNA antibody.  Her baseline creatinine was 
101µmol/L, and she was nephrotic with a PCR of 569mg/mmol and serum albumin of 26g/L.  On 
biopsy she was found to have an active Class IV LN. She was treated with the Rituxilup regimen. 
However, it proved impossible to get her on an adequate dose of MMF to achieve adequate MPA 
levels as she became profoundly leucopenic on even a small dose of MMF.  As a result, and 
because she also had psoriasis, her MMF was switched to Tacrolimus (without oral steroids) and 
she subsequently went into a complete remission.  Not surprisingly her psoriasis improved 
dramatically when she started the tacrolimus She has remained in renal remission ever since but 
did developed upper airway problems and a positive PR3 ANCA some years later.  At 5 years after 
initiation of treatment her serum was creatinine is 93umol/L. 
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3.1.1.6 Renal relapses 
At the census points there had been 12 relapses in 11 patients (22%), all of whom were nephrotic. 
The median time to relapse was 65 weeks (IQR 20-112 weeks). Of these, eight relapses (in seven 
patients) occurred from CR, and four from PR. One patient, with class V at baseline, did not have a 
repeat biopsy as relapse occurred in the context of severe systemic infection secondary to a 
diverticular abscess and CMV colitis, therefore the patient was not fit for further 
immunosuppression. In 4/11 patients, both the baseline and relapse biopsies showed Class V LN. 
Of these, one patient relapsed twice soon after B cell repletion – in the context of MMF having 
been withdrawn due to recurrent persistent upper respiratory tract infections.  Of the 6/11 with 
Class IV LN at baseline, repeat biopsy demonstrated active class IV nephritis in 3/6, Class III with 
fibrinoid necrosis and cellular crescents in 1/6 (who subsequently was found to have MPO positive 
ANCA vasculitis with pulmonary haemorrhage), Class V in one and one declined biopsy.   
Seven relapses (in six patients) were treated with further rituximab (two doses of 1g with or without 
methylprednisolone) with three achieving CR. One achieved PR and three failed to respond.  
 
3.1.1.7 Systemic Flares of SLE and use of oral steroids 
Of the 50 patients, six had systemic flares, mostly mild. One patient had skin involvement that 
resolved following an increase in MMF from 750mg BD to 1g BD. One patient developed 
thrombocytopaenia and neutropaenia, which responded to re-dosing with methylprednisolone and 
rituximab. Two patients required a single short course of prednisolone (<2 weeks) for systemic 
symptoms with a maximum dose of 30mg. Only two patients who stayed on the Rituxilup protocol 
required maintenance steroids: one patient required long-term oral steroid treatment for severe 
systemic symptoms (including tongue swelling and serositis) at the time of biopsy, tapering from 
30mg OD to 5mg OD. One patient had 3 short courses of prednisolone for flares of cutaneous 
lupus.  
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3.1.1.8 B-Cell Depletion 
Complete data is available on 42/50 patients of whom 39/42 (93%) showed depletion to <5 B 
lymphocytes/mL following Rituximab. Of the three patients who did not fully deplete (nadir counts 
of 9, 5 and 35 B lymphocytes/mL respectively) two achieved CR (at 73 weeks and 59 weeks 
respectively) and one was a non-responder.  
3.1.1.9 Significant adverse events:  
a) Adverse events requiring inpatient admission: nine (18%) patients required inpatient stays for 
possible adverse events and one further patient developed shingles. Only five (10%) infective 
episodes occurred requiring hospital admission throughout the period of follow-up (Table 4). 
 
Adverse events requiring hospital admission. 
Patient 1 Ruptured Achilles tendon 
Patient 2 Coronary angiogram for angina 
Patient 3 Empyema 
Peripheral vascular disease 
Patient 4 Menorrhagia 
Patient 5 CMV colitis, diverticular abscess 
Patient 6 Pneumonia 
Patient 7 Thymectomy (benign) 
Patient 8 Cellulitis 
Patient 9 Gastroenteritis 
 
Table 4:  Adverse Events requiring Hospitalisation in Rituxilup Cohort 
 
b) Diabetes: one patient (2%) developed Type 2 Diabetes following induction treatment with 
rituximab and methyl prednisolone. 
	   119	  	  
c) Deaths: two patients died (4%). A 61-year-old patient died 31 months after rituximab.  She was 
in CR at the time of death and died from the complications of surgery for severe peripheral 
vascular disease. The second was a 71-year-old man who died suddenly at home 28 months after 
first treatment with rituximab.  At 1 year he was in PR and was re-biopsied, re-dosed with rituximab 
at 18 months and was in PR at the time of death.  Cause of death is unknown. 
 
3.1.1.10  Mycophenolic Acid (MPA) levels 
MPA levels were measured in all patients at each clinic visit.  These were used to guide for dosing 
of MMF to a target trough MPA level of 1·2 – 2·4 mg/L.  The data for the MPA levels were 
available for 45/50 patients.  Median number of samples analysed per patient was 16 (range 0-47).  
The median value of the patient mean MPA levels was 1.44mg/L with a range of 0.28-3.51mg/L.  
29/45 (65%) patients had mean MPA levels between 1.2mg/L and 2.4mg/L.  It may have been that 
some samples did not represent a true 12 hour trough as some patients were followed up in an 
afternoon clinic; they were asked not to take their MMF before clinic so it may have been the some 
levels were deceptively low as they were 14-16 hour troughs. 
 
3.1.1.11  Outcomes in patients with poor prognostic indicators at baseline 
1. Impaired renal function  
Baseline renal function was significantly impaired with serum creatinine >120µmol/L  
(median 147.5 µmol/L; range 121-383 µmol/L) in 18/50 patients.  Of these 11 had Class IV 
LN and 7 had Class V. Over the original time period reviewed,1/18 was a non-responder 
(Patient No. 2 described in section 3.1.1.4); 2/18 achieved an early PR by 6 months but 
then had nephrotic relapses (1/2 went into CR with the Eurolupus regimen; 1/2 failed to 
respond to further treatment regimens and progressed to ESRF – both had high titre 
dsDNA >2000IU/ml and low complement levels at presentation); 11/18 achieved a stable 
complete biochemical remission and 3/18 showed histological remission on re-biopsies for 
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persistent proteinuria with a PCR >100mg/mmol at 12 months.  1 patient in a stable partial 
remission died during the follow up period (detailed in section 3.1.1.8).  At 1 year median 
creatinine 140µmol/L  (range 65-229µmol/L); only 2/18 had a deterioration in function 
(149µmol/Land 146µmol/L  at baseline to 175µmol/L and 151µmol/L  at one year, 
respectively), all the others had stayed the same or improved.   
2. High dsDNA Titre 
High titre dsDNA antibodies (defined as >100IU/ml) were seen in 14/50 patients - median 
611.5IU/ml; range 110-9750IU/ml.  Of these, 12/14 also had low levels of both C3 and C4 
demonstrating high immunological activity.  Of the 14, 10 (71%) patients had Class IV LN; 
2/14 Class III; 1/14 Class V and 1/14 Class III+V.  Overall, the strongly positive serology did 
not predict poor outcomes.  Whilst 1/14 failed to respond to treatment (Patient No.1 
described in section 3.1.1.4) and 2/14, both also with baseline creatinine >120µmol/L , 
achieved an early PR by 6 months but then had nephrotic relapses (see earlier), 10/14 
achieved CR and at a fast rate - median time of 16 weeks (range 4-65 weeks); 1/14 
demonstrated a histological remission on re-biopsy for persistent proteinuria.  The active 
serology also did not predict poor renal function with median creatinine at first biopsy of 
105µmol/L  (range 68-211µmol/L), falling to 75.5µmol/L  (range 59-222µmol/L) by 1 year.  
3.1.1.12 Fertility  
At least 5 women treated with the Rituxilup regimen have gone on to conceive naturally and have 
live births.  The advice given to patients was to wait until in CR for 6 months and then the patient’s 
MMF was switched to azathioprine for maintenance as not teratogenic.  Depending on the 
outcome of preconception counseling, the women were advised to stop taking their ACEI or ARB 
as soon as pregnancy confirmed but in some this was done preemptively depending on the 
woman’s preference.   
	   121	  	  
3.1.2  Discussion 
3.2.2.1 Outcomes 
This study demonstrates, in a sizeable cohort of lupus nephritis patients, treatment with a 
rituximab-based regimen (the Rituxilup protocol) that avoids the use of any oral steroids, is well 
tolerated and achieved high rates of renal remission.   
3.2.2.2 Comparison with published data 
Although this was a prospective observational study, not a clinical trial, the rates of CR 32% and 
CR or PR (62%) at 26 weeks compare favourably with those achieved by patients treated with 
steroids and MMF in the ALMS trial (8·5% and 56·2% respectively; (Appel, Contreras et al. 2009).  
At one year, the remission rates with the Rituxilup regimen (86% in CR or PR) are not as high as 
those in the MMF plus steroid treated patients in the trial reported by Chan et al. (97% in CR or PR 
(Chan, Tse et al. 2005)), particularly the proportion of patients in CR (52% in Rituxilup vs. 72·7% in 
the Chan trial). However, the similarity in outcome with the ALMS study suggests that ethnic 
differences between the patient groups may be responsible for this difference rather than the 
substitution of maintenance steroids with rituximab.  Furthermore, over the follow up period (i.e. 
beyond 1 year), increasing numbers achieved CR and it may be that the Rituxilup protocol leads to 
a slower pace of response in some patients in the absence of oral steroids. 
3.2.2.3  Other Steroid Sparing Regimens 
As published previously, the use of rituximab and MMF for the treatment of patients with acute LN 
already on oral steroids had demonstrated a steroid sparing effect (Pepper, Griffith et al. 2009). 
The use of rituximab and methylprednisolone, in the absence of any other immunosuppression, 
was reported to be effective in the treatment of flares of proliferative LN in a series of 3 patients 
(Moroni, Gallelli et al. 2010). Using a steroid sparing regimen, based on our Rituxilup regimen, in a 
group of patients with new onset non renal lupus, Ezeonyeji and colleagues demonstrated this 
regimen to be safe, effective and reduce the overall steroid burden in SLE, when assessed by the 
BILAG disease activity index (Ezeonyeji and Isenberg 2012). The repeat biopsies and the 
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achievement of excellent renal function in the majority of patients suggest that the possibly slower 
rates of response were not at the expense of long-term chronic histological damage. It was 
noteworthy that 8/19 patients who had achieved a stable PR (based on persistent proteinuria with 
a PCR >50mg/mmol) had repeat biopsies demonstrating histological remission (HR) on the basis 
of absence of active lesions and no new sub-epithelial deposits on EM.  Six of the eight went on to 
achieve CR at a median time of 26 weeks after their repeat biopsy without a change in treatment 
thus demonstrating that HR was an excellent predictor of a good outcome.  In 2012 Fischer-Betz et 
al. reported a cohort study of patients who had received a prolonged course of cyclosphosphamide 
(6 x 1 month IV cyclophosphamide then 3 monthly doses for 18 months) for renal lupus but only 
received oral steroids for extra renal manifestations. They undertook a retrospective comparison of 
those patients who received prednisolone < 20mg at baseline (n=21) versus those with >20mg  
(n=19).  There was no difference in renal outcomes in the short and long term with no increased 
incidence of relapse and similar outcomes at 10 years (Fischer-Betz, Chehab et al. 2012). In 2011 
Zeher et al. reported the MYLUPUS trial – an open label 24-week trial using Myfortic (enteric 
coated Mycophenolate sodium) with either standard (1 mg/kg baseline, n=42) or reduced (0.5 
mg/kg baseline, n=39) prednisolone.  Comparing the low dose steroid group with the high dose, 
there were no significant differences between outcomes – CR (20.5% and 19.0% respectively), 
PR, or extra renal manifestations at 24 weeks despite 50% less cumulative prednisolone.  There 
were however fewer severe infections and no varicella zoster infections in low-dose patients 
compared with 7 (16.7%) cases of zoster in the standard group.  More support for the idea of lower 
doses of steroids being associated with better outcomes comes from the Bilbao Cruces group. 
Ruiz-Irastorza et al. compared the outcomes and treatment related toxicity in patients on their 
current low dose treatment regimen of methylprednisolone (500 mg pulses) and low dose rapidly 
tapered prednisolone (down to 5 mg by 16 weeks) with either IV CyP or MMF with their historical 
cohort who had received much larger doses of prednisolone together with IV CyP. They found 
significantly better responses with their current treatment regimen and far less treatment related 
toxicity (Ruiz-Irastorza, Danza et al. 2014).  
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3.2.2.4  Prediction of Long-term Outcomes 
The high proportion of patients achieving remission at 6 months also suggests a favourable long-
term renal outcome for this group of patients, and importantly 50% of the cohort achieved a PCR of 
<100mg/mmol by 6 months.  Houssiau et al. has reported the long-term follow up of the Eurolupus 
trial and confirmed that an early (3-6 months) response (reduction in proteinuria to <1g/24 hour) 
predicted a good long-term outcome (creatinine <1.4g/dl at 10 years) (Houssiau, Vasconcelos et 
al. 2010).  
3.2.2.5  High proportion of Class V LN 
Forty four per cent of our patients, of whom half were nephrotic at presentation, had pure Class V 
LN at baseline. The combination of rituximab and cyclophosphamide, but with steroids, has been 
shown to be effective in refractory Class V LN (Jonsdottir, Gunnarsson et al. 2010, Jonsdottir, 
Sundelin et al. 2011).  In an analysis of outcomes of the patients with pure Class V LN in the US 
and ALMS trials, Radhakrishnan et al. demonstrated no differences in outcomes at 24 weeks 
whether patients were treated with MMF or cyclophosphamide (Radhakrishnan, Moutzouris et al. 
2010). Of those treated with MMF and steroids who had nephrotic Class V at presentation, CR at 
24 weeks was achieved in none of those in the US trial, and just 7% of those in the Aspreva Lupus 
Management Study (ALMS) trial.  In contrast, in our cohort, 18% of the nephrotic Class V patients 
achieved CR at 6 months, rising to 36% by 1 year.  Of the total group of 22 Class V patients, at 6 
months 32% were in CR, 23% in PR and by 12 months the proportions had risen to 38% and 24% 
respectively.   
3.2.2.6  Low frequency of Systemic Features 
Another feature of this cohort was the low rate of systemic features during treatment. This may 
reflect patients being treated relatively early in the course of their disease. This is analogous to the 
evidence in rheumatoid arthritis where early use of biological agents is associated with better long-
term outcomes and reduced damage (Venkateshan, Sidhu et al. 2009). It is also possible that 
titrating MMF dosing to trough blood MPA levels, may have reduced or successfully treated 
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systemic relapses, despite the relatively low MPA levels that were recorded in this cohort. Other 
authors who have reported the efficacy of MMF in treating extra renal disease in lupus though 
have queried whether responses are maintained beyond two years (Karim, Alba et al. 2002, 
Posalski, Ishimori et al. 2009). Hydroxychloroquine was also a useful adjunct, which is now part of 
the routine prescription in patients with LN.   
3.2.2.7  B-Cell Depletion 
Clearly a prospective observational study such as this cannot define the role of rituximab in 
treating lupus nephritis. Rituximab is a very attractive therapeutic agent for lupus not only because 
it has a very long safety record from its extensive use in non-Hodgkin’s lymphoma but also 
because it has a biologically relevant target, namely CD20, expressed on B cells from pre-B cells 
up to, but not including, plasma cells. Data from Emery’s group demonstrated that clinical 
responses to Rituximab in patients with lupus are strongly correlated with the degree, duration and 
specific B cell phenotypes that are depleted and repopulate (Vital, Dass et al. 2011).   
3.2.2.8  Comparison with Recent Data for Rituximab use in LN 
There is currently a mismatch between the perceived value of rituximab for the treatment of lupus 
nephritis and the published data.  The only randomised controlled trial of rituximab in lupus 
nephritis, the LUNAR trial, comparing MMF + steroids + placebo with MMF + steroids + rituximab 
in 144 patients with Class III or Class IV lupus nephritis, failed to achieve the primary end point of a 
difference of 20% in the proportion of patients in CR or PR at 52 weeks in the rituximab treated 
arm (Rovin, Furie et al. 2012). At one year there was no significant difference in the proportion 
achieving CR but a 15% increase in those achieving a PR in the Rituximab group; this was an 
overall difference of 11%, which fell short of their ambitious 20% target. LUNAR was 
underpowered to detect the significance of the increase in PR rates seen (Lightstone 2012).  
However looking at the 78-week exploratory end points definite significance between the two 
groups can be found demonstrating the benefit of Rituximab (Table 5).    
 
	   125	  	  
Exploratory endpoints at 78 weeks        
  Placebo Rituximab p 
At least 50% reduction in proteinuria  54.20% 70.80% 0.04 
CR or PR proteinuria 56.90% 73.60% 0.04 
Black patients overall response 52wks 45% 70% ns 
Black patients overall response 78wks 35% 60% ns 
Started CyP prior to week 52 11% 0 0.006 
Started CyP prior to week 78 15.30% 2.80% 0.02 
Average daily dose pred week 16-52 12.8 ± 6.5 10.9 ± 4.1 0.05 
 
Table 5:  Exploratory 78 week end points of LUNAR trial demonstrating significant improvement in outcomes with the 
addition of Rituximab. 
 
LUNAR, as with other observational studies demonstrated the continued reliance on long-term oral 
steroids.  In the LUNAR study the data suggest that patients were failing to have their steroids cut 
according to planned taper, highlighting how difficult it is to wean steroids once started.  This may 
reflect treatment for extra-renal manifestations but it is likely that clinicians were reluctant to cut 
steroids in the face of on-going proteinuria, and presumed disease activity in the absence of repeat 
biopsies.   
A fully humanised anti-CD20 antibody “Ocreluzimab” has also been used in a trial to assess it’s 
efficacy and safety in the treatment of active proliferative lupus nephritis (Mysler, Spindler et al. 
2013).  381 patients (from 123 sites in 23 countries) were recruited and were randomised 1:1:1 to 
receive placebo, 400mg Ocreluzimab or 1g Ocreluzimab given as an intravenous infusion on days 
1 and 15, followed by a single infusion at week 16 and every 16 weeks subsequently, 
accompanied by background glucocorticoids and either MMF or Cyclophophamide (followed by 
azathioprine).  The study was terminated early due to an imbalance in serious infections in the 
Ocreluzimab group receiving background MMF (but not cyclophosphamide) compared with 
placebo, however the MMF group received more steroids when compared with the 
cyclophosphamide group (median 500mg IV glucocorticoids compared with 100mg respectively, 
with many in the MMF group receiving ≥ 1000mg) and therefore when Ocreluzimab was added this 
culminated in more serious infections.  It was also shown that the patients experiencing serious 
infections had higher levels of equivalent prednisolone doses (mean ± SD 19 ± 10mg/day versus 
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15 ±8mg/day).  This large trial demonstrates clearly the adverse events that can occur with use of 
an anti-CD20 agent as an “add on” in patients who are already receiving a relatively strong 
immunosuppressive regimen already.  
3.2.2.9  Unique role for Rituximab in Rituxilup Regimen  
No trial has compared rituximab replacing a traditional agent with standard therapy. There is little 
argument that MMF plus steroids or IV cyclophosphamide plus steroids are effective combinations 
in the treatment of lupus nephritis. Our cohort suggests that the combination of rituximab, low dose 
IV methylprednisolone and MMF without oral steroids is also an effective regimen. The avoidance 
of steroids has huge potential benefits in this group of patients, particularly as they often require 
immunosuppression for many years, they may avoid not only the unpleasant cosmetic effects of 
steroids (with the associated psychological damage), but also the long-term damage attributable to 
steroids.  
3.2.2.10  Limitations to the Rituxilup Cohort 
This was a prospective cohort rather than a randomized control trial.  However there is strength in 
the fact that the patients were seen very frequently and data were collected prospectively. 
The influence of a single centre effect also must be taken into consideration. The Imperial Lupus 
Centre evolved during the cohort follow up but from the start lupus patients were seen weekly or 
more frequently as necessary, and latterly had access to a team that included not only 
nephrologists with an interest in lupus nephritis but rheumatologists as well. This was high input 
clinical care, which may have supported the patients in such a way that allows them to have high 
adherence and buy in with the treatment offered.  In smaller centres this degree of specialist care 
is often not possible as the prevalence of lupus nephritis would not warrant a specialist service 
such as this. 
Monitoring of mycophenolic acid (MPA) levels allowed the physicians to monitor adherence as well 
as allowing a titration of dose often beyond usual practice, safeguarding against both over and 
under treatment.  MPA data was collected for the majority of the patients but was influenced by 
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real world issues in particular the clinic moving to an afternoon session which made collection of 
12 hour troughs quite challenging.  Some of the low levels seen may reflect lack of adherence but 
may equally reflect long troughs as patients were wedded to omitting their morning dose on the 
day of clinic.  Importantly, the individual doses of MMF each patient received were not collected.  
To robustly report patient adherence and appropriate titration of dose to MPA level, these data 
would need to be collected.  This will be done in the planned RCT.   
3.2.2.11 Future Work 
This cohort may mark a step change in the approach to the treatment of lupus nephritis. For the 
first time in >60 years, it has suggested that oral steroids can be safely avoided in the treatment of 
lupus nephritis without apparent reduction in efficacy or increase in relapse rates, at least up to 
three years of follow up. The protocol will now be formally assessed in a prospective multicentre 
randomised trial (The Rituxilup Trial NCT01773616) and for the first time may offer a realistic 
possibility of discarding what may be the most toxic element in standard long-term treatment of this 
challenging disease.  
3.2.2.12 New Treatments on the Horizon 
In addition to Rituximab there are other B-cell depleting agents now available.  There are ongoing 
trials related to Epratuzumab, Belimumab and Atacicept. 
Epratuzumab is a humanized monoclonal antibody that targets CD22 on B cells and results in 
modulation of B-cell function and migration, as CD22 regulates adhesion and inhibits B-Cell 
Receptor (BCR) signaling.  In a phase II study a cumulative dose over 4 weeks has been shown to 
improve lupus disease compared with placebo 12 weeks after initiation of treatment.   
As previously described lymphocyte mitogens that are induced by DNA recognition include B 
lymphocyte stimulator (BlyS, also named B cell activating factor [BAFF]) and a proliferation-
inducing ligand (APRIL), which regulate B cell differentiation and Ig class switching (Liu and 
Davidson 2011).  The two APRIL/BLyS receptors (transmembrane activator and CAML-interactor 
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(TACI) and B cell maturation protein) promote plasma cell survival, therefore they are currently 
considered as potential therapeutic targets in SLE (Gayed and Gordon 2010) (Figure 13).   
Belimumab is a humanized monoclonal anti BLyS antibody. There have been two phase III trials in 
non-renal SLE (BLISS 52 (Navarra, Guzman et al. 2011) and BLISS 76 (Furie, Petri et al. 2011)).  
Both trials demonstrated that Belimumab plus standard SLE treatment resulted in significantly 
higher SLE Responder Index (SRI) response rates at one year compared with standard treatment 
alone (placebo).  SRI is a composite measure requiring improvements in SLE disease activity 
without worsening in specific organ domains or global disease activity (Furie, Petri et al. 2014).  
The results of both trials were combined in a single analysis that demonstrated that at 52 weeks 
the addition of Belimumab (at both 1mg/kg and 10mg/kg) resulted in a 7% and 12%, respectively, 
increase in patients demonstrating a SRI response when compared with a placebo response rate 
of 38.8%.  This response led to Belimumab being licensed for the management of systemic lupus 
in the US and in Europe.  Belimumab is now being trialled in LN, the BLISS-LN trial is currently 
recruiting.  It’s protocol is standard of care for all and then Belimumab versus placebo as an add 
on treatmentat a 1:1 randomisation. 
Atacicept is a humanized fusion protein that binds BLys and APRIL (a proliferation-inducing ligand) 
that might be more effective than Belimumab in the management of lupus (figure 14). 
Unfortunately a phase II/III trial of Atacicept in lupus nephritis had to be stopped due to the 
development of low immunoglobulin levels and pneumonias in some patients. However, in 
retrospect these complications may have been due to concomitant treatment with MMF and results 
of a 52-week, non-renal, phase III trial with Atacicept were recently reported and again did not 
demonstrate a significant result.  (Harvey and Gordon 2013)  
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Figure 14:  BAFF (BLyS) axis and its inhibition.  Membrane and soluble BAFF bind to TAC,BCMA and BAFFR, whereas 
APRIL binds only to TACI and BCMA.  Belimumab binds and neutralises soluble, but not membrane, BAFF, whereas 
Atacicept bind and neutralize soluble and membrane BAFF.  Atacicept also binds and neutralizes APRIL, whereas 
belimumab does not.   
Abbreviations: APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; BCMA, B-cell maturation antigen; 
BAFFR, BAFF receptor; TACI, transmembrane activator and CAML interactor.(Stohl 2013) 
 
 
One of the major challenges facing introducing new drugs in the treatment of lupus nephritis is 
designing the right trial and to know where these drugs fit in with the current repertoire available.  
For lupus nephritis it is also important that trials are of adequate duration to be able to demonstrate 
benefits of the newer therapies over conventional therapy; this is especially important in steroid 
sparing regimens where even if the regimen shows equivalence with regards response it will only 
be in many later years that the benefit of very minimal steroid exposure will be seen. 
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3.2 Hypothesis 2: Tacrolimus Monotherapy is an effective as a 
long term agent for maintaining remission in Idiopathic 
Membranous Nephropathy (IMN) 
Tacrolimus monotherapy (Tac) was introduced as a treatment regimen for nephrotic syndrome 
secondary to IMN at St. Mary’s Hospital in 2002 and this was continued at the ICHNT in 2005.  
There are already published data describing how effective calcineurin inhibitors are in inducing 
remission in patients with nephrotic syndrome secondary to IMN; however there is a reported high 
relapse rate on withdrawal of treatment.  The strategy described here is to continue patients on 
longer term Tac to maintain their remission when they have had previously difficult to treat disease 
or due to comorbid disease that would put the patient at risk of complications if they were to have a 
nephrotic relapse.  This is a retrospective review of the clinical outcomes of long term TM in IMN, 
including remission induction, renal function whilst on Tac, Tac level monitoring, relapses, 
withdrawal, adverse events and repeat biopsies.  These results are then discussed in comparison 
with published data and looking forward to new treatments and ongoing trials, including the 
currently recruiting MTac trial.  
 
3.2.1 Results   
3.2.1.1  Patient Characteristics 
Forty-three patients were identified who had been treated with tacrolimus monotherapy for more 
than 12 months.  Median time since commencement of Tac was 62 months (range 14-128); 26 
male and 17 female; median age of 45 years (range 23-82).  Ethnicity of cohort: 6 African origin; 
16 Asian; 19 Caucasian; 1 Persian and 1 Hispanic.  1 patient in this cohort was HIV positive at 
biopsy; there were no indications on the biopsy or on screening that this was a secondary 
membranous nephropathy.  
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For 35/43 patients Tac was the first line immunosuppressant for the treatment of their IMN.  The 
other 8 patients had failed to respond to or relapsed with alternative treatment regimens 
(“Ponticelli”; steroids alone; Cyclosporin +/- steroids).  Median duration of treatment with tacrolimus 
was 3.1 years (IQR 2.2-5.3) of whom 30 patients had been treated for 1 to 5 years and 13 had > 
than 5 years treatment.   
Baseline median creatinine. was 94µmol/L  (range 48-203µmol/L);  6 patients had baseline 
creatinine>150µmol/L  (range 172-203µmol/L).  The patients had significant nephrotic syndrome at 
baseline with a median albumin of 19g/L (range 13-38g/L).  Baseline PCR was available in 34/43 
patients, with a median of 718 mg/mmol (range 300-1643mg/mmol); of the remaining 9, 4 had 
urine dipstick indicating >3g/L proteinuria and 4 had 24 hour urine collections with 3.1, 7.0, 9.0 and 
14.6 g/24hr proteinuria respectively. 
3.2.1.2  Clinical Outcomes 
All but one of the patients (42/43, 98%) achieved a complete or partial remission. CR was 
achieved in 30 patients (70%) over a median time of 14 months (IQR 7-27) (Figure 15).   PR was 
achieved in 12 patients over a median time of 6 months (IQR 2-82). The one patient who never 
achieved sustained remission from his nephrotic syndrome had a brief, non-sustained PR, but 
overall was an infrequent attender at clinic and variably adherent.  
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Figure 15:  Kaplan-Meier demonstrating time to Complete Remission 
 
 
3.2.1.3  Renal Function 
 
Change in function on commencement of Tacrolimus 
As expected there was a small but significant rise in mean creatinine during the first year of 
treatment (p=0.0026); this was not found during subsequent years.  The median % change in 
creatinine at 3 and 12 months was 9% and 20% respectively (Figure 16). 
By 12 months, 14 patients had greater than 30% rise in creatinine compared to baseline: mean 
baseline creatinine 71µmol/L (range 53-189µmol/L) and mean 12 months creatinine 144µmol/L  
(72-322µmol/L).   
• At 12 months; 4/14 were in CR and a further 7 were in PR from their nephrotic syndrome; 
the remaining 3 patients achieved PR at 13, 21 and 31 months respectively and 2 of those 
patients went on to CR at 27 and 65 months respectively.   
• Two patients were re-biopsied for rising creatinine; 1 patient demonstrated an active 
interstitial nephritis and was commenced on prednisolone and the other patient 
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demonstrated electron dense deposits in other areas suggesting a more lupoid picture and 
was switched to Rituximab and MMF.   
• One patient, whose creatinine had plateaued at >30% above baseline, had their tacrolimus 
withdrawn as they were in CR for > 12 months; subsequently function improved and is 
currently at 20% above baseline.   
• With close monitoring of target trough tacrolimus levels to ensure levels no greater than 
8ng/L and tight blood pressure control, six of the fourteen patients demonstrated 
improvement in creatinine over the next 12 months whilst continuing on tacrolimus (from a 
median creatinine of 138µmol/L (range 94-184µmol/L) at 12 months to median 118µmol/L 
(87-173µmol/L) at 24months.   
• One patient who was in PR had their tacrolimus withdrawn due to a rising creatinine; 
however they progressed to ESRF 12 months after withdrawal (creatinine 189µmol/L at 
baseline and 322µmol/L at 12 months when tacrolimus was withdrawn).   
• Of the remaining four patients:  
o One had only 14 months follow up at reporting.  
o One had a rise in creatinine between 12 and 24 months (115 to 136µmol/L), 
subsequently had a fall in creatinine to 90µmol/L at 30 months and was in CR from 
nephrotic syndrome at 18 months.  
o One had a baseline creatinine of 53µmol/L, at 12 months it had risen to 72µmol/L and 
at 24 months it was stable at 76µmol/L and had reached CR from nephrotic syndrome 
at 22 months;  
o One had a baseline creatinine of 64µmol/L, at 12 months it had risen to 88µmol/L and 
at 24 months it was 104µmol/L, they were in CR from nephrotic syndrome at 6 months 
and therefore was having their Tac withdrawn at time of reporting. 
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Figure 16:  Serum creatinine (µmol/L ) for each patient up to 60 months.  Red line denoting median creatinine at each 
time point. 
 
Patients with poor baseline function 
As previously described, 6/43 patients had a baseline creatinine >150µmol/L , which is 
approaching the KDIGO recommendation of the upper limit of when to treat a patient with IMN 
(they recommend to only treat if GFR is >25-30mls/min).  Only one of these six patients had a 
decline in function of more than 30% at 12 months.  Of the remaining 5, median creatinine at 0, 12 
and 24 months was 174, 188 and 146µmol/L  respectively. At 12 months, all five patients were in 
PR and by 24 months two had gone on to CR. 
One patient progressed to ESRF and it is really not clear if he received any significant tacrolimus; 
he had a variable adherence/attendance over a 9-year period, achieving a non-sustained PR 
during that time.  
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3.2.1.4  Tacrolimus Levels 
The Tacrolimus dose was titrated according to measured levels, aiming to achieve a trough level of 
6-9ng/L.  The median Tacrolimus level at each time point achieved was slightly lower, between 5-
7.2ng/L (Figure 17). 
 
 
 
Figure 17:  Median trough Tacrolimus level recorded up to 60 months.  Red line denoting median level. 
 
 
3.2.1.5  Tacrolimus Withdrawal 
Of the 23 patients who achieved a sustained CR for >12 months, Tacrolimus withdrawal has so far 
been attempted in 18 patients.  Of these, 10 had biopsies prior to withdrawal and no patient 
demonstrated any new subepithelial deposits on EM prior to withdrawal.  
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Importantly, 11/18 (61.1%) remain in CR off Tacrolimus at median time of 26 months (range 9-42 
months) since cessation of tacrolimus.  Of the remaining seven; 3 relapsed during withdrawal and 
4 relapsed at 4, 4, 7 and 8 months after cessation of Tacrolimus respectively.  There was no 
significant difference in the time to CR between the relapse and no relapse groups. On relapse, 6/7 
patients were recommenced on Tac, and 1 was switched to alternative treatment as the patient 
had a significant decline in GFR at the time or relapse.  Of the other 5 patients in a sustained CR: 
2/5 are currently having Tacrolimus withdrawn; 2/5 had previously relapsed after withdrawal of 
other therapy and 1/5 is an elderly gentleman who is maintained on low dose Tac. 
3.2.1.6  Nephrotic Relapses whilst on tacrolimus 
Of the 43 patients, 3 relapsed whilst they were still on tacrolimus (after 22, 57 and 30 months of 
treatment respectively).  Of these, 1 had low trough tacrolimus levels (1.1ng/L) at relapse, 
suggesting adherence may have been an issue.  Two patients had renal biopsies at the time of 
relapse showing active disease with stage 1 or 2 subepithelial deposits and were switched to 
alternative treatment. The other patient was initially successfully treated by an increase in 
tacrolimus dose; however he went on to have a further relapse and re-biposy at that time 
confirmed active disease and he was switched to alternative treatment. 
3.2.1.7  Patients treated with Tacrolimus for Over 5 years  
Thirteen patients have had >5 years of treatment with Tac including the 1 patient with variable 
attendance and adherence. Of the remaining 12, by 5 years, 5 patients were in CR and 7 achieved 
PR.   
Of the patients in CR 2/5 relapsed from CR on Tac and therefore Tac was continued with higher 
targeted trough tacrolimus levels and 1 of the 2 required MMF in addition to the Tac to re-establish 
CR.  3/5 patients were in a stable CR for greater than 12 months had withdrawal attempted; 1/3 
relapsed during withdrawal and recommenced Tac, 2/3 remain in CR now off Tac. 
Of the 7 patients in a stable PR Tac was continued in all; three patients had previously relapsed on 
alternative treatment regimens. 
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3.2.1.8  Adverse Events –Diabetes,  Malignancy and Deaths. 
One patient who was not previously known to be diabetic required commencement of an oral 
hypoglycaemic agent 3 years after commencement of Tac; he had previously been treated with 
Cyclosporin and prednisolone.  One patient developed facial basal cell carcinoma (after 6 years of 
Tac monotherapy), 1 patient was diagnosed with MGUS and 2 patients were found to have colonic 
tubulovillous adenoma.  
4 patients have died during follow up:   
Patient 1: 74 yrs at commencement of Tac, had 1 year of Tac and achieved a PR but had a 
progressive decline in renal function and reached ESRF 1 year after Tac stopped, she died 4 years 
after commencing haemodialysis.   
Patient 2: 71 yrs at commencement of Tac, had 6 years of Tac and achieved a stable PR however 
was admitted after a fall at home with sepsis and acute kidney injury, Tac was stopped and patient 
was commenced on haemodialysis, he died 3 months later.   
Patient 3: 82 yrs at commencement of treatment, had nearly 3 yrs of Tac and achieved a stable 
PR, however was admitted to another hospital with a septic illness and died during that admission.  
Patient 4: 61 years at commencement of Tac, had 4 yrs of Tac initially, but relapsed after 
withdrawal so was recommenced on Tac for a further 5 yrs and achieved a CR, died due to 
pneumonia 9 yrs after Tac commenced; the patient was also known to have pulmonary fibrosis 
and severe ischaemic heart disease. 
 
3.2.1.9  Histological findings on re-biopsy  
A number of patients in this cohort were re-biopsied during the study period. These biopsies were 
reviewed to ascertain the relationship of proteinuria with active immunological deposition and to 
look for scarring and evidence of tacrolimus toxicity. 
Twenty three patients (53%) have had a repeat biopsy (12/23 for consideration of withdrawal 
(10/11 in CR and 2/11 in stable PR); 5/23 for nephrotic relapse (3/5 on tacrolimus, 1/5 during 
tacrolimus withdrawal and 1/5 7months after tacrolimus withdrawn); 2/23 for persistent nephrotic 
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range proteinuria; 3/23 for rising creatinine on Tac; 1/23 for increasing proteinuria after Tac 
withdrawal.  Median time from commencement of tacrolimus monotherapy to re-biopsy was 41 
months (IQR 25-56 months).  Tacrolimus had been withdrawn in 2/23 within the 12 months prior to 
re-biopsy, all others were on tacrolimus at re-biopsy   All 23 patients were nephrotic at the time of 
their baseline biopsy.   
 
Proteinuria and Immunological activity in re-biopsy. 
At the time of repeat biopsy 11/23 had PCR <50mg/mmol; 4/23 had PCR between 50-300mg/mmol 
and 8/23 had PCR >300mg/mmol.  Results shown in Table 1.  It is significant to note PCR 
<50mg/mmol was associated with a lack of stage 1 and 2 deposits on renal biopsy.  Of those with 
PCR >50mg/mmol, 100% of patients had stage 1 + 2 subepithelial deposits consistent with 
proteinuria (not specifically nephrotic range) being a good surrogate marker for immunological 
activity in IMN. 
 
Proteinuria (patients) 
Stage 1&2 
Deposits 
Stage 3&4 
Deposits 
No Deposits 
<50mg/mmol (11) 1/11* 10/11 1/11 
>50 - <300mg/mmol (4) 4/4 4/4 0 
PCR>300 (8) 8/8 3/8 0 
*<10% stage 1&2 immune deposits, >90% stage 3&4 deposits. 
Table 6:  Relationship of immunological activity with proteinuria 
 
 
Proteinuria and renal function in relation to scarring on re-biopsy 
With respect to their GFR: 17/23 had stable serum creatinine at re-biopsy (median creatinine at 
first biopsy 96µmol/L  (IQR 77-130µmol/L) and median creatinine at re-biopsy was 121µmol/L  
(IQR 88-160µmol/L)); 6/23 had a >20% rise in creatinine in the 6 months prior to biopsy (median 
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creatinine at first biopsy 100µmol/L (IQR 70-138µmol/L); median creatinine at re-biopsy 201µmol/L 
(IQR 155-206µmol/L)). 
 
 Median  Change 
in % Tubular 
Atrophy from 
baseline to re-
biopsy (range) 
Median Change 
in % Segmental 
Sclerosis from 
baseline to re-
biopsy  (range) 
Change in % of 
patients with 
Arteriolar 
Hyaline 
Other findings not 
present on original 
biopsy 
Pts with CR of 
proteinuria at re-biopsy 
N=11  
+10% (-15 to +35) 0 (-51 to +50) +18% 1 pt TIN* 
Pts not in CR from 
proteinuria at re-biopsy 
N= 12  
+25% (-10 to +40) 0 (-8 to +40) 0 
1 pt TIN; 1 pt sub 
endothelial 
deposits; 1 pt 
mesangial deposits 
Stable function in 6 
months pre rebiopsy  
N= 17  
+10% (-15 to +35) 0% (-51 to +40) +6% 1 pt TIN; 1 pt mesangial deposits 
>20% rise in creat in 6 
months pre rebiopsy 
N= 6  
+13% (+5 to +40) +9% (+5 to +50) +17% 
1 pt TIN; 1 pt 
subendothelial 
deposits 
*TIN – Tubulointerstitial nephritis  
Table 7:  Relationship of scarring with proteinuria and renal function   
 
Even though we are reporting a relatively small cohort of biopsies we can show that CR does 
seem to be protective against tubular atrophy; however the number of patients with arteriolar 
hyaline is greater in this group – clearly illustrating the delicate balance between treatment success 
with TM and the known toxicity Tacrolimus can have on the kidney.  It was interesting to see that 
among the patients who were biopsied with a rising creatinine or with persistent proteinuria there 
were some with pathology other than on-going IMN or changes related to Tac treatment; 
demonstrating the importance of re-biopsy in this situation. 
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3.2.2  Discussion  
The results of this retrospective review of the novel treatment demonstrates that tacrolimus can be 
a useful therapeutic option when treating resistant IMN especially in patients who fail to reach a 
sustained CR but who are in a stable PR and in those where frailty and comorbid disease means 
that they have poor reserve for prolonged periods of nephrotic syndrome.  Two of the main 
concerns of TM in the treatment of IMN have been examined: that of relapsing/slow to respond 
disease and nephrotoxicity on longer term TM.  There is little published on the long-term use of 
tacrolimus monotherapy in the treatment of IMN, so whilst retrospective, these data add a valuable 
information to the literature. 
3.2.2.1 Patient Population 
The population that is described here is typical of an “all comers” IMN population. Twenty-five of 
the 43 (58%) patients we describe in this cohort are >50 years in whom more potent 
immunosuppression may be much more problematic due to a greater burden of pre-existing co-
morbid disease.  Additionally, this cohort adds useful data on using tacrolimus effectively in 
patients whose eGFR approaches the KDIGO treatment cut off of <25-30ml/min.  Importantly, only 
1/6 with a baseline creatinine >150µmol/L  had significant deterioration in function over the first 
year.   
3.2.2.2.  Remission Induction 
Consistent with previous studies (Praga, Barrio et al. 2007), this study shows that TM is an 
effective regimen for the induction of remission in idiopathic membranous nephropathy with 98% of 
patients achieving either a complete (70%) or partial remission (28%).  However, long-term 
treatment is often required to achieve a full response – patients went into CR up to 2 years after 
commencement of treatment. It was the case however, that during this time the biochemical 
parameters were consistently improving.  Relapses whilst on TM were very strikingly infrequent – 
occurring in only 7% of patients – indicating that whilst the patient remains on treatment their 
relapse risk is low.  From a clinical point of view it can be difficult to manage patients who achieve 
	   141	  	  
a stable PR without achieving a CR, as these patients have a higher risk of relapse after 
withdrawal of treatment, as demonstrated by Cattran et al. in 2001.  These are patients where TM 
is effective in maintaining patients in remission and avoiding nephrotic relapses. 
3.2.2.3  Nephrotoxicity 
As expected there was an initial rise in serum creatinine on commencement of TM (when used in 
combination with ACEI +/or ARB); however this then plateaued in subsequent years with no further 
significant rises.  When patients were re-biopsied in the context of a rising serum creatinine other 
pathologies were demonstrated histologically and treatment was reviewed.  This demonstrates the 
importance of re-biopsy in IMN when there is a significant decline in function.  It also demonstrated 
the importance of BP control and close monitoring of Tac levels in maintaining GFR when patients 
are being treated with TM.  Tac levels were monitored closely in this patient cohort.  An initial 
target range was set at 6-8ng/l; however on analysis remission was achieved at median Tac levels 
of 5-7.2ng/l; this lower level of Tac treatment may have had a favourable impact on preservation of 
renal function whilst on TM.    
In a similar haemodynamic fashion to ACEIs and ARBs there was a non sustained initial rise in 
serum creatinine; however as our non attender/ variably adherent patient demonstrated, those that 
are not monitored closely and/or have variable adherence/multiple relapses, have a higher risk of 
progressive renal impairment.  The balance of long-term immunosuppression needs to be 
balanced against the risks associated with recurrent or long-term nephrotic syndrome (especially 
thrombotic events and the risks associated with anticoagulation in an older population).  Many 
older patients with comorbid disease may not tolerate relapses. In these patients, in line with 
current evidence, a cyclophosphamide based regimen is may be more appropriate.  From our 
data, we demonstrated that it is possible to maintain a sustained remission from nephrotic 
syndrome in some patients without deterioration in GFR.  Therefore Tac could be considered for 
those in whom a cyclophosphamide based regimen is not suitable, but these patients would 
require particularly close monitoring of their GFR. 
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3.2.2.4  Re-biopsy  
The histology data clearly showed that proteinuria is a very good surrogate marker of 
immunological disease activity in IMN, in that all patients in a PR had evidence of on-going active 
disease.  This reinforces the previously reported higher risk of relapse after withdrawal of CNI from 
those in PR (Cattran, Appel et al. 2001).  Therefore, there should be caution if withdrawing 
treatment from a patient in a PR.  Disappointingly, from our cohort we did not find that pre-
withdrawal biopsies in those patients in a stable CR offered any indicative pathology to help predict 
relapse after withdrawal of treatment.  It is hoped that the on-going work into the role of anti-
phospholipase A2 receptor (PLA2R) antibodies, may provide a better prognostic indicator as to risk 
of relapse in complete responders (Beck, Fervenza et al. 2011).   
Our histology data also indicated that scarring is increased in patients with persistent proteinuria, 
therefore aiming to decrease proteinuria as much as possible may lead to preservation in renal 
function. Close monitoring of Tac levels is required as arteriolar hyalinosis was evident as a marker 
of Tac nephrotoxicity, even in patients with stable renal function. 
3.2.2.5  Withdrawal of Tacrolimus 
It was our usual clinical practice to attempt withdrawal of Tac after a period of >12 months from 
CR, unless the patient had significant comorbid disease where the risk of relapse was considered 
greater than the risk of continued immunosuppression.  It was reassuring to find that of the patients 
who had their TM withdrawn 61% remained in CR off treatment.  This is in comparison to Praga et 
al., where all patients were treated with 12 months Tac and then had treatment withdrawn over the 
following 6 months and only 53% remained in remission off treatment (Praga, Barrio et al. 2007). It 
may be that the strategy of only withdrawing treatment after a prolonged period of remission in our 
cohort resulted in the sustained remission rates achieved.  Clearly better ways of predicting those 
who will relapse are needed to limit prolonged immunosuppression only to those requiring it. 
3.2.2.6  Adverse Events 
It has been shown that even when underlying malignancy has been screened for at baseline 
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patients who are diagnosed with MN have an increased risk of developing cancer, which persists 
for many years.  This was reported in data from the Norwegian Kidney Biopsy Registry and the 
Norwegian Cancer Registry, where 15% (24/161) of patients went on to develop cancer within 15 
years of diagnosis of MN.  The MN population was compared with the age and sex adjusted 
general Norwegian Population (Bjorneklett, Vikse et al. 2007). From our study there was one facial 
basal cell carcinoma but no other overt malignancies were identified during the follow up period; 
this may be due partly to the thorough screening assessment done prior to commencement of 
immunotherapy and partly may relate to the low toxicity of this regimen. 
One new diagnosis of non-insulin dependent diabetes was made in a patient who had prior 
exposure to CyA and oral steroids; this suggests that Tac in this cohort was not diabetogenic; as 
previously reported this more often occurs when Tac is used in combination with steroids. 
The four patients who died during follow up were all over seventy when they died.  All 4 had >1 
years treatment with Tac and had all achieved at least a partial remission.  All four patients had 
comorbid disease and at the time of death and 3 of the 4 were approaching 80 or over 80 at the 
time of their death.   Sepsis was a contributing factor to their deaths, which could be attributed to 
immunotherapy; however it should be remembered that sepsis is often a contributing factor to 
death in the elderly population. 
3.2.2.7  Comparison with Published Trials   
In a very broad comparison with the seminal RCT comparing conservative management with 
methylprednisolone and chlorambucil (Ponticelli, Zucchelli et al. 1995), our cohort includes 7 
patients over their upper limit of 65 years and 5 patients with baseline creatinine >150µmol/L, all of 
whom would have been excluded from their trial.  The 98% CR or PR response rate to TM 
described here is much better than that of their methylprednisolone/chlorambucil arm, where a 
66% remission rate from nephrotic syndrome was reported at 3 years (Ponticelli, Zucchelli et al. 
1992) In view of the less toxic side effect profile of Tac treatment, our cohort study demonstrates 
how it can be continued to ensure a maintained good response. Despite the non-nephrotoxic 
nature of the Ponticelli regimen, the 10 year follow up data demonstrated a deterioration in function 
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in the treatment as well as the non treatment arms. The deterioration in function was delayed in the 
treatment arm, but was particularly pronounced after 90 months where 2 patients in the treatment 
arm had progressed on to ESRF.  This demonstrates that even with the current preferred 
treatment regimen a deterioration in function will occur in a proportion of patients. 
Howman et al. in the UK RCT comparing conservative treatment vs Ponticelli regimen vs 
ciclosporin treatment in those with IMN and who have already had a progressive decline in their 
GFR prior to starting treatment, demonstrated no advantage of adding a calcineurin inhibitor to 
placebo where the Ponticelli regimen was superior to placebo (Howman, Chapman et al. 2013).   
There is new published data demonstrating the efficacy of 12 months treatment with low dose 
Tacrolimus used in combination with corticosteroids (Chen, Liu et al. 2013, Yuan, Liu et al. 2013) 
for IMN and its superiority to cyclophosphamide (used in combination with corticosteroids), for 
remission induction (64% CR in Tac group compared with 29% in the Cyclophosphamide group at 
12 months) (He, Peng et al. 2013, Xu, Zhang et al. 2013).  The study reported here is the first 
cohort of Tacrolimus being used alone to maintain a long-term remission in IMN, therefore avoiding 
the more severe side effects of a dual treatment, especially the propensity towards diabetes. 
 
3.2.2.8  Limitations to Tacrolimus Monotherapy Cohort 
This is a retrospective collection of data from across two hospitals.  The data were collected using 
the most thorough methods possible (looking at all electronic data and reviewing all the patients 
notes). However there will be events that are not documented in the notes or recorded 
electronically and therefore this needs to be considered when interpreting the results.  Patients 
were treated according to a clinical protocol, but without the rigours of a trial protocol there may 
have been deviation.  Also interpreting clinical decisions in a retrospective manner can often be 
quite subjective. 
  From the outset, there was no pre-determination with regards to who would be on long-term TM 
and who would have treatment withdrawn. These decisions were generally made in a consistent 
manner in response to clinical outcomes. It may, however, have made the data more transparent if 
this was determined prospectively in a protocolised manner. 
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3.2.2.9 Future Work 
In response to the outcome of this retrospective review and the 2007 RCT of TM versus 
conservative management for the treatment of nephrotic syndrome secondary to IMN (Praga, 
Barrio et al. 2007), both demonstrating a significant relapse rate after the withdrawal of treatment 
(39% and 47% respectively) a RCT was designed to investigate whether by combining TM with 
MMF (MTac trial), the relapse rate may be reduced.  This trial is described detail in section 2.1.3. 
Patients are randomized to either Tacrolimus alone or Tacrolimus in combination with MMF. Once 
patients are in CR for 1 year the treatment is withdrawn and the primary outcome is time to relapse 
after withdrawal.   The trial is currently recruiting and should have first results available in February 
2016.   
This cohort also demonstrated how TM can be used to maintain remission in patients who have 
relapsing or resistant disease.  This is another area that could be investigated in the fashion of a 
RCT.  However, this would be a more difficult trial to design as by the point a patient has had 
relapses or it has been recognized that they have resistant disease, the patients’ would have been 
exposed to various treatment regimens and would therefore belong to a more diverse population.    
3.2.2.10 New Treatments on the Horizon 
There has been interest in using B-cell depletion as a treatment option for IMN for the past 5-10 
years. This was particularly reinforced with the identification of anti-PLA2R antibodies in IMN in 
2009, in particular looking at Rituximab therapy.  There have been various case reports and cohort 
studies reporting the success of rituximab in the treatment of IMN, but as yet there have been no 
published RCTs. Over 10 years ago Rituximab was first reported to induce remission when used to 
treat IMN (Ruggenenti, Chiurchiu et al. 2003). Busch et al. reported on its safety and efficacy as a 
2nd or 3rd line agent in the treatment of IMN, with a 71% response rate at 1 year (21% CR and 50% 
PR) (Busch, Ruster et al. 2013). Probably the largest cohort reported was by Ruggenenti et al. in 
2012, who described the outcomes of 100 consecutive IMN patients: 65% (27% CR and 38% PR) 
achieved remission during a median 29 months follow up period with a median time to remission of 
7 months.  Eighteen of the 65 patients achieving remission had a relapse of proteinuria from 7-116 
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months (median 42 months) after rituximab administration.  All received a second course of 
rituximab with 4/18 achieving CR and 7/14 achieving PR.  After initial treatment with Rituximab, no 
other courses of rituximab were given except when the patient had relapses (Ruggenenti, Cravedi 
et al. 2012). These cohort reports of rituximab use in IMN appear to demonstrate comparable 
remission rates to cyclophosphamide-based regimens and tacrolimus-based regimens (70% CR in 
the Tac Monotherapy cohort), but within the “remission” the proportion of CR is smaller when 
compared with the other regimens. 
As per https://clinicaltrials.gov, there have been two pilot studies looking at the efficacy and safety 
of rituximab in IMN, both have completed recruiting and have reported reasonable outcomes: 70% 
response rate at 1 year (CR=20%) in one cohort and a 65% response rate in a larger cohort, but 
again CR rates lower than PR.  There are now three RCTs recruiting involving Rituximab: the first 
using tacrolimus for 6 months then at that point patients receive a dose of rituximab prior to 
tacrolimus withdrawal versus a modified Ponticelli regimen of cyclical corticosteroids and 
cyclophosphamide (STARMEN). The second comparing non-immunosuppressive supportive 
treatment alone versus non-immunosuppressive supportive treatment + Rituximab at day 1 and 
day 8 (GEMRITUX). The third compares Rituximab at day 1 and day 15 (redosing at 6 months if 
not in CR) versus 6 months of cyclosporin treatment (continued for another 6 months if not in CR) 
(MENTOR).   
What is clear from the variation in regimens from these three trials is that there currently isn’t a 
clear “standard of care” worldwide consensus for the treatment of IMN.  As the original and the 
now more commonly used modified Ponticelli regimen was a treatment for a finite period (i.e. 6 
months), there does seem a tendency in these trials to treat patients for a finite period regardless 
of their response to treatment.  It maybe that treating patients for a finite period after they have 
achieved the desired response would be another approach that may produce a better long-term 
response.   It may also be, as demonstrated in the tacrolimus monotherapy cohort described here, 
that some patients require longer term treatment to maintain them free from nephrotic syndrome 
and therefore avoid the associated decline in renal function associated with multiple nephrotic 
relapses.  In the future, once there is a clearer understanding of the role of anti-PLA2R antibodies, 
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they may give further information to identify those at higher risk of relapse and therefore require a 
prolonged treatment course.   
Another treatment that is also being currently investigated is AdenoCorticoTrophic Hormone 
(ACTH).  ACTH is currently the only US Food and Drug Administration (FDA) approved therapy for 
the treatment of nephrotic syndrome.  In animal models of membranous nephropathy, stimulation 
has been demonstrated to reduce podocyte injury and loss.  A pilot study of 20 patients with IMN 
with nephrotic range proteinuria but with an eGFR >40mls/min, has recently been published 
demonstrating the safety of the drug; a significant improvement in proteinuria, but without a 
significant remission rate at 1 year.  Therefore ACTH could be a potential treatment that would 
deserve further study (Hladunewich, Cattran et al. 2014). 
  
	   148	  	  
3.3  Summary 
Two cohort studies have been described and reported.  The Rituxilup cohort demonstrated the 
effectiveness of a novel treatment regimen without the use of oral steroids and the TM cohort 
described a novel approach to the treatment of IMN with prolonged treatment in patients who had 
recurrent relapses or who failed to achieve a CR.  Both cohort studies have contributed to the 
design of follow on RCTs; one currently recruiting in IMN and one multinational trial in its final 
stages of preparation prior to recruiting.  This demonstrates the importance of cohort reporting to 
the aid the design of clinical trials, particularly with respect to expected outcomes to allow 
adequate power calculations. 
As extensively discussed there are many RCTs currently recruiting and reporting in both diseases, 
which will create a more secure knowledge base when making decisions on the most appropriate 
treatments to offer individual patients.  However the current challenge is designing the “right” trial 
to give the most clinically relevant results; in these 2 rare diseases this can often be the stumbling 
block.  Some of these issues will be addressed by using the UK registry for Rare Renal Diseases 
(RaDaR).  This is where any health professional can register a patient and enter information about 
them if they have a listed rare renal disease, in the hope that it will lead to a much better 
understanding of how these illnesses affect people and that it will allow a more integrated multi 
centre approach to research. 
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CHAPTER 4 –– NOVEL BIOMARKERS 
 
 
In this chapter I present work on biomarkers in LN and in IMN. The first section reports the results 
of the data analysis of the ELISA tests performed on the stored urine samples from patients with 
lupus nephritis, quantifying the concentration of two potential urine biomarkers:  Macrophage 
Migration Inhibitory Factor (MIF) and Angiogenin (highlighted during a discovery cytokine array 
experiment).  There are then discussions looking at their feasibility as disease biomarkers, 
identifying further work that would need to be done to define their biomarker status and assessing 
their potential to be therapeutic targets.  In the second section I present the results of the indirect 
immunofluorescence test for the identification of anti-PLA2R antibodies from the serum of patients 
with biopsy proven IMN from the MTac trial.  The test itself is discussed and compared with tests 
that have now become commercially available.   
 
4.1 Hypothesis 3 - Urinary Macrophage Migration Inhibitory 
Factor (MIF) is a valid biomarker of Lupus Nephritis Activity 
The biological activity of MIF was first described in 1966. As described in detail in section 1.3.1.2,  
it has a pathogenic role in kidney disease. Up-regulation of MIF is detected in kidney tissue in both 
human and experimental kidney disease including renal allograft rejection. It contributes 
significantly to macrophage and T-cell accumulation and progressive renal injury.  It mediates renal 
injury through the innate and adaptive immune systems, the induction of cytokines, chemokines 
and adhesion molecules as well as interactions with glucocorticoids and the hypothalamic-pituitary-
adrenal axis. Its functional importance in kidney disease has been demonstrated with the use of 
anti-MIF antibody preventing and reversing renal injury in crescentic anti-GBM glomerulonephritis.  
It has been shown to be present in the urine of patients with active LN. I report the first cohort 
study analysing urinary concentrations of MIF in relation to treatment response, histological 
classification of LN, proteinuria, renal function and degree of steroid exposure.  In this cohort 
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approximately 50% of samples were from those patients receiving the steroid sparing RL regimen 
and the remaining 50% were from patients treated for lupus nephritis with alternative treatment 
regimens, which would have exposed the patient to oral steroids. 
4.1.1 Results 
4.1.1.1  Urinary MIF and response to treatment 
As described in section 2.2.1.2, 73 samples from +/- 5 weeks of renal biopsy and 81 samples from 
26-52 weeks post-biopsy (36 CR; 29 PR; 16 NR) were analysed.  uMIF/creat is significantly 
reduced in all patients at 26-52 weeks post biopsy compared with biopsy (Figure 18). 
 
Figure 18: Significant difference between uMIF/creat at biopsy and at 26-52 weeks p<0.0001 (Mann-Whitney Test).  Red bars denote 
median and IQR for each group.  Normal range uMIF/creat is <200ng/mmol. 
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The more significant the clinical response the more significant the reduction (Mann-Whitney Test). 
• CR = 58% (p<0.0001) (Figure 19) 
• PR = 44% (p=0.0002) 
• NR = 37% (p=0.0175) 
There is a significant correlation between uMIF/creat and uPCR (Figure 20) at time of active biopsy 
(p=0.027, Spearman's correlation R=0.26), but not with serum creatinine. 
uMIF/creat at biopsy did not show a significant correlation with time to CR (Figure 21) or with class 
of LN (Figure 22). 
 
 
 
 
 
Figure 19: Plot demonstrating Median and IQRs of uMIF at biopsy and at Complete Remission.  Significant reduction in uMIF/creat 
(ng/mmol) from biopsy to CR p<0.0001.   Normal range MIF/creat is <200ng/mmol. 
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Figure 20: Scatter Plot of uMIF/creat against uPCR.  Significant correlation between uPCR and uMIF/creat at biopsy p=0.027 
(p=0.027, Spearman's correlation R=0.26)   
 
 
Figure 21:  Scatter plot demonstrating no significant correlation between uMIF/creat at biopsy and time to CR (r=-0.03). 
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Figure 22:  Box and whisker plot of uMIF/creat at biopsy by Class of LN.  No significant difference found between classes. 
4.1.1.2 Relationship between Steroid Exposure and Urinary MIF 
MIF levels were compared between those treated with the steroid sparing regimen (RL) 
and those treated with other regimens.  One of the enrolment criteria to receive the RL 
regimen was that the patient was not already receiving oral steroids.  Therefore it can be 
presumed that the patients receiving the “other” treatment regimen would have already 
received oral steroids at the time of biopsy or as a part of their treatment regimen.  It was 
found that those patients who received the RL regimen had higher baseline MIF levels, 
approaching statistical significance (p=0.054).  (Figure 23) 
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Figure 23:  Plot of Median and IQR uMIF/creat according to treatment received.  Demonstrates a trend for lower 
uMIF/creat in patients receiving therapeutic Glucocorticoids.  Difference between RL and “Other” at +/- 5 weeks from 
biopsy approaching significance; p=0.054. 
 
 
  
RL
Ot
he
r RL
Ot
he
r
0
200
400
600
800
1000
Treatment Regimen
uM
IF
/c
re
at
 n
g/
m
m
ol
+/- 5 weeks from biopsy
26-52 weeks from biopsy
	   155	  	  
4.1.2 Discussion  
MIF has been previously shown to be detectable and measurable in proliferative glomerular 
disease.  It is released from macrophages, lymphocytes, glomerular and tubular epithelial cells, 
endothelial cells, fibroblasts and vascular smooth muscle cells.  It is preformed and stored within 
the cells and released in response to cellular stress, endotoxin, exotoxin, infection, inflammation 
and immune responses (such as in lupus nephritis).  
In this study, we investigated urinary MIF (uMIF) longitudinally in a cohort of patients in response 
to immunotherapy and evaluated its predictive value of outcome at time of biopsy.  We were able 
to differentiate between patients who had received the steroid sparing “Rituxilup” regimen and 
other treatment regimens where longer term steroid exposure is inherent to the regimens.   
4.1.2.1 uMIF in active LN and Remission 
Consistent with the findings of Brown et al. and Kerschbaumer at al. it was found that urinary MIF 
was elevated in patients with active lupus nephritis (Brown, Nikolic-Paterson et al. 2002, Randolf J. 
Kerschbaumer 2012). In the current study, active lupus nephritis was further defined by class and 
we showed that uMIF is elevated in all classes of LN; this contrasts with urinary MCP1, which has 
been shown to be within the normal range in patients with Class V LN.  As the patients responded 
to treatment the levels of urinary MIF decreased and when patients achieved complete remission 
the urinary MIF levels fell within normal range.  As previously mentioned MIF is constitutively 
expressed, stored in the cytoplasm and constantly present in the circulation of healthy subjects.  
uMIF is abundant in all patients with active Lupus Nephritis on renal biopsy, but as the disease 
goes into remission the levels fall significantly.  Since only small amounts of uMIF can be detected 
in healthy subjects, any increase in uMIF might be presumed to be pathological and maybe 
indicative of a “smouldering” disease process, which would correlate with my findings.  
4.1.2.2 Variation in uMIF between “standard” treatment for LN and Steroid Sparing Regimen 
(Rituxilup) 
As described in section 1.3.1.2 MIF can act as a physiological counter-regulator of glucocorticoid 
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action within the immune system.  MIF is preformed and released in LN after stimulation by 
inflammation and the immune response.  Unlike the other pro-inflammatory cytokines, which are 
inhibited by glucocorticoids, MIF is induced by glucocorticoids and acts as an antagonist of 
glucocorticoid action within the immune system, therefore promoting further inflammation.  The 
process of glucocorticoid induced MIF secretion is tightly regulated and follows a bell-shaped 
dose-response curve, indicating that MIF release is inhibited at high anti-inflammatory 
concentrations of glucocorticoids. It has been hypothesized that MIF induced renal injury may be 
associated with it’s antagonistic action upon the anti-inflammatory and immunosuppressive effects 
of glucocorticoids.  
This MIF/glucocorticoid response has only been demonstrated in vitro and in animal models; and 
this has not been demonstrated in any human studies to date.  Both in vitro and in animal work it 
has been demonstrated that there is a dose related relationship between glucocorticoids and 
serum MIF (Calandra, Bernhagen et al. 1995).  The conclusion of this work was that “MIF is a 
critical component of the immune system and acts together with glucocorticoids to regulate 
inflammation and immunity”.   
Given this unique relationship with glucocorticoids, evaluating its usefulness in a group of patients 
treated with a steroid-sparing regimen, may provide a clearer indication of the role of MIF in the 
pathogenesis of LN without the influence of exogenous glucocorticoids.  In the absence of 
exogenous steroids it would be hoped that you could see more purely the stimulation and effect of 
MIF that is related to the autoimmune process, rather than having a mixed picture of both MIF 
stimulation by the autoimmune process but also due to the presence of glucocorticoids.  In the 
patient’s who receive a non-steroid-sparing regimen, you would expect that in the first 26 weeks of 
treatment they would have a relatively high level of exposure to glucocorticoids placing them at the 
far end of the Bell shaped curve. They therefore would have both inflammation dampened by the 
steroids and MIF release would likely also be inhibited.  Interestingly however, at the mid-point in 
the curve, if there still is LN activity when the steroid dose is being reduced, it is probable that you 
would at that point get a “release” of MIF.  
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The data presented does demonstrate that the group exposed to high dose steroids as a part of 
their treatment regimen did have reduced uMIF/creat (p=0.054) at the time of induction, but not 
quite reaching significance.  By 26-52 weeks most patients are going into remission so lower levels 
are seen in both groups due to the reduced inflammation and autoimmune activity.  It may be due 
to this that even as the dose of steroids is weaned a MIF resurgence is not detected.   
There are limitations to this work as the groups were divided crudely into those receiving the 
Rituxilup steroid sparing regimen and those receiving standard treatments.  It is possible that a 
proportion of the uMIF samples in the “peri-biopsy” period may have been taken after the initial 
methylprednisolone doses at the commencement of the treatment.   
The more interesting group to characterize would be the patients who did not respond to a steroid 
based treatment. It could have been that the dose of steroid that they received was not sufficient to 
suppress MIF release and therefore in that situation the steroids are promoting the action of MIF.  
A further question to ask about the early responders is: are they steroid-sensitive in such a way 
that MIF is suppressed at lower doses of steroid compared with others?  
To examine the relationship of human uMIF to glucocorticoids many patients would need to be 
followed in a longitudinal manner and uMIF measured in relation to disease activity with accurate 
recording of their steroid dose.  However, in the situation where steroid dose is changed according 
to disease activity it may be difficult to clearly see uMIF in response to glucocorticoids.  
4.1.2.3 Future work 
Active MIF 
Kerschbaumer et al. studied an isoform of MIF rather than total MIF.  In their work they found that 
an isoform of MIF is produced in diseases and cannot be detected in healthy subjects and it is 
specifically recognised by human monoclonal anti-MIF antibodies, which have shown benefits in 
animal models of glomerulonephritis.  With this more specific targeting of MIF much lower doses of 
steroids would be required to produce the same effect as they would not need to overcome the 
initial MIF response to lower dose steroids.  With this more targeted MIF antibody it may improve 
it’s safety profile when it is eventually trialed in human subjects.   
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MIF genotyping and Steroid Resistance 
In paediatric patients with nephrotic syndrome studies have demonstrated a relationship between 
MIF genotypes and steroid resistance.  The MIF promoter contains a G/C polymorphism that is 
functionally relevant, with the C allele being associated with higher MIF production and linked to 
susceptibility to inflammatory diseases.  When this polymorphism was genotyped in children with 
idiopathic nephrotic syndrome there was a significantly higher frequency in those patients 
compared with controls.  Also the carriers of this phenotype had a significantly higher probability of 
ESRF compared with G/G homozygous patients (however this could be said to be due to treatment 
resistance rather than disease process per se) (Vivarelli, D'Urbano et al. 2008).  MIF gene 
polymorphisms (The MIF promoter polymorphism mentioned above (-173 G>C (rs755622) and 
another MIF risk allele (-794 CATT5-8 (rs5844572)) have been found to have a significant 
association with susceptibility to SLE when compared with controls (De la Cruz-Mosso, Bucala et 
al. 2014). 
Bucala has hypothesized that MIF has a dual influence on the immunopathogenesis of SLE; in that 
high expression MIF alleles are associated with a reduced susceptibility to SLE (perhaps by 
enhancing clearance of autoimmunogenic pathogens). But once SLE develops, low expression 
MIF alleles protect against ensuing inflammatory end-organ damage. This would suggest a 
potential evolutionary advantage of maintaining a (autoimmunity) susceptibility gene in the 
population, in that high-expression MIF alleles may allow for a maximal anti-infective response 
despite risk of autoimmunity.  From a pharmacological prospective MIF antagonism may be most 
appropriate in those with more MIF-dependent autoimmunity (Bucala 2013). 
 
Therapeutic Target 
Due to the clearly defined pro-inflammatory action of MIF it has been considered as a potential 
therapeutic target in Lupus.  The data I have presented demonstrates the high levels of uMIF in 
active disease and then reduction as the disease goes into remission.  It is clear that current 
treatment regimens available (both steroid using and steroid sparing) address the inflammatory 
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and immune triggers for the release of MIF, however being able to target MIF directly may reduce 
the toxicity of these regimens.  
Also, in view of its unique antagonistic relationship with glucocorticoids it may be a therapy that 
could be used in a steroid sparing capacity, as lower doses of glucocorticoid would be required to 
produce the same anti-inflammatory effect but fewer adverse steroid-related side effects. 
A diverse panel of fully human anti-MIF antibodies has been developed.  Work both in vitro and in 
animal models is currently under way to identify the most clinically efficient antibody that could 
eventually be used as a therapy in patients (Kerschbaumer, Rieger et al. 2012). The 
pharmaceutical company Baxter has identified a fully human monoclonal antibody against MIF - 
BAX B01.  In 2012, they demonstrated that BAX B01 is efficacious in a rat model of proliferative 
nephritis, even after a single administration.  No related signs of toxicity were observed after 
administration (Bernhard Baumgartner 2012). This may be a potential new therapy for proliferative 
lupus nephritis. 
4.1.2.4  Is uMIF a useful urinary biomarker in Lupus Nephritis? 
uMIF is biologically plausible and relevant to disease pathogenesis.  It has previously been shown 
that in kidney disease it is only uMIF that relates to disease activity and not serum MIF, indicating 
that the production of MIF is confined to the kidney.  However this was not studied in patients who 
have both systemic features of SLE in addition to active LN and it may be that elevated serum MIF 
is found in these patients but this has yet to be studied. 
The current study has shown that uMIF distinguishes well between active disease and remission 
with a significant reduction in uMIF between baseline and complete remission.  However it was not 
possible to demonstrate a predictive value of baseline uMIF and time to CR. It was possible to 
demonstrate a correlation between urinary Protein:Creatinine ratio and uMIF/Creatinine, probably 
showing that uMIF relates to PCR in the same way PCR is a very good marker of disease activity.  
The method used for measurement of uMIF, namely a commercial ELISA, has already been 
shown to be reproducible.  It is a test that could be made available for routine use if a unique 
clinical application was found.  Therefore more work is required to look for the unique role uMIF 
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may have in LN; this may be related to its role in patients with persistent proteinuria as from this 
study it has been shown that if the proteinuria is related to any class of LN the patient will have an 
elevated uMIF level. 
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4.2 Hypothesis 4 – A novel urine biomarker can be identified 
using a discovery method and then be validated. 
The results and limitations of the discovery cytokine array are presented here along with the 
analysis of the validation work on the novel urinary cytokine Angiogenin highlighted in the array 
experiment.  Specific ELISA had been performed to validate and quantify urinary angiogenin 
(uAng) in 342 urine samples from 34 patients collected over a 4 year period, during which all 
patients had at least 1 episode of biopsy proven ISN/RPS Class III/IV/V LN treated with the same 
treatment protocol: the steroid sparing Rituxilup regimen. The biological activity of angiogenin is 
then discussed, along with its potential as a disease biomarker in LN, the future work required for 
this and its potential as a therapeutic target. 
4.2.1  Results 
4.2.1.1  Discovery Human Cytokine Array 
As described in 2.2.2 an array based approach was used to discover new chemokines that 
distinguish active/inactive Class III/IV LN and class V LN.  The arrays included cytokines, MCP-1 
and MIF and had already been described in Lupus Nephritis.  Urine from 8 patients was 
individually screened for the presence of novel cytokines with this technique. 
• 2 patients with active Class IV LN prior to any treatment being given 
• 2 patients with active Class V LN prior to any treatment being given 
• 2 patients with Class IV LN in complete remission 
• 2 patients with proteinuria due to primary Focal Segmental Glomerular Sclerosis (FSGS) 
Both MCP-1 and MIF had particularly strong signals in the urine samples from the patients with 
active LN. 
Additionally, the results of the discovery cytokine array demonstrated high concentration of a not 
previously described cytokine in the urine samples of patients with active LN – Angiogenin (also 
referred to as Ribonuclease 5). 
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To validate and define Angiogenin as a novel urinary cytokine in LN we used an ELISA based 
method to measure urinary Angiogenin levels in the urine samples we had collected from the 
patients receiving the Rituxilup Regimen.   
4.2.1.2  Validation of Novel Cytokine 
Specific angiogenin ELISA was performed to validate and quantify cytokines discovered by 
antibody array. Urine Angiogenin (uAng) was measured in 342 urine samples from 34 patients 
collected over a 4-year period.  During that time all patients had at least 1 episode of biopsy 
proven ISN/RPS Class III/IV/V LN, for which they received the steroid sparing “Rituxilup” regimen. 
uAng levels were normalised for urinary creatinine (creat) level. 
To demonstrate if there was a relationship between uAng/creat and outcomes, samples from the 
time of renal biopsy (n=33), partial remission (n=28) and CR (n=30) were analysed. There is a 
significant correlation between uAng/creat and serum creatinine at time of active biopsy (p=0.011, 
Spearman’s correlation R=0.45) (figure 24), but not with uPCR (figure 25).  uAng/creat is 
significantly reduced in PR and CR by 51% (p<0.05) and 84% (p<0.001) respectively (figure 26). 
 
Figure 24: Scatter Plot of uANG/creat against serum creat at time of biopsy. uAng:creat pg/mmol is significantly 
correlated with serum creatinine.  (p=0.011, Spearman’s correlation R=0.45) 
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Figure 25: Scatter Plot uANG/creat against uPCR at time of biopsy.  uAng:creat (pg/mmol) does not correlate with uPCR.  
(p=0.384, Spearman’s correlation R=0.16) 
 
 
 
Figure 26: uAng:creat (pg/mmol) at biopsy, PR and CR.  Patients with Class III, IV and V LN were all included.  
Significant difference between groups,  p<0.001 using Kruskal-Wallis Test.  Normal range uAngiogenin is < 110pg/mmol 
creat.  Red lines denote median and IQR. 
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4.2.2  Discussion 
4.2.2.1 Biological Activity 
Angiogenin (Ang), also known as Ribonuclease 5, is a 123 amino acid protein (Strydom, Fett et al. 
1985). It has been described quite extensively as a tumor angiogenic factor (Li and Hu 2010), but 
its biological activity has been extended from inducing angiogenesis to stimulating cell proliferation 
and more recently, to promoting cell survival (Li and Hu 2012).  
 
• Under growth conditions, Angiogenin is translocated to the nucleus where it accumulates in 
the nucleolus and stimulates ribosomal RNA (rRNA) transcription, thus facilitating cell 
growth and proliferation.  
 
• Under stress conditions, Angiogenin accumulates in cytoplasmic compartments and 
modulates the production of tiRNA, a novel class of small RNA that is derived from tRNA 
and is induced by stress. tiRNA suppress global protein translation. Ang-mediated tiRNA 
reprograms protein translation, saves anabolic energy, and promotes cell survival.  
 
Angiogenin presents a novel mechanism of action in regulating cell growth and survival, which is 
summarised in Figure 27.  The presence of Ang in glomerular disease is not known. This is the first 
description in relation to activity of lupus nephritis (LN). 
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Figure 27: Mechanism of action of ANG.  Growth signals stimulate nuclear translocation of ANG, whereas stress signals 
direct ANG to stress granules.  Both pathways are mediated by a cell surface receptor that remains to be identified.  
Nuclear ANG stimulates rRNA transcription, enabling ribosome biogenesis and therefore cell growth and proliferation.  
Under stress conditions, ANG is not translocated into the nucleus but is rather accumulated in cytoplasmic 
compartments such as stress granules where is mediates the production of tiRNA, reprograming protein translation and 
promoting survival.  (Li and Hu 2012) 
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4.2.2.2 Angiogenin in Kidney Disease 
There are no published peer reviewed data reporting Angiogenin in kidney disease.  In 2013 
Bouvier et al. presented some early work at the American Kidney week in abstract format.  They 
reported that Angiogenin is secreted by the renal epithelium in response to endoplasmic reticulum 
(ER) stress.  This work was undertaken in vitro using human renal epithelial cells in culture and in 
vivo in a rat kidneys challenged with tunicamycin, cyclosporin and ischaemic stress.  They also 
used recombinant human Angiogenin to demonstrate a reduction in apoptotic cell death, 
autophagy and ER stress.   
They showed that inhibition of Angiogenin expression by RNA interference reduces pro-
inflammatory cytokine secretion, suggesting that Angiogenin promotes tubular inflammation.   In 
100 patients with kidney disease (no specifics provided) they found that uANG/creat levels 
positively correlated with estimated GFR, consistent with our data on patients with LN.   
Using immunohistochemistry analysis of human kidney biopsies they demonstrated angiogenin 
expression in ischaemic kidneys and in those with cyclosporin nephrotoxicity, but not in normal 
kidneys.  They suggested angiogenin maybe a potential non-invasive diagnostic biomarker of 
tissue injury (Nicolas Bouvier and Mami. 2013).  We are planning on performing 
immunohistochemistry to demonstrate angiogenin on the biopsies from our patients with active LN, 
in the first instance. 
4.2.2.3 Potential as Urinary Biomarker in Lupus Nephritis 
As this was a completely novel biomarker for lupus nephritis, we only analysed uANG in patients 
treated with a single regimen (Rituxilup) to enable its validation in relation to the disease process 
rather than in relation to variations in treatment.  
In this well described cohort, uAng was associated with the severity of renal impairment at the time 
of biopsy of active lupus nephritis, and showed significant reduction in patients with remission 
following immunotherapy.  The lack of correlation of uAng with uPCR at presentation suggested 
that uAng is an independent marker that is not a consequence of proteinuria.   
With the correlation with active disease and with the severity of renal impairment but not with 
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proteinuria, the role of angiogenin in the pathogenesis of lupus nephritis must in some way be 
independent of the podocyte injury, but be integral to the proliferative damage of active lupus 
nephritis.  In a similar way to how MIF was initially investigated it would be incredibly valuable to 
measure serum Angiogenin as well as to stain for Angiogenin on biopsies from patients with 
various types of proliferative and non-proliferative glomerular disease.  As it was also related to 
renal impairment it would be interesting to see if angiogenin is active in patients with renal 
impairment from other non-proliferative disease processes such as tubulo-interstitial nephritis. 
4.2.2.4 Summary 
uANG has been found in urine samples from patients with active LN.  As the disease goes into 
remission uANG levels fall significantly.  There is an association between uANG and the degree of 
renal impairment but not with the degree of proteinuria.  This is the first time uANG has been 
described in a defined glomerular disease.  These data indicate that angiogenin may have a 
pathological role in LN and may be relevant in other renal diseases. 
Further work is required to further define the role of angiogenin in the pathogenesis of LN and to 
investigate its role in other renal diseases.  It may be that this can be done with further patient 
urine samples, histology and serum samples, ideally from a prospective trial in lupus nephritis. 
Animal model work, however, may give a more detailed explanation with regards the pathological 
role of angiogenin. 
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4.3  Hypothesis 5:  Serum Anti-PLA2R antibodies can be used 
as a biomarker for Idiopathic Membranous Nephropathy in 
routine clinical practice. 
 
The first description of PLA2R antibodies in association with IMN was in 2009.  Anti-PLA2R 
antibodies have been found in approximately 70% of patients with biopsy proven IMN, but are not 
found in the healthy population (Murtas, Bruschi et al. 2012). In the 2009 publication, Beck et al. 
detected the anti-PLA2R antibodies in the serum of patients with IMN using Western Blot 
technique, which can be time consuming, laborious and difficult to replicate, and has proven 
unsuitable for routine clinical use.  In 2011/12 an indirect immunofluorescence test (IIFT) became 
commercially available (Euroimmun©).  It was designed to qualitatively or semi-quantitatively 
determine human anti-PLA2R antibodies in serum or plasma.   
At ICHNT RTC there was a very well defined group of patients with IMN who had been enrolled in 
the MTac trial, which commenced recruiting in 2009.  As described in section 2.2.4, patients were 
randomized in one of two treatment arms – tacrolimus or tacrolimus PLUS MMF – for the treatment 
of IMN.  By 2012, serum was available on 24 of the 31 patients enrolled in the trial.  Serum had not 
been collected prospectively from the outset of the study, so not all patients had pre-treatment 
samples available.   
4.3.1  Results 
Fifty-nine samples were tested in total from 24 patients.  23/59 samples were either pre-treatment 
or within 6 weeks of commencing treatment.  11/59 samples were within 52 weeks after the patient 
had reached CR (range 0-46 weeks).  Of the remaining 25 samples 9 were in patients >52 weeks 
after reaching CR, when the patient would have been withdrawing from immunotherapy and the 
remaining 16 were >6 weeks after commencing immunotherapy and before reaching CR (range of 
18-161 weeks after initial enrolment).   
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A qualitative result is reported in all samples, i.e. they are either positive or negative.  From those 
59 samples in 24 patients; 15 patients (62%) had at least one positive test.   
In a further analysis we looked at pre-treatment to up to 6 weeks after the commencement of 
treatment there were 23 samples from 19 patients; 11 of those 19 patients (58%) had a positive 
test.  Comparing the baseline proteinuria of the anti-PLA2R antibody positive group with the 
negative group there was not a significant difference (p=0.95 Mann-Whitney test) (see figure 28).  
As results of trial not yet published correlating anti-PLA2R antibodies with clinical response is not 
possible. 
 
Figure 28: Comparison of baseline uPCR in patients with detectable and undetectable anti-PLA2R antibodies within 4 
weeks of biopsy.  No Significant difference detected between groups, p 0.95 Mann-WhitneyTest. Red lines denote 
median and IQR. 
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Hofstra et al. 2014).  The test in itself was at times difficult to interpret it was not automated and 
had to be done manually; however it was reassuring to find that repeat analysis gave the same 
results. It may have been that with formal training with more with regards to interpreting the 
fluorescence, or even with more experience, there would have been more confidence with 
reporting. 
4.3.2  Discussion 
4.3.2.1  Analysis of the Indirect Immunofluorescence Test  
These are very preliminary data in a cohort of trial patients without formally reported clinical 
outcomes on a test that was new to the laboratory and Renal Centre.  The test in itself came in a 
kit with detailed instructions.  There was a commercially available analysis machine to report the 
slides; however this would have been a large investment for a laboratory to make.  The slides were 
reported manually which naturally led to a degree of subjective interpretation.  As a purely 
qualitative test, these variations had less of a bearing on the results as it was either a positive or 
negative outcome.  However, if this test was to be used in a quantitative manner where the slides 
would have had to be reported as weak, moderate or strong, then all slides would have needed to 
be double-checked for consistency of reporting.  Also to do accurate quantitative testing the 
samples would initially be tested at the screening concentration of 1:10, but then any positive 
samples would then be diluted further.   
Despite the limitations of the analysis of the results, the work reported here is consistent with the 
published data; the detection rate of 62%, which may have been higher if true pre-treatment 
samples were available for all patients; and the subjective interpretation of the IIFT.  Very similar 
comments were also made by Behnert et al. when comparing the different tests for the detection of 
anti-PLA2R antibodies.  They described IIFT as “relatively inexpensive and easy to perform”; 
however they then go on to say that: “it is not well suited to high through put laboratories and can 
be troubled by subjective interpretation” (Behnert, Schiffer et al. 2014). 
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4.3.2.2  Published data and newer available tests 
The three tests Behnert et al. compared were the indirect immunofluorescence test (IIFT), the 
addressable laser bead immunoassay (ALBIA) and a commercially available ELISA kit 
(Euroimmun) based on purified human recombinant PLA2R extracted from transfected cells.   
ALBIA, first described in 2013 (Behnert, Fritzler et al. 2013), is a multiplexing laser bead 
technology in which specific autoantigens are covalently coupled to microspheres labeled internally 
with different ratios of two fluorochromes. After incubation with human sera and a fluorochrome 
(i.e. phycoerythrin) conjugated secondary antibody, beads are analysed with two lasers.  One laser 
is used to detect the “colour” of the bead bearing the coupled antigen of interest (i.e. PLA2R), while 
the second laser is used to determine the binding of fluorochrome-coupled secondary antibody 
bound to the target antigen-autoantibody complex on the bead. The fluorescence intensity is 
digitally interpolated and expressed as median fluorescence intensity (MFI). The ALBIA offers 
simultaneous testing for multiple targets in a single assay and requires only small serum sample 
volumes of 2–20 𝜇 L.  (Behnert, Schiffer et al. 2014) 
The ELISA is a commercially available standard kit from Euroimmun using recombinant PLA2R.  It 
can be interpreted in both a semi-quantitative and a quantatitive manner with 5 calibrators.   There 
are two 30 minute and one 15 minute incubations. (Figure 29). 
 
Figure 29:  Diagram of anti-PLA2R antibody ELISA 
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All three assays were compared in 157 patients with IMN, 50 healthy controls, 41 nephrotic 
disease controls, 26 patients with SLE (Class not described) and 25 patients with granulomatosis 
polyangitis (GPA), from 2 centres in Boston and Hanover.  They compared the ALBIA and the 
ELISA method against a “standard” of the IIFT.  This was done on the basis that IIFT is an 
inexpensive and easy test to perform with good reliability in a qualitative assay.  They found that 
the ALBIA correlated better with the results of the IIFT than the ELISA testing.  It was hypothesized 
that the differences in the performance of the different assays may have been due to the 
differences in the antigen binding matrices on the three different platforms (Behnert, Schiffer et al. 
2014). The conclusion of this study was that the ALBIA offered a more accurate, reliable and 
sensitive measure of anti-PLA2R antibodies when compared against the Euroimmun ELISA. 
It is likely that in the future the ALBIA test will become commercially available and will provide 
accurate results in a shorter amount of time and in a more reproducible manner. As the ELISA is 
already commercially available it now offers a more reproducible and quantitative measure of anti-
PLA2R antibodies.  
4.3.2.3  Use of measurement of anti-PLA2R antibodies in practice. 
Anti-PLA2R antibodies have been measured in different ways and in various cohorts of patients to 
try to ascertain its most effective role as a disease biomarker.  A lot of the work published has used 
the Western Blot method developed by Beck et al. (Beck, Bonegio et al. 2009), with the 
measurements being undertaken by their group (Beck, Fervenza et al. 2011, Hofstra, Beck et al. 
2011, Qin, Beck et al. 2011).  The Manchester group, led by Paul Brenchley, developed its own 
ELISA, which has since been used in collaborations with other centres (Kanigicherla, Gummadova 
et al. 2013, Bech, Hofstra et al. 2014). Recent publications have used the commercially available 
IIFT and ELISA Euroimmun kits; the ELISA-producing quantitative results (Hoxha, Thiele et al. 
2014). 	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4.3.2.4  Anti-PLA2R Antibodies as a Biomarker in IMN 
For Diagnosis: 
Anti-PLA2R antibodies are consistently being identified in approximately 70% of patients with what 
has clinically and histologically been labeled as IMN (Beck, Bonegio et al. 2009, Hofstra, Beck et 
al. 2011, Bech, Hofstra et al. 2014). A not insignificant rate of positivity has also been found in 
patients with cancer-associated secondary MN where Qin et al. found a 30% positivity rate in this 
population (Qin, Beck et al. 2011). It therefore remains important to exclude secondary causes in 
all patients regardless of whether they have detectable anti-PLA2R antibodies. 
To Monitor Disease Activity: 
As discussed in section 1.3.2.1 a correlation between anti-PLA2R antibody levels, clinical status 
and proteinuria was found in two separate cohorts (Hofstra, Beck et al. 2011, Hoxha, Thiele et al. 
2014). However, as with disease biomarkers in LN, a correlation with proteinuria – already an 
excellent marker of disease activity in itself – does not add any extra information for the clinician 
when assessing the patient, unless the biomarker changes at a different rate and can therefore be 
a predictor of a future change in proteinuria. It has been shown that anti-PLA2R antibody depletion 
correlated with remission in patients treated with Rituximab, but perhaps more importantly the lack 
of anti-PLA2R antibody depletion was associated with poor response to Rituximab (Beck, 
Fervenza et al. 2011).  This was also discussed in the data recently published by Bech et al., who 
found that those patients who remained anti-PLA2R antibody positive at the end of a treatment 
regimen (CYP or MMF in combination with corticosteroids) had all relapsed by 2 years (Bech, 
Hofstra et al. 2014). Therefore, is it the patients who do not deplete the anti-PLA2R antibodies that 
should be offered prolonged or alternative immunosuppression?  
In the post-transplant population anti-PLA2R antibodies have been used to suggest disease 
recurrence in a patient with MN in their graft and previously known to have IMN (Debiec, Hanoy et 
al. 2012). Staining for the PLA2R has also been found in 83% patients with recurrent MN in their 
transplant compared with only 8% with de novo MN, suggesting perhaps a different pathogenic 
mechanism, such as a different antigen in de novo MN (Larsen and Walker 2013). 
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Currently anti-PLA2R antibody positivity on its own is not sufficient to replace a kidney biopsy as 
the gold standard test in IMN.  When a histological diagnosis of MN has been made having a anti-
PLA2R antibody is suggestive of a “primary/idiopathic” disease process but malignancy cannot be 
excluded.  However, anti-PLA2R antibody positivity at the end of a treatment course appears to be 
an important predictive factor for the increased risk of relapse and may now change clinical 
practice.   
Once more quantitative data are available for anti-PLA2R antibody levels there may be “threshold” 
values that accurately predict IMN as the primary diagnosis or predict when a relapse will occur. 
However, as with anti-dsDNA antibody values or Anti-Neutrophil Cytoplasmic Antibodies, values 
vary from patient to patient but is it the change in those values over time that indicate response to 
treatment or likelihood of relapse?   
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4.4  Summary 
In this chapter three disease biomarkers have been examined: urinary MIF and the novel urinary 
biomarker Angiogenin – both in patients with Lupus Nephritis; and anti-PLA2R antibody in patients 
with Idiopathic Membranous Nephropathy.  The work was done to validate MIF as a marker of 
disease activity in LN. We also wanted to find a new urinary biomarker via a discovery technique 
and to validate it. Lastly, we assessed whether anti-PLA2R antibodies could be measured and 
used in routine practice within a clinical trial setting. 
All three biomarkers were assessed against the quoted required criteria for a valid biomarker: 
(1) It is biologically plausible and relevant to disease pathogenesis,  
(2) It should accurately reflect changes in disease activity, and  
(3) It is simple to measure for routine use (Liu, Manzi et al. 2005).  
It was clearly described how all three were found to be biologically plausible and relevant to 
disease pathogenesis.  Within the limits of the data in this thesis they did all reflect a change in 
disease activity, but from the data presented it would be difficult to extrapolate a unique predictive 
role at this time. Further work is being carried out, especially in relation to anti-PLA2R antibodies.  
All tests used for measurement were commercial kits; all of which could potentially be used for 
routine measurement.  The IIFT used for the detection of anti-PLA2R antibodies proved most 
difficult to interpret, however less laborious tests are now becoming available. 
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CHAPTER 5:  SUMMARY OF FINDINGS 
 
The steroid sparing Rituxilup regimen was found to be a safe and effective treatment regimen in 
Class III, IV and V LN with an 86% response rate at 1 year (52% CR and 34% PR).   
 
Tacrolimus monotherapy is a safe and effective treatment (98% response rate) and longer term 
treatment is valuable in some patients with IMN who have relapsing or resistant disease as it can 
be used to maintain remission.  In this population it is particularly important to monitor the patients 
closely to ensure a stable glomerular filtration rate is maintained. 
 
uMIF very accurately reflected the change in disease activity with a significant reduction in uMIF 
between baseline and complete remission. Baseline uMIF did not predict time to CR .  There was 
also a correlation between urinary PCR and uMIF/Creat, probably showing that uMIF relates to 
PCR in the same way PCR is a very good marker of disease activity. The data do not yet 
demonstrate any advantage of uMIF over the use of uPCR to monitor disease activity. 
 
Angiogenin was identified as a novel biomarker in urine samples from patients with active LN.  As 
the disease goes into remission the detectable uANG levels fell significantly.  There is an 
association between uANG and the degree of renal impairment but not with the degree of 
proteinuria.  This was the first time uANG was described in a defined glomerular disease.   
 
The indirect immunofluorescence test for the detection of circulating anti-PLA2R antibodies is 
effective and reproducible, but the test itself is laborious and can have subjective variability when 
used in a quantitative manner.  
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CHAPTER 6:  FINAL CONCLUSIONS 
Both Idiopathic Membranous Nephritis and Lupus Nephritis are complex relapsing autoimmune 
conditions.  The current standard treatment regimens have adverse long-term effects that 
negatively impact on patients.  This thesis examined two novel treatment regimens in LN and IMN 
along with a currently recruiting RCT in IMN, with the aim of minimising toxic side effects, by 
avoiding steroids and cytotoxic drugs. The current gold standard diagnostic test in both diseases is 
the renal biopsy. Renal biopsy has an associated morbidity, and the current biomarkers in use for 
monitoring disease progression are crude and relatively non-specific.  Urinary MIF and urinary 
Angiogenin were both explored as potential biomarkers in LN and anti-PLA2R antibodies as a 
biomarker in IMN.  
The results from the Rituxilup cohort may mark a distinct change in the approach to the treatment 
of lupus nephritis. For the first time in more than 60 years, the data suggest that oral steroids can 
be safely avoided in the treatment of lupus nephritis without apparent reduction in efficacy or 
increase in relapse rates for (at least) up to three years of follow up.  These results have led to the 
Rituxilup protocol now being formally assessed in a prospective multicentre randomised trial (The 
Rituxilup Trial NCT01773616) and for the first time may offer a possibility of not using oral steroids, 
which may be the most toxic element in standard long-term treatment of this challenging disease. 
The results of the retrospective review of long term tacrolimus monotherapy demonstrates that it is 
an effective therapy for IMN and it can be a useful tool to maintain remission in relapsing and 
resistant disease especially in patients who fail to reach a sustained CR but who are in a stable PR 
and in those where frailty and comorbid disease means that they have poor reserve and cannot 
tolerate prolonged periods of nephrotic syndrome. The data collected in a retrospective manner 
are not as robust as a prospective randomized controlled trial. However, the published data on the 
long-term use of tacrolimus monotherapy to induce and sustain remission in IMN are sparse and 
the current data add a valuable new prospective of this treatment.  The preliminary data collected 
from this cohort by Lever et al. (unpublished currently) formed part of the rationale that led to the 
design of the MTac trial discussed in this thesis.  
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Both these studies demonstrate the importance of cohort data when examining novel treatment 
regimens particularly for providing essential data to support the design of ensuing Randomised 
Controlled Trials. 
uMIF accurately reflected the change in activity but baseline levels were not indicative of time to 
CR.   Due to it’s correlation with uPCR it is unlikely to offer an advantage over uPCR as a marker 
of disease activity and it is also not a substitute for a repeat biopsy.  A key goal for biomarker 
studies in LN would be to have a biomarker that could avoid the need for repeat biopsy to assess 
the significance of persistent proteinuria.  If uMIF was shown to be low in those patients with 
persistent proteinuria but with inactive disease on repeat biopsy, uMIF may then have a future 
clinical role as a non-invasive biomarker in LN and may avoid repeat biopsies in these patients. 
We identified uANG in urine samples from a very well defined cohort of patients with active LN and 
showed a positive correlation with renal impairment, but not proteinuria, and a clear significant 
reduction once patients reach remission.  Knowing that angiogenin has been detected in the urine 
of patients with LN and observing an association with disease activity may stimulate further work to 
look at the pathogenic role it may play and it’s potential as a specific therapeutic target. 
Both these studies of urinary biomarkers in LN were done in very well defined cohorts of patients.  
When investigating novel biomarkers or attempting to “discover” a new clinically significant 
biomarker; excluding as many variables as possible in the cohorts of patients is incredibly 
important so that robust conclusions can be drawn.  The newly established MAximizing Sle 
ThERapeutic PotentiaL by Application of Novel and Stratified approaches” (MASTERPLANS) UK 
Lupus Consortium (funded by the MRC Stratified Medicine Call) aims to do exactly this by 
collecting samples from blood and tissue from well-defined cohorts and clinical trial patients to 
evaluate biomarkers in lupus in general and lupus nephritis in particular.   
Anti-PLA2R antibodies were detectable with the IIFT in a proportion of patients enrolled in the 
MTac trial that was comparable with current published data.  The IIFT was found to be relatively 
laborious and subjective if used in a quantitative manner, so it is probably not a suitable test for a 
high throughput laboratory.  From the current published data, the role for the detection of anti-
PLA2R antibodies in clinical practice is evolving at a rapid pace.  Currently it is most useful as a 
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predictive marker of likely relapse if it remains positive despite completion of a course of treatment.  
Once the more accurate quantitative tests become more widely available it is likely that anti-
PLA2R antibodies will become a sensitive marker of disease activity and as a predictor of relapse 
or transplant recurrence in those patients with previously known to have anti-PLA2R antibodies.  
Going forward from this time serum has been collected in a prospective manner in all the trial 
patients and antibodies will be correlated with outcomes in due course. 
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APPENDIX 
 
1.  Total uMIF ELISA Methods (R&D Systems cat. DY289) 
 
REAGENT PREPARATION 
Bring all reagents to room temperature before use. Allow all components to sit for a minimum of 15 
minutes with gentle agitation after initial reconstitution. Working dilutions should be prepared and 
used immediately. 
 
Capture Antibody: Reconstitute with PBS, as recommended in the product datasheet. After 
reconstitution, store at 2 °C to 8 °C for up to 60 days or aliquot and store at -20 °C to -70 °C in a 
manual defrost freezer for up to 6 months.  Dilute to the working concentration as recommended in 
the product datasheet.  
 
Biotinylated Detection Antibody: Reconstitute with Reagent Diluent, as recommended in the 
product datasheet. After reconstitution, store at 2 °C to 8 °C for up to 60 days or aliquot and store 
at -20 °C to -70 °C in a manual defrost freezer for up to 6 months.  Dilute to the working 
concentration as recommended in the product datasheet.  
 
Standard: Reconstitute the standard with Reagent Diluent, as recommended in the product 
datasheet. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to 
making dilutions. Aliquot and store reconstituted standard at -70 °C. Refer to the product datasheet 
for the length of time the reconstituted standard may be stored. A seven point standard curve using 
2-fold serial dilutions in Reagent Diluent. Refer to the product datasheet for the concentration of 
the high standard recommendation. 
 
Streptavidin-HRP (1 vial): 1.0 mL of streptavidin conjugated to horseradish-peroxidase. Store at 2 
°C to 8 °C for up to 6 months after initial use.  DO NOT FREEZE. Dilute to the working 
concentration specified on the vial label using Reagent Diluent.  Provided this is within the 
expiration date of the kit. 
 
GENERAL ELISA PROTOCOL 
 
Plate Preparation 
1 Dilute the Capture Antibody (to the working concentration stated in the product datasheet ) 
in PBS without carrier protein. Immediately coat a 96-well microplate with 100 µL per well 
of the diluted Capture Antibody. Seal the plate and incubate overnight at room 
temperature. 
2 Aspirate each well and wash with Wash Buffer, repeating the process two times for a total 
of three washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt 
bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is 
essential for good performance. After the last wash, remove any remaining Wash Buffer 
by aspirating or by inverting the plate and blotting it against clean paper towels. 
3 Block each well of the microplate as recommended in the product datasheet. Incubate at 
room temperature for a minimum of 1 hour. 
4 Repeat the aspiration/wash as in step 2. The plates are now ready for sample addition. 
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PRECAUTION 
 
The Stop Solution suggested for use with this kit is an acid solution. Wear eye, hand, face and 
clothing protection when using this material. 
Assay Procedure 
1 Add 100 µL of sample or standards in Reagent Diluent, or an appropriate diluent, per well. 
Cover with an adhesive strip and incubate 2 hours at room temperature. 
2 Repeat the aspiration/wash as in step 2 of Plate Preparation. 
3 Add 100 µL of the Detection Antibody, diluted in Reagent Diluent (as recommended in the 
product datasheet), to each well. Cover with a new adhesive strip and incubate 2 hours 
at room temperature. 
4 Repeat the aspiration/wash as in step 2 of Plate Preparation. 
5 Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the plate and 
incubate for 20 minutes at room temperature. Avoid placing the plate in direct light. 
6 Repeat the aspiration/wash as in step 2. 
7 Add 100 µL of Substrate Solution to each well. Incubate for 20 minutes at room 
temperature. Avoid placing the plate in direct light. 
8 Add 50 µL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing. 
 
Determine the optical density of each well immediately, using a microplate reader set to 450 nm. If 
wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not 
available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will 
correct for optical imperfections in the plate. Readings made directly at 450 nm without correction 
may be higher and less accurate. 
 
CALCULATION OF RESULTS 
 
Average the duplicate readings for each standard, control, and sample and subtract the average 
zero standard optical density. Create a standard curve by reducing the data using computer 
software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, 
construct a standard curve by plotting the mean absorbance for each standard on the y-axis 
against the concentration on the x-axis and draw a best fit curve through the points on the graph. 
The data may be linearized by plotting the log of the concentrations versus the log of the O.D. and 
the best fit line can be determined by regression analysis. This procedure will produce an 
adequate but less precise fit of the data. If samples have been diluted, the concentration read from 
the standard curve must be multiplied by the dilution factor. For typical data generated using this 
kit, please see the product datasheet. 
 
TECHNICAL HINTS AND LIMITATIONS 
5 This DuoSet kit should not be used beyond the expiration date on the label. 
6 The use of high quality Bovine Serum Albumin (BSA) for the Reagent Diluent is crucial for 
the optimum performance of the DuoSet ELISA Development kit. Impurities such as 
proteases, binding proteins, soluble receptors or other interfering substances can be 
found to varying degrees in virtually all BSA preparations and can inhibit or interfere with 
the detection of certain analytes. If the standard curve appears suppressed, consider 
evaluating a different preparation of BSA.  
7 We recommend the use of R&D Systems’ Reagent Diluent (Catalog # DY995) or the use of 
Millipore Bovine Serum Albumin, Fraction V, Protease free (Catalog # 82-045), to 
prepare your own Reagent Diluent. 
8 It is important that the diluents selected for reconstitution and for dilution of the standard 
reflect the environment of the samples being measured. The diluent suggested in this 
protocol should be suitable for most cell culture supernate samples. Validate diluents for 
specific sample types prior to use. 
9 The type of enzyme and substrate and the concentrations of capture/detection antibodies 
used can be varied to create an immunoassay with a different sensitivity and dynamic 
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range. A basic understanding of immunoassay development is required for the 
successful use of these reagents in immunoassays. 
10 A thorough and consistent wash technique is essential for proper assay performance. 
Wash Buffer should be dispensed forcefully and removed completely from the wells by 
aspiration or decanting. Remove any remaining Wash Buffer by inverting the plate and 
blotting it against clean paper towels. 
11 Use a fresh reagent reservoir and pipette tips for each step. 
12 It is recommended that all standards and samples be assayed in duplicate. 
Avoid microbial contamination of reagents and buffers. This may interfere with the sensitivity of the 
assay. Buffers containing a large quantity of protein should be made under sterile conditions and 
stored at 2 °C to 8 °C or be prepared fresh daily. 
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2.  Angiogenin ELISA Protocol 
ANG (detection Ab) BAF265, 50ug 
Reconstitute with sterile Tris-buffered saline pH 7.3 (20 mM Trizma base, 
150 mM NaCl) containing 0.1% BSA. If 1 mL of buffer is used, the antibody concentration will 
be 50 µg/mL. 
To store in 50ug allocates (20 in total) 
Concentration required 50ng/ml. 
 
50ug ----------------------------------- 1ml 
1ug   ------------------------------------1/50 = 0.02 
1000ng --------------------------------- 0.02mls 
1ng -------------------------------------- 0.02/1000 
50ng ----------------------------------- 0.02/1000*50 = 0.001mls == 1ul 
 
So 1ul = 50ng 
 
Add 7ul of above to 7ml of Diluent for ELISA. 
 
ANG (capture Ab) MAB265, 500ug 
Reconstitute with sterile PBS. If 1 ml of PBS is used, the antibody concentration will be 
500µg/ml. 
To Store in 60ul allocates (16 in total) 
Concentration required 2ug/ml 
 
500ug ---------------------------------- 1ml 
1ug -------------------------------------- 1/500 
2ug -------------------------------------- 1/500*2 = 0.004ml = 4ul 
So 4ul = 2ug 
 
Add 28ul of above to 7ml of PBS for ELISA. 
 
ANG (Standard Ab) 265-AN-050, 50ug 
Reconstitute with Sterile Phosphate Buffered Saline containing 0.1% Human Serum Albumin or 
BSA be added to make a stock solution of no less than 1ug/ml. 
Store 50ul in 0.5ml allocates (20 in total) – Stock 50ug/ml 
Optimal dilution required 4ng/ml 
 
1000ul ------------------------------------- 50ug 
1ul ------------------------------------------ 50/1000 = 0.05ug = 50ng 
5ul ------------------------------------------ 50/1000*5 = 0.25ug = 250ng = 250,000pg 
 
So to use 5ul in 2.5ml dilution it would be  
 
2500ul  -----------------250000pg 
1ul ---------------------- 250000/2500  = 100pg 
500ul ------------------- 50000pg 
 
 
Method 
1. Cover one plate with Capture Ab. Capture Ab 28ul in 7ml PBS and put 100ul in each well 
of the plate. 
2. Cover the plate for overnight. 
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3. Wash three times with washing solution. 3 x 360ul. 
4. Add Blocking solution 300ul/w. Cover for one hour. 
5. Prepare Standards. 
• Add 5ul of Stock to 2500ul of Diluent (stand). 
• Label 12 ml tubes with the following concentration. 
• 50000, 25000, 12500, 6250, 3125, 1562.5, 781.25, 390.62, 195.31, 97.65, and 0. 
Add Diluent 500ul to each tube. 
• Now add 500ul from tube (stand) to tube 50000 and then 25000 continuing serially 
except tube 0.  
• Use only tubes labelled 12500 to 0 (total 9 tubes) 
Prepare samples – for PDF dilute 1:50 times. 
6. Wash three times. 3 x 360ul. 
7. Add Standards 100ul/w in the standard part of the plate. 
8. Add samples 100ul/w in each well of remaining plate. 
9. Cover the plate for two hours. 
10. Take out Detection Abs. 
11. Wash plate three times 360ul/w. 
12. Prepare Detection Ab 7ul in 7mls Diluent. 
13. Add Detection Ab 100ul/w. 
14. Cover the plate for two hours. 
15. Take out Substrate from the fridge. 
16. Wash three times 3 x 360ul. 
17. Prepare Streptividine 2ul in 20mls of PBS. 
18. Add streptividine to the plate 100ul/w. 
19. Cover for 20 minutes. 
20. Prepare Substrate five minutes before use (before washing Streptividine). Add 3.5ml of A 
to 3.5ml of B. 
21. Wash the Streptividine three times 3 x 360ul/w. 
22. Add Substrate to the plate 100ul/w. 
23. Cover and protect from direct sunlight for 10-30 min. Until the 12.5pg/ml Standard becomes 
deep blue. 
24. Prepare Stop Solution. 
25. Set up the plate reader machine. 
26. Add Stop Solution to the plate 50ul/w and mix gently – samples and standards will 
become yellow in colour. 
27. Read the plate at 450nm. 
 
